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Polycationic nanoparticles were synthesized with an activators regen-
erated by electron transfer for atom transfer radical polymerization-based
(ARGET ATRP-based) emulsion in water method and investigated for their
utility as biomaterials for drug delivery. The polycationic nanoparticles
were composed of 2-(diethylamino)ethyl methacrylate (DEAEMA) for pH-
responsiveness, poly(ethylene glycol) methyl ether methacrylate (PEGMA)
for improved biocompatibility, tert-butyl methacrylate (tBMA) to impart hy-
drophobicity, and a tetraethylene glycol dimethacrylate (TEGDMA) cross-
linking agent for enhanced colloidal stability. Dynamic light scattering
demonstrated pH-responsive swelling, and cell-based assays demonstrated
pH-dependent membrane disruption. The polycationic nanoparticles demon-
strated low toxicity to cells.
viii
The polycationic nanoparticles were evaluated for use as drug delivery
biomaterials by investigating the interactions with the drug and cells. Delivery
remains a major challenge for translating small interfering RNA (siRNA) to the
clinic, and overcoming the delivery challenge requires effective siRNA delivery
vehicles. The polycationic nanoparticles demonstrated efficient siRNA load-
ing. Evidence of siRNA-induced knockdown in cells was observed following
transfection with the polycationic nanoparticle/siRNA complexes. Imaging
techniques confirmed enhanced siRNA internalization using the polycationic
nanoparticle/siRNA complexes compared to naked siRNA.
An array of polycationic nanoparticles synthesized using ARGET
ATRP or UV-initiated polymerization methods was characterized to examine
the effect of polymerization method on material properties and the connec-
tion to molecular structure. An improved understanding of molecular struc-
ture, and its connection to polymerization method and material characteristics,
may aid the design of advanced materials. The ARGET ATRP polycationic
nanoparticles demonstrated increased nanoscale homogeneity compared to the
UV-initiated polymerization polycationic nanoparticles; increased nanoscale
heterogeneity in the UV-initiated polymerization polycationic nanoparticles
was associated with broader transitions.
The polycationic nanoparticles promoted cellular uptake of siRNA and
induced knockdown, thus demonstrating potential as siRNA delivery vehicles.
The ARGET ATRP method provides an alternative route to creating polyca-
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Chapter 1
Introduction and Research Objectives
1.1 Introduction
Biomaterials researchers operate at the interface between biology and
materials science in order to create new materials that can aid patients by de-
tecting, treating, or preventing disease. Drug delivery remains an active focus
for biomaterials researchers as well as researchers in the area of nanomedicine,
which is the medical application of nanotechnology.1–3 Nano- or micro-scale
delivery vehicles can enhance therapeutic efficacy compared to free-drug (no-
carrier) by avoiding rapid clearance,4 preventing enzymatic degradation of the
therapeutic agent,5 or bypassing efflux pumps with chemotherapeutic-loaded
nanoparticles.6
Nano- and micro-scale stimuli-responsive polymer hydrogels may be
used as drug delivery biomaterials.7–11 Hydrogels are three-dimensional net-
works of cross-linked polymer chains, which, due to their hydrophilicity swell
in water or biological fluids.12;13 Stimuli-responsive polymers respond to en-
vironmental triggers, such as swelling in response to low pH values, and this
response to stimuli can be used to release loaded therapeutic drugs.14–18
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There has been renewed interest in nanoscale biomaterials for drug de-
livery as a result of research interest in siRNA (small interfering RNA) and
RNA interference.19–21 First reported by Fire and Mello,22 RNAi is an innate
mechanism within cells to alter gene expression in response to small RNAs;
the small RNA initiates a catalytic mechanism to degrade specific mRNA
molecules.23 RNAi-based therapeutic agents offer the potential to correct aber-
rant gene expression to treat disease.24–31 This impressive potential is matched
by the challenges of delivery; siRNA must avoid degradation by nucleases, be
internalized by the target cells, and escape the endosome in order to be ac-
tive in the cytosol.32;33 Drug delivery vehicles such as pH-responsive nanogels
are one delivery strategy designed to help the siRNA overcome these delivery
challenges.34–37
New technologies in controlled radical polymerization have created op-
portunities to make drug delivery biomaterials with controlled chemical struc-
tures.38;39 Controlled radical polymerization, in contrast to traditional free
radical polymerization, provides enhanced control over molecular structure
by minimizing the concentration of free radicals to suppress termination reac-
tions.40–42 While advanced polymerization chemistries have been typically con-
ducted in organic solvents in order to avoid side reactions that make aqueous
polymerizations challenging, the reports of aqueous controlled radical poly-
merization reactions are growing43–45 as are reports of advanced chemistries
for the synthesis of drug delivery vehicles using hydrophilic polymers.46–51
ARGET ATRP (activators regenerated by electron transfer for atom
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transfer radical polymerization) is a recently-reported controlled radical poly-
merization technique.52;53 In contrast to traditional ATRP which makes use
of a “forward” chemical mechanism with active copper(I) catalysts, reverse
ATRP techniques such as ARGET ATRP make use of a “reverse” chemical
initiation strategy where inactive copper(II) catalyst is reduced in order to
activate the reaction.54 The copper(II) is more air-stable than copper(I) and
can be activated by the addition of a reducing agent;55 as a result, ARGET
ATRP can take place in the presence of residual air.56
Advances in controlled radical polymerization technology create op-
portunities for new, and possibly improved, biomaterials for drug delivery by
enhancing control over molecular structure. New chemistries, such as ARGET
ATRP, may offer advantages over previously developed technologies, but the
ultimate utility of these chemistries for the synthesis of biomaterials for drug
delivery will depend on careful investigations that seek to better understand
the material properties and the interactions between the material and relevant
biological systems.
1.2 Research objectives
In order to advance the goal of creating and investigating new ARGET
ATRP-based materials and understanding their utility as biomaterials for drug
delivery, the research objectives were to:
1. Develop an ARGET ATRP-based technique to synthesize polycationic
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nanoparticles;
2. Evaluate the suitability of the polycationic nanoparticles for drug deliv-
ery; and
3. Examine the effect of polymerization method on material properties and
the connection to molecular structure.
The objectives of this research are part of a broader research project to cre-
ate an oral delivery system for siRNA therapeutics. The research to achieve
this broader goal is collaborative and ongoing. The polycationic nanoparti-
cle research represents a piece of the work to overcome the many challenges
associated with creating an oral delivery system for siRNA therapeutics.The
polycationic nanoparticles have utility for intracellular delivery as part of this
future oral delivery system. The specific challenges associated with creating
an siRNA delivery system suitable for oral administration are being tackled
by another researcher; this research focuses on the polycationic nanoparticles
and their interactions with siRNA and cells.
Develop an ARGET ATRP-based technique to synthesize polyca-
tionic nanoparticles This work represents the first report in the litera-
ture of polycationic nanoparticles synthesized using an ARGET ATRP-based
emulsion in water synthesis method. Polycationic nanoparticles composed of
2-(diethylamino)ethyl methacrylate (DEAEMA), poly(ethylene glycol) methyl
ether methacrylate (PEGMA), and tert-butyl methacrylate monomers with
4
tetraethylene glycol dimethacrylate (TEGDMA) cross-linking agent were syn-
thesized with the ARGET ATRP-based emulsion. While the new method may
offer unique properties in the resulting materials, the advantage of the new
method may come from an alternative route to creating polycationic nanopar-
ticles. The Chemistry background (Chapter 2) provides an introduction to
ARGET ATRP, examples of relevant polycationic nanoparticles found in the
literature, and a discussion of the toxicity of the chemicals used in synthe-
sis. The protocol for the new synthesis technique and initial characterization
results are first presented in Chapter 4.
Evaluate the suitability of the polycationic nanoparticles for drug
delivery The polycationic nanoparticles synthesized using the new ARGET
ATRP-based technique were investigated for use as drug delivery vehicles. The
successful delivery of siRNA to cells to induce knockdown was a central goal.
The siRNA background (Chapter 3) provides a discussion of the therapeutic
potential of small RNA and DNA, continuing challenges in drug delivery, and
a discussion of oligonucleotide oral delivery systems found in the literature.
Material characterization relevant to drug delivery including size, biocompat-
ibility, pH-responsiveness, and the loading and release of a small molecule
(representing a model chemotherapeutic) is first described in Chapter 4. The
polycationic nanoparticles are investigated for for siRNA delivery to an easy-
to-transfect cell line and a hard-to-transfect cell line in Chapter 5. The siRNA
binding is evaluated to determine loading efficiency and the uptake of siRNA
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is investigated. Chapter 4 and Chapter 5 provide a comparison of four dif-
ferent formulations. Chapter 6 takes a closer look at a single ARGET ATRP
formulation in order to better understand the interaction of the polycationic
nanoparticles with siRNA and with cells.
Examine the effect of polymerization method on material properties
and the connection to molecular structure. An improved understand-
ing of molecular structure, and its connection to synthesis techniques and
material properties, may facilitate the design of enhanced materials. In Chap-
ter 7, four formulations of polycationic nanoparticles were characterized using
a variety of techniques designed to probe the molecular structure. Nanoscale
heterogeneity represents a critical aspect of molecular structure, as heterogene-
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2.1 Introduction to ARGET ATRP
Advances in Atom-Transfer Radical Polymerization (ATRP) technol-
ogy have led to methods that combine the versatility and control of controlled
radical polymerizations (CRP) with mild reaction conditions1 more charac-
teristic of a traditional free radical polymerization. For example, Activators
ReGenerated by Electron Transfer (ARGET) ATRP can occur in the presence
of limited amounts of air1;2 and uses copper(II) catalyst, which is significantly
less sensitive to oxidation compared to copper(I) catalysts.2;3 In addition, AR-
GET ATRP significantly reduces the copper catalyst concentration compared
to conventional ATRP; for example, reduction from a typical value of 1000 ppm
to ~10 ppm was achieved for styrene polymerization with a targeted degree
of polymerization of 1000 while maintaining a molecular weight polydispersity
less than 1.2.2
The mechanisms for ARGET ATRP and traditional ATRP are shown
in Figure 2.1. Both the significant reduction in catalyst concentration as
well as the ability to conduct polymerizations in the presence of limited
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amount of air are possible due to the addition of a reducing agent (RA)
such as vitamin C,1;3;4 glucose,2;4 or tin(II) 2-ethylhexanoate.1;5 The reduc-
ing agent scavenges oxygen and reduces the inactive copper(II) to the ac-
tive copper(I) catalyst.1–3 The ligand (L) complexes with the active copper(I)
catalyst. Ligands such as tris[2-(dimethylamino)ethyl]amine (Me6TREN)and
tris(2-pyridylmethyl)amine (TPMA) are “103-105 times more active than the
originally used CuBr/bipyridine complexes”,2 and these ligands are commer-
cially available.6 Improved ligand stability can improve control of the polymer-
ization, so ligand selection is critical;7 TPMA provided the best control for the
polymerization of n-butyl acrylate.8;9 It was also reported that increasing the
excess of TPMA ligand from 3-fold to 10-fold also resulted in an increase in
reaction conversion.8
A primary difference between traditional free radical polymerizations
and those frequently termed “controlled” polymerizations is that termination
reactions between free radicals are significantly reduced.10 In traditional free
radical polymerizations, growing chains are quickly terminated. In controlled
radical polymerizations, active growing chains may be quickly deactivated
(which is a reversible process), but they are rarely terminated.11 Amore precise
designation for these “controlled” reactions is Reversible-Deactivation Radical
Polymerization (RDRP), which is defined by IUPAC as a “chain polymeriza-
tion, propagated by radicals that are deactivated reversibly, bringing them
into active-dormant equilibria of which there might be more than one”.12 This
reversibility creates opportunities for new polymer architectures such as block
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copolymers via chain extension (rather than functionalization/conjugation
strategies using synthesized polymer chains).
An important similarity between traditional free radical and controlled
radical polymerizations such as ARGET ATRP is that for both methods, the
composition of copolymers is a function of the feed composition and of the
reactivity ratios. The feed composition is in turn a function of conversion.
These facts lead to difference in the distribution of chain composition; in tra-
ditional free radical polymerizations, the lifetime of growing chains is very
short with respect to the total reaction time, so a diverse population of chain
compositions would be expected, while in controlled radical polymerizations,
the lifetime of growing chains is comparable to the total reaction time and
so probability suggests that the chains will have a narrower distribution of
composition. Whether this difference in composition distribution as well as
the difference in molecular weight distribution affects material properties (and
hence, performance) for a specific application is an important question when
studying which type of polymerization to use.
2.1.1 Aqueous ARGET ATRP
Reports of aqueous ARGET ATRP are growing in number, but the
synthesis techniques are largely restricted to polymerization of polyethylene
glycol acrylates or methacrylates. The rare exceptions are DMAEMA13 and
N -isopropylacrylamide,14 for which there is a reported aqueous technique. The
ARGET ATRP or AGET ATRP strategies for the polyethylene glycol acry-
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lates or methacrylates include traditional copper halide catalyzed,15–19 as well
as metalloenzyme techniques14;20;21 or iron halide catalysts.22;23
2.1.2 Emulsion with ARGET ATRP
Inverse miniemulsion with ARGET ATRP or AGET ATRP has been
used to prepare hydrogel nanoparticles of poly(2-hydroxyethyl methacrylate)24
and oligo(ethylene glycol) monomethyl ether methacrylate.16;25 Such nanopar-
ticle systems may incorporate biodegradable cross-linking agents with disulfide
groups,15;26 which are cleaved in a reductive environment. These nanoparticle
systems were investigated for drug delivery applications.27 This nanoparti-
cle drug delivery system is composed of the hydrophilic polymer polyethylene
glycol, and so lacks a responsive component to improve targeted delivery.
There are reports of standard oil-in-water miniemulsion polymeriza-
tions as well as inverse emulsion polymerizations. AGET ATRP has been
used to prepare poly(butyl acrylate) in a standard miniemulsion (monomer
in water) in the presence of limited air.28 AGET ATRP and ARGET ATRP
were used to prepare poly(methyl methacrylate) in a standard miniemulsion
(monomer in water) using an amphiphilic ATRP initiator without additional
surfactant.29 ARGET ATRP was used to prepare butyl methacrylate in a
standard miniemulsion with only 50 ppm copper(II) catalyst.30
Both ARGET ATRP and AGET ATRP rely upon a reducing agent
such as ascorbic acid or tin(II) 2-ethylhexanoate to activate the copper(II)
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catalyst, and extra reducing agent can be used to conduct reactions in the
presence of limited air. In AGET ATRP, the molar amount of reducing agent
is set based on the molar amount of copper with 0.1-0.5 mole reducing agent
per mole copper for deoxygenated mixtures and 1.5 mol reducing agent per
mole copper for mixtures with air.28 In contrast, in ARGET ATRP, a large
excess of reducing agent (50-100x) is added to “regenerate” the active catalyst
throughout the reaction, and as a result, the copper concentration can be
significantly reduced.1
2.2 Polycationic polymers
Cationic monomers such as 2-(dimethylamino)ethyl methacrylate
(DMAEMA) and 2-(diethylamino)ethyl methacrylate (DEAEMA) may be
used to make pH-responsive polymers and polymer hydrogels. PDMAEMA
and PDEAEMA polymers find applications in various fields including waste-
water treatment,31 paints and coatings,31 filtration techniques,31 as well as
biomaterials.32–36 These polymers undergo a “pH-dependent hydrophobe-to-
hydrophile phase shift”37 when going from high pH values to low pH values. At
low pH values, the amino group of the DMAEMA and DEAEMA is protonated
and positively charged. The positively charged groups repel and the hydrogel
swells. The reported pKa of PDMAEMA is ~7.538;39 and reported values for
the pKa of PDEAEMA range from ~7.0-7.340–42 to 7.68.43 PDMAEMA44–48
and PDEAEMA48 and are also temperature responsive because they have a
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“characteristic temperature-dependent solubility (lower critical solution tem-
perature, LCST) in water.”47
There is a broad range of creative synthesis strategies for the synthe-
sis of polycationic polymers. A survey of the strategies for making cationic
nanoparticles using 2-(diethylamino)ethyl methacrylate (DEAEMA) is shown
in Table 2.2. In the group of ARGET ATRP-based techniques, there are
several reports for polycationic polymers synthesized with the monomer 2-
(diethylamino) ethyl methacrylate (DEAEMA) as well as the related monomer
2-(dimethylamino)ethyl methacrylate (DMAEMA) (see Table 2.1). Note that
both Siegwart, et al.,5 and Dong and Matyjaszewski49 found that DMAEMA
acts as an intrinsic reducing agent to reduce copper(II) to copper(I), but that
an additional reducing agent is needed in the presence of limited amounts of
air.
2.3 Toxicity of chemicals used for nanoparticle synthe-
sis
A concern of researchers regarding the use of ATRP methods to pre-
pare polymeric biomaterials is the presence of copper in the polymerization
and in the final product. The use of the heavy metal copper merits consider-
ation of cytotoxicity effects, but careful analysis suggests the use of copper at
sufficiently low concentrations may not be a barrier to use as a biomaterial.
While copper ions are an essential enzyme cofactor for oxidation-
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reduction reactions,50 copper ions are harmful at sufficiently high concentra-
tions. As a result, it is perhaps not surprising that the body has a robust
system to maintain copper homeostasis. Copper is relatively easily absorbed
and excreted by most mammals, and little is stored,50 with an exception per-
haps in the livers of newborns where the copper concentration greatly exceeds
that of normal adults.51 Copper is even present in breast milk (602 µmol/L in
human breast milk for the first week after birth50).
The use of copper as a biomaterial has been approved for use in the
ParaGard® T 380A Intrauterine Copper Contraceptive device (IUD).52 The T-
shaped IUD measures 32 mm horizontally and 36 mm vertically and it contains
more than 300 mg copper. The contraceptive effectiveness is enhanced as the
copper is continuously released into the uterine cavity; however, the mechanism
for this effectiveness is not known.53
Copper is present in drinking water; the EPA sets the maximum con-
taminant level goal (MCLG) for copper in water at 1.3 mg/ml, which means
that public water systems must take action if more than 10% of tap water
samples this concentration. This concentration was selected “based upon the
best available science to prevent potential health problems”.54
The daily dietary copper intake is between 0.6 and 1.6 mg, and about
half is absorbed by the intestines.50 The liver plays a primary role in copper
homeostasis55 because bile produced in the liver is the primary excretory route
for excess copper.50;55 While some of the 4.5 mg or more of copper excreted
daily in the bile into the intestines will be reabsorbed, contributing to “cycling”
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of copper, the copper in bile is not easily reabsorbed.50 Copper overload is rare
since the liver has an “enormous capacity” to increase copper excretion;55 in
fact, studies with intravenously injected copper in mice demonstrated that
increased copper load results in increased copper in bile.56 The liver also plays
an important role by synthesizing ceruloplasmin; 95% of copper in plasma is
bound to ceruloplasmin, which can carry up to six copper atoms.55 The role of
ceruloplasmin in copper transport remains unsettled;55 what is settled is that
ceruloplasmin is a multifunctional protein “that overcomes the one gene-one
function concept”.57
Nevertheless, the harmfulness of excess copper may be witnessed in the
case of Wilson’s disease, which is a condition where normal copper homeostasis
is disrupted by the lack of a specific copper transporter protein. If untreated,
Wilson’s disease is fatal; the lack of transporter protein leads to an accumu-
lation of copper in the liver exceeding 250 mg/kg (compared to healthy state
concentrations below 50 mg/kg)58 followed by damage to kidneys, brain, and
eyes.59 Toxicity studies have investigated the use of copper as a biomaterial,
particularly as a component of dental alloys.60–63 The source of the copper ions
matters; pure metals released ions more slowly than copper salts, and greater
toxicity was observed with increased exposure concentration.63
ATRP techniques typically rely on organic solvents (due to poor con-
trol19;64;65 and problems with loss of terminal functionality66 in water), but for
the biomaterials application as a drug delivery system, concerns about mini-
mizing toxicity led to adapting the ARGET ATRP technique to synthesis in
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water. Toxicity from residual methacrylate monomer is a concern that would
need to be addressed by careful purification and cytotoxicity. For example,
although tetraethylene glycol dimethacrylate has a low reported health hazard
(0 on both Hazardous Materials Identification System (HMIS) and National
Fire Protection Association (NFPA) scales),67 leaching from dental resin can
cause inflammation of dental pump and necrosis. This is a challenge shared
by all biomaterials researchers using methacrylate or acrylate monomers.68
The TPMA ligand used for the ARGET ATRP synthesis should be less of a
toxicity concern than the methacrylate monomers, both due to its low concen-





Table 2.1: Strategies to create polycationic polymers using DEAEMA. AR-
GET ATRP: activators regenerated by electron transfer atom transfer radical
polymerization, CCL: core cross-linked, EGDMA: ethylene glycol dimethacry-
late, PCL: poly(ε-caprolactone), PEGDMA: poly(ethylene glycol) dimethacry-
late, PPGDA: poly(propylene glycol) diacrylate, RAFT: reversible addition-
fragmentation chain transfer, SCL: shell cross-linked, SCVCP: self-condensing
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Table 2.2: Strategies to create polycationic DEAEMA and DMAEMA
polymers using ARGET ATRP. ARGET ATRP: activators regenerated
by electron transfer atom transfer radical polymerization, PCL: poly(ε-
caprolactone), PEGMA: poly(ethylene glycol) methyl ether methacrylate,
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Figure 2.1: Comparison of traditional ATRP and ARGET ATRP (top) and
ARGET ATRP (bottom) mechanisms. ARGET ATRP uses excess reducing
agent to form the active form of the transition metal (Mt) catalyst, while tra-
ditional ATRP starts out with the active form of the catalyst added directly to
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3.1 Therapeutic potential of small RNA and DNA
Small RNA and DNA therapeutics may offer improved treatment
strategies for a full range of conditions including hypercholesterolemia, glau-
coma, viruses, cancer, and inflammatory bowel disease. In spite of their
promise, delivery to the action site of the cytosol remains a significant obstacle.
While small interfering RNAs (siRNA) have enjoyed recent popularity due to
their potent and specific gene silencing, other oligonucleotides including mi-
croRNA (miRNA), antisense oligonucleotides (AS-ODNs), and transcription
factor decoys also show promise for therapeutic applications. Oligonucleotides
are susceptible to degradation, particularly by nucleases, so efficacy may be
enhanced by polymer carrier strategies that protect the drug. Also, oligonu-
cleotides are only effective inside the cytosol of the cell. Therefore, the delivery
strategy must achieve not only cellular uptake but also evade the biological
defense strategy of endosomal sequestration without activation of the immune
system.
Most oligonucleotide delivery strategies in laboratory or clinical trials
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are injection-based; thus, there remains a paucity of data on the development
of oral delivery systems. Intravenous administration is the most common strat-
egy, but subcutaneous, intralesional, intravitreal, and intratumoral injections
are also used. From a drug delivery standpoint, the oral route of administra-
tion is advantageous because it increases patient compliance and comfort over
injection, provides a simple, repeatable administration, and provides a large
surface area of absorption. Efficient oral delivery of fragile biotherapeutics,
such as peptides, proteins, and nucleic acids, has long been considered a chal-
lenge of drug delivery and is still one of the field’s most compelling and difficult
problems. Successful development of oral delivery systems for oligonucleotides
such as siRNA would provide patients a powerful, specific therapeutic in a
convenient form that most would consider less invasive than injections.
3.2 Small RNAs and DNAs
Small interfering RNA (siRNA), microRNA (miRNA), antisense
oligonucleotides (AS-ODNs), and transcription factor decoys are oligonu-
cleotides that can regulate gene expression when delivered to the cytosol.
These four strategies all use a short sequence of nucleotides (approximately
20 base pairs), and each strategy requires intracellular delivery and endosomal
escape of the oligonucleotides. The oligonucleotides differ in the nucleotide
type (RNA or DNA) and the number of strands (single or double stranded),
and these differences change important physicochemical properties that affect
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drug delivery such as molecular weight, configuration, and stability.1 Another
difference is the mechanism of action of the oligonucleotide; decoys work by
a pre-transcriptional mechanism while siRNA and AS-ODNs work by a post-
transcriptional mechanism (see Figure 3.1).2;3 Despite these differences, deliv-
ery strategies share fundamental similarities because the oligonucleotides have
similarities in structure and site of action.
The pre-transcriptional mechanism of action for transcription factor
decoys is distinct from the post-transcriptional regulation by RNA interference
(RNAi) and antisense oligonucleotides. Transcription factor decoys imitate
chromosomal DNA target sequences so that transcription factors bind to the
decoy rather than to the cDNA.4 The typical action of the transcription factor
is to regulate gene expression, so some factors up-regulate while other factors
down-regulate specific genes by interacting with transcriptional machinery in
the nucleus.5
Antisense oligonucleotides may act via a stoichiometric binding ap-
proach to block translation of mRNA or by a catalytic, RNAi-like mech-
anism.2;6;7 Antisense oligonucleotides are typically single-stranded DNA or
chemically modified DNA derivatives.7 In the RNAi-like mechanism, the
RNA/DNA heteroduplex of mRNA and antisense oligonucleotide activates
RNase H to degrade the mRNA strand.2 The antisense oligonucleotide disso-
ciates and is free to bind to another mRNA strand to repeat the degradation
process.6 In addition to targeting mRNA, the next generation of antisense
oligonucleotides can be designed to repress over-expressed miRNA.8 The dis-
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advantage of antisense oligonucleotides is that they are less potent and shorter
lasting than siRNAs.9
RNA interference (RNAi) has received much attention since its initial
report in 1998 by Fire and Mello10 as a powerful strategy to alter gene ex-
pression, and a number of RNAi-based therapeutic strategies have progressed
to clinical trials (see Table 3.1). Inducers of the RNAi mechanism include en-
dogenous miRNA, synthetic siRNAs, and “vector based” short hairpin RNA
(shRNA). While the field of shRNA therapeutics is largely based on viral
vector transfection methods,11 a novel, orally administered, bacterial-based
system may offer an improved delivery strategy (see Table 3.2 for clinical tri-
als of shRNA-based therapeutics).12–14 siRNA has been an intense focus of
gene therapy researchers and its therapeutic potential has been likened to a
“magic bullet”15due to its potent, catalytic-type mechanism and specific gene
knockdown.
The mechanism of siRNA is characterized by degradation of a specific
mRNA sequence with a perfectly complementary sequence. Translation of the
mRNA sequence to proteins is therefore downregulated and gene expression is
silenced. The endogenous RNAi inducers miRNA,16 in contrast, may down-
regulate 250-500 different mRNA sequences that are partially complementary
by translational repression. Early research focused on the cytoplasm as the
site of action for RNAi, but later work has identified a role for RNAi in the
cell nucleus as well.11;17;18
Research continues to identify similarities in the RNAi mechanisms of
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siRNA and miRNA so that the basic classifications of Figure 3.1 are sub-
ject to some qualifications; each small RNA may act like the other. Per-
fect complementarity of the miRNA sequence results in mRNA degradation;19
likewise, siRNA may induce off-target effects that occur via a miRNA-like
mechanism through down-regulation of partially complementary mRNA se-
quences.20–22 This crossover should perhaps come as no surprise since before
being completely processed to mature, single-stranded miRNAs, pre-miRNAs
from the nucleus are processed into siRNA-like double-stranded RNA before
strand separation.19 The crossover can result in interference with endogenous
miRNA mechanisms.23 Another complication is that there are at least 3 classes
of action for siRNA, of which at least one is independent of the traditional
Argo/RISC mechanism.24
Recent studies have demonstrated that siRNA can provoke the innate
immune system into an inflammatory response,25–28 and this is particularly
troubling for the treatment of IBD whose strategy is to suppress the immune
response. For example, PKR (protein kinase R) “can react to as little as 11
base pairs of dsRNA in a nonsequence-specific fashion”27. Particularly for the
treatment of IBD which is connected with a abnormal immune response and
inflammation, an effective siRNA-based therapeutic must do more than silence
an important gene, it must also avoid causing an immune response and addi-
tional inflammation. Adding complexity to experimental design, since immune
stimulation is sequence-dependent, the use of a “scrambled” siRNA control is
insufficient to test for an innate immune response27. These interactions may
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be hybridization-independent, meaning the interaction is not dependent on
Watson and Crick RNA base pairing.29
3.3 Oral delivery of small RNAs and DNAs
Delivery of all types of oligonucleotides is challenging because the neg-
atively charged (anionic), water soluble molecules are large (molecular weight
~12,500 Da with 3 nm diameter and 5 nm height for siRNA30) with very low
membrane permeability.31;32 If the oligonucleotide is taken up by the cell, it
will still need to escape endosomal sequestration because the site of action is
the cytosol. The magnitude of these challenges is being met by an impressive
effort to design improved oligonucleotide delivery systems and a number of
excellent reviews22;33–47 have been published.
It is not surprising that early RNAi delivery efforts were focused on
disease targets amenable to site-specific delivery (either by direct injection or
topical application) such as ocular diseases where the drug could be injected
into the eye for a local, rather than systemic, effect. However, a number
of important disease targets are not amenable to direct injection or topical
application, resulting in widespread work in systemic delivery, particularly
intravenous injections.38;48–51 Delivery with a more patient-friendly, broad-
utility platform is needed.
Oral delivery systems may be less invasive than current treatments
to improve patient comfort and compliance.52 However, such systems would
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only be effective if they could protect the payload during transit to ensure
safe delivery of the oligonucleotide to the cytosol of the targeted cells (see
Figure 3.2). An oral oligonucleotide delivery system must provide protection
from the acidic gastric environment as well as from enzymatic attack from
nucleases until the drug is absorbed.52;53
Many proposed oral delivery systems include multicomponent design
with a cationic component to interact with the negatively charged siRNA. In
addition, many of these proposed systems are designed for intestine-specific
delivery to treat inflammatory bowel disease. A summary of the limitations
of proposed siRNA oral delivery systems is found in Table 3.3.
3.3.1 Chitosan modified poly(d,l-lactide-co-glycolide) nanospheres
(CS-PLGA NS) loaded with a transcription factor decoy
The chitosan modified poly(d,l-lactide-co-glycolide) nanospheres (CS-
PLGA NS) for delivery of a transcription factor decoy developed by Tahara
and associates54 use classical biomaterials to achieve colon-specific oral de-
livery of oligonucleotides; a representation of the system is shown in Figure
3.3a. The nanospheres are formed by the emulsion solvent diffusion method
(ESD) using ethanol/acetone organic phase with dissolved PLGA and com-
plexed siRNA/DOTAP and an aqueous phase with 2% w/v polyvinyl alcohol
(PVA).55 Although widely used for transfection studies and less toxic that
other cationic lipids, DOTAP can damage cells56 and thus may be another
regulatory concern. Advantages of the ESD method over other emulsion tech-
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niques include “mild conditions” (ethanol/acetone versus dichloromethane or-
ganic phase) as well as the use of propeller-type stirring rather than sonication,
which is more amenable to scale-up.55
Both chitosan modified and unmodified PLGA provided 4 hours of pro-
tection for the DNA cargo from DNase I degradation, and the chitosan modi-
fied PLGA also provided protection from acidic pH for 2 hours.54 While both of
these advantages should be noted, the use of the cationic lipid DOTAP intro-
duces cytotoxicity concerns analogous to those for the thioketal nanoparticles
developed by Wilson and associates.57 Cytotoxicity studies in vitro indicated
that the CS-PLGA NS showed “no adverse effects” for 2 and 24 h incubation
with up to 5 mg/ml concentrations.
The transcription factor decoy-loaded CS-PLGA NS proved an effec-
tive orally administered treatment for dextran sodium sulfate (DSS)-induced
experimental colitis in Wistar rats; however, dosing was high compared to
other oligonucleotide studies with 2 mg oligonucleotide per rat.54 The high
dose suggests that either the transcription factor decoys are inherently less
powerful than siRNA-based therapeutic strategies or that the delivery system
may not be as effective as other orally administered oligonucleotide delivery
systems. The high dose may be needed due to the burst release of as much
as 40% of the oligonucleotide, which will likely degrade before reaching the
cytosol. The author notes that an adding an enteric coating may improve the
“protective effect”54 so the oligonucleotide is less susceptible to degradation,
particularly in the gastric environment. Researchers noted greater adhesion
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and penetration for the nanospheres in inflamed versus non-inflamed tissues.54
This effect may be beneficial as the work of Wilson and associates suggests
that targeting delivery to sites of inflammation may improve overall efficacy.57
3.3.2 Eudragit® coated capsules with sodium caprate permeation
enhancer minitablets loaded with antisense oligonucleotides
The antisense oligonucleotide oral delivery system developed by Isis
Pharmaceuticals (Carlsbad, CA) uses two different Eudragit® coatings to
achieve site-specific delivery as well as time-delayed release of the sodium
caprate permeation enhancer.32;58 In vivo studies in beagle dogs and humans
reported an average plasma bioavailability of 1.4% (relative to IV) and 9.5%
(relative to subcutaneous dose),32 respectively, for the oligonucleotide.58 This
oral delivery systems is designed for systemic rather than intestinal delivery of
oligonucleotides, unlike the other reported oral delivery systems. As a result,
it may exhibit the problems associated with other systemic approaches such
as off-target effects, particularly in areas of oligonucleotide accumulation such
as the kidneys and liver.58
The Eudragit® L30 D55 (poly(methacrylic acid-co-ethyl acrylate) in
1:1 ratio) outer coating for the gelatin capsules32 is designed for pH-specific
delivery to the duodenum (first segment of the small intestine).59 Minitablets
for extended release of sodium caprate (C10) are contained within the gelatin
capsule (see Figure 3.3b); the minitablets are coated with Eudragit® RS30D,32
which is designed for time-controlled, pH-independent release and composed
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of a terpolymer of ethyl acrylate, methyl methacrylate, and low content of
methacrylic acid ester with quaternary ammonium groups present as salts.60
Sodium caprate is the sodium salt of the 10-carbon saturated fatty
acid capric acid (also known as decanoic acid), which is a naturally occur-
ring, dietary fatty acid that can be found in palm kernel and coconut oil.61
It has been used in Japan62 as well as Sweden (Doktacillin™)58 to improve
drug absorption; sodium caprate causes dilation of tight junctions, resulting
in increased paracellular transport.62;63 Sodium caprate has FDA approval as
a food additive is an emulsifier or binder food additive.64–67 While sodium
caprate is permitted as a food additive, its use as a pharmaceutical additive
must carefully evaluate its effect on intestinal epithelium. Caco-2 cell studies
demonstrate transient and reversible alterations in permeability;58 while no
wounds to cells are observed, recovery may take a few hours.62
3.3.3 Eudragit® coated capsules with bovine serum albumin (BSA)
encapsulated antisense oligonucleotides
Uddin and associates68 created a system for antisense oligonucleotide
oral delivery by microencapsulation of the antisense oligonucleotide with albu-
min. The antisense oligonucleotide-loaded albumin microspheres are created
using a spray-drying method. First, albumin is glutaraldehyde cross-linked for
24 h with continuous stirring followed by the addition of sodium bisulphate to
neutralize excess glutaraldehyde. Next, the antisense oligonucleotide drug is
added, and the mixture is spray-dried using a Büchi mini spray-dryer. The pro-
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cess produced 2 µm diameter spherical particles designed for ready uptake by
antigen-presenting cells such as macrophages. Tablets of albumin-encapsulated
oligonucleotide microspheres were coated with Eudragit L100-55 (see Figure
3.3c). The release kinetics of the enteric-coated tablets were evaluated us-
ing a standard drug dissolution experiment. The enteric coating prevented
premature release and the micro-encapsulation resulted in a sustained release
profile for 30+ h. The albumin microencapsulation improved the bioavailabil-
ity of antisense oligonucleotide following oral delivery compared to the naked
antisense oligonucleotide (70% versus 9% bioavailability).
3.3.4 β1,3-d-glucan-encapsulated siRNA particles (GeRPs) loaded
with siRNA
Oral delivery of siRNA was first reported in 2009 by Aouadi and asso-
ciates69 in a β1,3-d-glucan-encapsulated siRNA particles (GeRPs). The outer
β1,3-d-glucan shell was purified from baker’s yeast with base and solvent ex-
tractions followed by hydrolysis of the outer cell wall and cell contents. Using
a layer-by-layer approach to build the core and encapsulate the siRNA, the 2
to 3 µm porous, hollow shells were filled with negatively charged tRNA, posi-
tively charged polyethylenimine (PEI), negatively charged unmodified siRNA,
and then another PEI layer, like the representation shown in Figure 3.3d. The
GeRPs were targeted to the M cells of the Peyer’s patches in the intestines
in order to reach the gut-associated lymphatic tissue (GALT) located below.
Over time, the ingested GeRPs may migrate throughout the lymphatic tissue
55
away from the gut;69 the effects of this delocalization of the delivery system
need to be evaluated in order to anticipate possible off-target effects.
Studies in vitro with 106 macrophages concluded that “as little as 40
pmoles siRNA within GeRPs” resulted in 70 to 80% knockdown of the targeted
mRNA. Studies in vivo found gene silencing persisting for about 8 days in
mice following 8 days of oral gavage of about 20 µg siRNA / kg in 200 µl
containing about 108 GeRPs .69 The results are promising; this reported mass
of siRNA required to achieve knockdown per mass of mouse is competitive
with the best cationic lipid systems (10 to 20 µg siRNA / kg in mice).44 While
baker’s yeast is an extremely well characterized system, as with any system
containing natural components, the potential for significant and unexplained
batch-to-batch variation may exist. In addition, although PEI is widely used
in gene therapy, the polymer is cytotoxic70 and so may cause adverse effects.
3.3.5 Nanoparticles-in-microsphere oral system (NiMOS) loaded
with siRNA
The biodegradable nanoparticles-in-microsphere oral system (NiMOS)
developed by Amiji and colleagues was used for plasmid DNA delivery71–73 be-
fore its adaptation by Kriegel for siRNA delivery74;75. Poly(ε-caprolactone) mi-
crospheres (2 to 4 µm diameter) were loaded with type B gelatin nanoparticles
(280 nm diameter) containing “physically” encapsulated siRNA, such as the
representation in Figure 3.3e. The outer poly(ε-caprolactone) is stable to acidic
pH and so it protects the siRNA cargo during transit through the stomach,
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and the polymer is degraded by lipases in the intestines to release the siRNA-
loaded gelatin nanoparticles.74;75 The gelatin nanoparticles are degraded by
proteases to release the siRNA cargo. Early work found improved biodistribu-
tion with poly(ε-caprolactone) encapsulated gelatin nanoparticles compared
to the gelatin nanoparticles alone because gelatin degrades too rapidly during
gastrointestinal transit for effective delivery to the intestines.71
The NiMOS was evaluated in a murine model with 1.2 mg NiMOS/kg
dosing in 200 µl.74;75 While loading efficiencies of the final system are reported
as over 50%,75 the total siRNA content of the NiMOS as well as the siRNA
dosing of the in vivo studies seem to have been omitted from the reported
results. Acute colitis in mice was induced by treatment with dextran sul-
fate sodium (DSS). The DSS-treated mice were treated with the anti-TNF-α
siRNA-loaded NiMOS which achieved significant reductions in TNF-α con-
centrations so that the DSS-treated mice had “similar” concentrations as the
healthy control mice.75 Another study found that a “combined” treatment us-
ing two anti-inflammatory siRNAs was able to achieve a better outcome than
use of a single anti-TNF-α siRNA.74
An effective NiMOS for siRNA delivery to the intestines in a clinical
setting would require careful tuning to the specific transit time and degrada-
tion conditions characteristic of human physiology, which vary depending on
disease state. The broad, delocalized expression in both the small and large
intestines, identified in earlier work with the system and transfection with
plasmid DNA,71 may be undesirable for some applications; the siRNA studies
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indicate the large intestine was removed for analysis but no analysis of the
small intestine was included in the reports.74;75
3.3.6 Thioketal nanoparticles (TKNs) loaded with siRNA
The thioketal nanoparticle (TKN) system developed by Wilson and
associates57 uses specialized polymer chemistry to protect the siRNA from
degradation in the gastrointestinal tract and release the siRNA “specifically”
at sites of inflammation. The poly(1,4-phenyleneacetone dimethylene thioke-
tal) (PPADT) polymer resists acidic, basic, and enzymatic degradation but it
degrades in the presence of increased concentrations of reactive oxygen species
(ROS) characteristic of sites of intestinal inflammation. The 600 nm diameter
PPADT nanoparticles contain siRNA complexed with DOTAP (cationic lipid
1,2-dioleoyl-3-trimethylammonium-propane) (Figure 3.3f); the DOTAP gives
the nanoparticles an overall positive surface charge. The siRNA/DOTAP-
loaded nanoparticles are synthesized using a single emulsion; siRNA/DOTAP
complexed in dichloromethane and methanol is combined with PPADT dis-
solved in dichloromethane to form the organic phase and the aqueous phase
is composed of 5% polyvinyl alcohol (PVA) in pH 7.4 phosphate buffer saline
(PBS).57
Toxicity in vitro was reported as comparable to that of poly(lactic-co-
glycolic acid) (PLGA) siRNA loaded nanoparticles; no toxicity was detected up
to 5.0 mg/ml.57 While these toxicity results are positive, the chemicals used in
synthesis have serious known or suspected negative health effects, so regulatory
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approval of the final product might prove to be challenging. Benzene and
dichloromethane are the solvents used for the PPADT polymer synthesis and
emulsion, respectively; while subsequent purification steps should significantly
reduce the concentrations of benzene and dichloromethane to perhaps even
below limits of detection, the known potent carcinogenicity of benzene, and
suspected carcinogenicity of dichloromethane, mean that any residual solvent
could have adverse health effects in long-term use, such as for the management
of chronic disease.
Studies in vivo demonstrated that 5 days of oral gavage of 2.3 mg
siRNA/kg and 0.23 mg siRNA/kg achieved 10-fold and 3-fold, respectively,
decrease in the targeted mRNA concentration in the colon. The TKNs were
more effective than β-glucan particles (similar to those used by Aouadi and
associates69) at achieving mRNA reduction at the same 0.23 mg siRNA/kg
dose; β-glucan particles do not deliver siRNA specifically to sites of inflam-
mation, so the results suggest that targeting delivery to sites of inflammation
may improve the therapeutic efficacy.57
3.3.7 Nanoparticles made with chitosan loaded with siRNA
There are several reports in the literature of chitosan-based nanopar-
ticles for oral siRNA delivery. Chitosan may be chemically modified and
nanoparticles are formed using a double emulsion or by ionic gelation. The
chitosan nanoparticles may be used alone76–80 (as shown in Figure 3.3g) or




The chitosan/siRNA nanoparticles used by Ballarín-González and asso-
ciates80 represent the most straight-forward synthesis approach of the various
chitosan-based techniques; unmodified chitosan was combined with siRNA to
form nanoparticle complexes in a single-step process. These complexes were
approximately 150 nm in diameter, as determined using particle tracking anal-
ysis (see Figure 3.3g). Biodistribution experiments following oral administra-
tion to mice confirmed uptake of siRNA by the intestine and translocation to
the liver, spleen, and kidney. The chitosan conferred enhanced stability for the
siRNA, as confirmed using northern blotting and qPCR analysis. Although
the report does not include confirmation of siRNA-induced knockdown, the
enhanced stability and uptake of siRNA imparted by the chitosan (compared
to naked siRNA) demonstrates the advantages of carrier-enhanced delivery.
3.3.7.2 Thiolated trimethyl chitosan (TTMC), galactosylated
trimethyl chitosan–cysteine (GTC) nanoparticles, and
mannose-modified trimethyl chitosan-cysteine (MTC) con-
jugate nanoparticles
Zhang, et al. used thiolated trimethyl chitosan (TTMC)77 and galacto-
sylated trimethyl chitosan–cysteine (GTC) nanoparticles (NPs)78 for siRNA
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delivery (two separate reports), and the GTC nanoparticles were investigated
for use in siRNA oral delivery. Thiolated trimethyl chitosan (TTMC) was syn-
thesized by adding trimethyl and thiol groups to chitosan.77 Galactosylated
trimethyl chitosan–cysteine (GTC) contains galactose modifications in addi-
tion to the trimethyl and thiol groups.78 A related approach using chitosan
modified to contain sugar, trimethyl, and thiol groups was used by He and as-
sociates76 to create trimethyl chitosan-cysteine nanoparticles82 and mannose-
modified trimethyl chitosan-cysteine (MTC) conjugate nanoparticles.
The use of various functional groups represents an alternative approach
to designing multi-component systems for siRNA delivery; rather than mix-
ing or combining different components, the components are chemically bound
along the chitosan chain. The nanoparticles were formed by ionic cross-linking
of the positively charged chitosan with a negatively charged component such
as thiamine pyrophosphate (TPP),76 or in the case of the work by Zhang and
associates, TPP or hyaluronic acid.77;78 An siRNA/TPP or siRNA/hyaluronic
acid solution was added drop-wise to a solution of chitosan conjugate under
stirring. The nanoparticles had a positive surface charge, as determined using
dynamic light scattering, and an approximate diameter of 120 nm diameter for
the MTC-NPs and 150 nm for the GTC- and TTMC-NPs (see Figure 3.3g).
Both TTMC-NPs and GTC-NPs outperformed the Lipofectamine2000
(a commercially available transfection reagent) control to induce significant
knockdown in vitro for RAW264.7 murine macrophage cells.77;78 Biodistribu-
tion experiments confirmed that the TTMC-NPs promoted intestinal absorp-
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tion of siRNA (compared to naked siRNA), and their success was attributed to
enhanced intestinal stability and permeation.77 The GTC-NPs were used for
oral delivery of Map4k4 siRNA to mice with DSS-induced colitis. A dose of 250
μg Map4k4 siRNA/kg/day for seven days resulted in significant knockdown in
the mRNA of Map4k4 and TNF-α in colonic tissue (92.1% and 69.0%, respec-
tively). Treatment with MAP4k4 siRNA GTC-NPs resulted in no significant
weight loss, no significant colon shortening, and improvements in histology
such as minimal damage and neutraphil infiltration, as compared to signifi-
cant weight loss, colon shortening, and evidence of abnormality, cell death,
and neutraphil infiltration in PBS-treated mice with DSS-induced colitis.78
For the MTC-NPs, the knockdown efficiency in vitro in RAW264.7 cells
of the MTC-NPs exceeded that of the Lipofectamine2000 for the knockdown
of TNF-α, and the MTC nanoparticles demonstrated negligible cytotoxicity.
Studies in vivo demonstrated increased siRNA concentration (compared to
naked siRNA) in the liver, spleen, lung, and intestine of mice. Delivery of
anti-TNF-α siRNA using MTC nanoparticles resulted in significant TNF-α
knockdown in the liver, lung, and spleen of mice. The MTC nanoparticles
outperformed β1,3-d-glucan-encapsulated siRNA particles (GeRPs) in vivo,
requiring less siRNA (3.75 nmol/kg versus 12 nmol/kg) to achieve the same
knockdown.76
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3.3.7.3 N -((2-hydroxy-3-trimethylammonium) propyl) chitosan
chloride (HTCC) nanoparticles
The chitosan-based system developed by Wei and associates79 makes
use of a Shirasu porous glass membrane emulsification technique for
size control rather than the TPP-based ionic gelation scheme used by
Zhang and associates77;78 and He and associates.76 The N -((2-hydroxy-3-
trimethylammonium) propyl) chitosan chloride (HTCC) is a partially quat-
ernized derivative of chitosan with good cell-adhesion as well as permeation-
enhancing effects.79 The 150 nm diameter nanoparticles are formed by an
oil/water/oil double emulsion method which permits loading of paclitaxel
nanocrystals in addition to siRNA (see Figure 3.3g).
In vitro studies with mouse telomerase reverse transcriptase (mTERT)
siRNA demonstrated that the HTCC nanoparticles successfully delivered
siRNA to cells to induce knockdown. In order to enhance the anti-tumor
efficacy, paclitaxel was incorporated to create a dual-delivery system. Tumor-
bearing mice were treated with nanoparticles with 0.2 μg siRNA/kg/day and
6.5 μg paclitaxel/kg/day, and treatment resulted in significantly inhibited tu-
mor growth and increased survival time compared to mice treated with naked
mTERT siRNA.
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3.3.7.4 Chitosan/siRNA and polyethylenimine (PEI)/siRNA com-
plexes combined with polylactide (PLA), coated with
polyvinyl alcohol (PVA) and encapsulated in chi-
tosan/alginate hydrogel
The multicomponent systems developed by Laroui and associates are
designed to protect the siRNA during gastrointestinal transit and to release
the payload in the colon using a pH-responsive hydrogel.81 Synthesis is a com-
plicated, multistep process of complexation: a single emulsion followed by a
double emulsion, purification of the nanoparticles, and then encapsulation in a
chitosan/alginate hydrogel.81;83 The system’s complexity (as illustrated in Fig-
ure 3.3i) represents a fundamental barrier to clinical use. The PEI-containing
nanoparticles had improved loading, protection, and transfection compared to
the chitosan containing nanoparticles.
The chitosan (see Figure 3.3g) and PEI (see Figure 3.3h) nanoparti-
cles contain 9.6 ng siRNA/mg and 15.2 ng siRNA/mg, respectively. The PEI-
containing nanoparticles are 300-500 nm in diameter at pH 6-7 (size of chitosan
nanoparticles not given). The cationic polymer (chitosan or PEI) complexed to
the siRNA is designed to reduce burst release in order to increase the fraction
of drug that makes it to the delivery site; after 30 minutes in PBS buffer, only
about 30% of the siRNA was released from the PEI/siRNA complexes (identi-
fied as an “optimal” result”),81 while without a complex, a burst effect is typi-
cally observed. The PEI-containing nanoparticles were evaluated in vitro and
they demonstrated improved cell viability and transfection compared to the
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transfection agent Lipofectamine without resulting in macrophage inflamma-
tion. The siRNA-loaded PEI-containing nanoparticles in an alginate/chitosan
hydrogel were administered orally in mice at 5 mg NP/ml hydrogel;81 the total
volume administered is not specified, so the total quantity of siRNA admin-
istered is unclear. The treatment significantly reduced concentrations in the
colon as well as blood of the targeted TNF-α, but not liver concentrations.
While the therapeutic effect was not truly site-specific to the intestines, it is
promising that the treatment did not alter the concentration of TNF-α cy-
tokines in the liver because systemic anti-TNF-α approaches using biological
therapeutics have been limited by “profound systemic toxicity”81 that alters




Table 3.1: Clinical trials for RNAi therapeutics. Information was gath-
ered from a variety of sources including ClinicalTrials.gov, company press
releases, and reports in the literature. Updates about the status of
clinical trials can be found at ClinicalTrials.gov with the NCT number;
http://clinicaltrials.gov/show/NCT#.
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Table 3.2: Clinical trials for shRNA therapeutics. Information was gath-
ered from a variety of sources including ClinicalTrials.gov, company press
releases, and reports in the literature. Updates about the status of
clinical trials can be found at ClinicalTrials.gov with the NCT number;
http://clinicaltrials.gov/show/NCT#.
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Table 3.3: Disadvantages of current oral delivery systems for oligonucleotides
reported in the literature.
Oral siRNA delivery systems
reported in the literature
Limitations of the reported
oral siRNA delivery systems
Chitosan modified
poly(d,l-lactide-co-glycolide)
nanospheres (CS-PLGA NS) with
a transcription factor decoy54;55
- low delivery efficiency
- burst release
- PLGA is expensive84




- designed for systemic delivery
Eudragit® coated capsules with
albumin-encapsulated antisense
oligonucleotides
- designed for systemic delivery
β1,3-d-glucan-encapsulated siRNA
particles (GeRPs) with siRNA69
- complicated, multistep,
multicomponent synthesis
- 5 layer system
- 2 yeast-derived components
Nanoparticles-in-microsphere oral
system (NiMOS) with siRNA74;75
- delivery not colon-specific
Thioketal nanoparticles (TKNs)
with siRNA57










Figure 3.1: Overview of transcription factor decoys, antisense oligonucleotides,
small interfering RNA and microRNA. A table by Mack19 containing specifics
for siRNA and miRNA is available in the literature. Abbreviations: bp: base
pairs, nt: nucleotides, RISC: RNA induced silencing complex, Argo: Arg-
onaute 2 protein in RISC responsible for mRNA cleavage20
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Figure 3.2: Delivery challenges for polymer carrier and oligonucleotide cargo:
a) acidic pH, b) nucleases, c) mucus layer, d) cell membrane, e) endosomal
membrane, for final f) release into the cytosol.
72
Figure 3.3: Oral delivery systems for small RNA and DNA. Images are shown
as schematics and scale bars are approximate. a) Chitosan modified poly(d,l-
lactide-co-glycolide) nanospheres (CS-PLGA NS) with transcription factor de-
coy oligonucleotides, b) Eudragit® coated capsules with sodium caprate per-
meation enhancer minitablets and antisense oligonucleotides, c) Eudragit®
coated capsules with bovine serum albumin (BSA) encapsulated antisense
oligonucleotides, d) β1,3-d-glucan-encapsulated siRNA particles (GeRPs) e)
Nanoparticles-in-microsphere oral system (NiMOS) with siRNA, f) Thioke-
tal nanoparticles (TKNs) with siRNA, g) chitosan nanoparticles with siRNA,
h) Polyethylenimine (PEI)/siRNA complexes, i) PEI/siRNA complexes with
siRNA combined with polylactide (PLA), coated with polyvinyl alcohol (PVA)
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Polycationic Nanoparticles Synthesized Using
ARGET ATRP for Drug Delivery
4.1 Introduction
Advances in controlled radical polymerization technology create op-
portunities for new biomaterials for drug delivery that have seen widespread
interest. These biomaterial carriers require well-controlled, advanced prepara-
tion techniques to achieve controlled molecular structures for the final prod-
uct. Both RAFT (reversible addition-fragmentation chain transfer polymeriza-
tion)1;2 and ATRP (atom transfer radical polymerization)3;4 are used for the
synthesis of these new classes of biomaterials that seek to translate improved
control over architecture into improved technologies for biomedical applica-
tions. ATRP biomaterials have been reported to have improved colloidal sta-
bility,5;6 pH-responsiveness,5 and degradation upon inclusion of a degradable
cross-linking agent as well as increased swelling ratios6;7 compared to bioma-
terials produced using traditional radical polymerization techniques. These
controlled radical polymerization techniques are characterized by propagating
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radicals “that are deactivated reversibly” such that there is an “equilibrium”
between active and dormant chains.8 The instantaneous concentration of prop-
agating radicals is kept low because at any time, most of the chains are in a
dormant state, which in turn minimizes transfer and termination reactions.8
In contrast, in traditional free radical polymerization, the propagating chains
lack a dormant state and are instead quickly terminated irreversibly,9 resulting
in greater heterogeneity than with controlled polymerization techniques.10
A recently developed variety of ATRP, termed Activators ReGenerated
by Electron Transfer (ARGET) ATRP, is particularly attractive for bioma-
terial synthesis because unlike most types of controlled radical polymeriza-
tions, it can occur in the presence of limited air11 and requires relatively low
concentrations of copper catalyst that are significantly lower than traditional
ATRP.12 ARGET ATRP avoids UV-initiation, which confers advantages in-
cluding ease of conducting multiple simultaneous reactions, synthesis protocols
that can be scaled without consideration of the UV light source intensity and
duration, as well as the ability to use photosensitive components such as dyes
or biologically derived components in the polymerization reaction.
Drug delivery carriers may increase therapeutic efficacy compared to
free drug due to avoiding rapid clearance,13 preventing enzymatic degradation
of the therapeutic,14 or bypassing efflux pumps with chemotherapeutic-loaded
nanoparticles.15 Carriers may also permit new modes of administration, such
as the oral delivery of siRNA,16 chemotherapeutic agents, or fragile proteins.17
In the case of nucleic acid-based therapeutics such as siRNA where
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delivery remains the most important challenge,18 drug delivery carriers can
facilitate uptake of the siRNA19 and prevent degradation by nucleases.20 Most
commonly reported siRNA carriers include synthetic cationic polymers, such
as PEI,21 or lipid-based nanoparticles;22 however, concerns exist regarding
cytotoxicity of certain cationic lipid and polymers particles.23
Determining if the new techniques result in better drug delivery bio-
materials requires direct comparison data for the two polymerization meth-
ods. Existing comparative studies between ATRP and traditional free radical
polymerizations report improved performance for traditional ATRP synthe-
sized materials,5–7 but additional work is needed to see if this improvement
occurs in other systems that have been better optimized for traditional free
radical polymerization or for ARGET ATRP synthesized biomaterials. This
work converts a previously optimized traditional free radical photoemulsion
nanoparticle synthesis24;25 to an ARGET ATRP-based scheme and provides a
systemic comparison of ARGET ATRP and UV-initiated nanoparticles. The
ARGET ATRP synthesis in water represents, to the best knowledge of the
authors, the first report of an ARGET ATRP synthesis of cross-linked poly-
cationic nanoparticles in water26 without an inverse (continuous oil phase)
emulsion.27 The resulting polycationic hydrogel nanoparticles may be used for
the delivery of proteins such as insulin,25 oligonucleotides such as siRNA,13 as
well as co-delivery of siRNA with small molecule drugs.
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4.2 Materials and methods
4.2.1 Chemicals
Poly(ethylene glycol) methyl ether methacrylate (PEGMA) solu-
tion (Mn 2000 for PEG chain, 50 wt% in water), 2-(diethylamino)
ethyl methacrylate (DEAEMA), tert-butyl methacrylate (tBMA), tetraethy-
lene glycol dimethacrylate (TEGDMA), ethyl 2-bromoisobutyrate (EBIB),
tris(2-pyridylmethyl)amine (TPMA), myristyltrimethylammonium bromide
(MyTab), ascorbic acid, trypsin-EDTA solution, and Dulbecco’s Modified Ea-
gle’s Medium (DMEM) - high glucose without l-glutamine, penicillin, strep-
tomycin, and fluorescein were purchased from Sigma-Aldrich.
1 N Hydrochloric acid (HCl), 1 N sodium hydroxide, 10x phosphate
buffered saline (PBS), sodium chloride, monosodium phosphate monohydrate,
and disodium phosphate heptahydrate were purchased from Fisher Scientific,
Brij-30® and Copper(II) bromide were purchased from Acros Organics, and
Irgacure 2959 was purchased from Ciba Specialty Chemicals Corp. Dimethyl
Sulfoxide 99+% (DMSO) was purchased from Alfa Aesar. Amicon® Centri-
con® centrifuge filter devices, 15 ml, MW Cut Off 30,000 were purchased from
Millipore and 12,000-14,000 MW cut off Dialysis tubing was purchased from
Spectra/Por® . Ultrapure water was used for all studies. All chemicals were
used as received.
1xPBS without calcium and magnesium and 200 mM l-glutamine so-
lution (MediaTech), CellTiter 96® AQueous Non-Radioactive Cell Proliferation
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Assay (MTS) and CytoTox-ONE Homogeneous Membrane Integrity Assay
from Promega, Thermo Scientific HyClone USDA Tested Fetal Bovine Serum
and Thermo Scientific Nunc Microwell 96-well Microplates were used for cell
culture experiments. L929 and PANC-1 cells were obtained from American
Type Culture Collection (ATCC) and sheep blood in citrate buffer was pur-
chased from Hemostat Laboratories. KDalert™ GAPDH Assay Kit, Lipofec-
tamine® 2000 Transfection Reagent, Silencer® GAPDH siRNA, and Silencer®
Negative Control #1 were purchased from Life Technologies .
4.2.2 Nanoparticle synthesis and purification
This work represents the first reported use of ARGET ATRP to synthe-
size cationic nanoparticles, the first reported use of an oil-in-water emulsion
for the ARGET ATRP synthesis of hydrogel nanoparticles, and one of the
first reports of ARGET ATRP-based techniques in water. The newly reported
ARGET ATRP synthesis technique stands out due to its ease of execution;
it does not require rigorous exclusion of air or inhibitors and it does not re-
quire a UV source for initiation. As a result, the reaction can be conducted
without applying vacuum, freeze-pump-thaw cycles, or other techniques typi-
cally required for controlled radical polymerizations. Commercially available
monomers may be used without removing the inhibitor prior to the reaction.
Avoiding UV-initiation confers advantages including ease of conducting mul-
tiple simultaneous reactions, synthesis protocols that can be scaled without
consideration of the UV light source intensity and duration, as well as the
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ability to use photosensitive components such as dyes or biologically-derived
components in the polymerization reaction. The technique is relatively rapid
(3 hour reaction time) and the synthesis does not make use of organic solvents.
Cross-linked polymer nanoparticles were synthesized using a UV-
initiated polymerization previously developed by Fisher and colleagues24 or a
newly developed ARGET ATRP.28 Briefly, a mixture of 2-(diethylamino) ethyl
methacrylate (DEAEMA), poly(ethylene glycol) methyl ether methacrylate
(where Mn of PEG chain is 2000) (PEGMA), tetraethylene glycol dimethacry-
late (TEGDMA), and tert-butyl methacrylate (tBMA) was combined with an
aqueous solution of 8 mg/ml Brij® 30 and 1.35 mg/ml myristyltrimethylam-
monium bromide (MyTab) for a 0.1 weight ratio of monomer to solvent.
For the UV-initiated polymerization, Irgacure® 2959 was added at a
0.005 weight ratio initiator to monomer. For the ARGET ATRP polymeriza-
tion, copper(II) bromide (CuBr2), tris(2-pyridylmethyl)amine (TPMA), and
ethyl 2-bromoisobutyrate (EBIB) were added at CuBr2:TPMA:EBIB::0.5:0.5:4
with respect to 100 mol of DEAEMA in the feed. See Figure 4.2 for the
reagents used for nanoparticle synthesis.
Following probe sonication for 10 min at amplitude 90 using a S-
4000 Misonix Ultrasonicator, the mixtures were purged with nitrogen for 20
min. The UV-initiated polymerization was reacted by exposure to a UV light
source (Dymax BlueWave™ 200 UV) for 2.5 h at 140 mW/cm2 with con-
stant stirring. The ARGET ATRP polymerization was reacted for 3 h with
constant stirring following addition of degassed ascorbic acid solution (ascor-
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bic acid:DEAEMA::0.5:100). Purification was done by a technique described
previously by Fisher and Peppas.25 Briefly, 1 N hydrochloric acid (HCl) was
added to the reaction mixture (equal volumes) and after 30 min, the poly-
mer nanoparticles were precipitated with acetone. A pellet of the precipitated
nanoparticles was formed by centrifugation at 3200 RCF (relative centrifugal
force) and the supernatant removed. The pellet was resuspended in 0.5 N HCl
and the process was repeated 4 more times. The nanoparticles were finally
re-suspended in water, dialyzed, and freeze dried.
As shown in Table 4.1, 4 formulation were investigated: 30UV, 45UV,
30ARGET, 45ARGET, where the number describes the moles of tBMA in the
feed per 100 mol DEAEMA, and UV or ARGET describes the polymerization
technique. The 30UV formulation is analogous to that reported by Fisher
et al.24 and Liechty et al..29 The polycationic nanoparticles are represented
schematically in Figure 4.1.
4.2.3 Characterization
4.2.3.1 Light scattering
The z-average diameter and zeta potential were measured using a
Malvern ZetaSizer NanoZS instrument equipped with a 633 nm laser source
and MPT-2 Autotitrator. Zeta potential and the z-average diameter of 0.5
mg/ml nanoparticles were measured in water and 5 mM phosphate buffer at
pH 6.5 and 7.4. The z-average diameter was also measured in pH 7.4 PBS. The
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pH-responsive swelling was determined as the z-average diameters in water;
the autotitrator increased the pH to 10 and then stepwise decreased the pH
while measuring the z-average diameter.
4.2.3.2 TEM
Nanoparticles were imaged using a FEI Tecnai Transmission Electron
Microscope (TEM) (80 kV) with 16,500x to 220,000x magnification. A 0.02
mg/ml suspension of freeze-dried particles in water was drop-cast onto a
Formvar-coated 400 mesh copper grid (Electron Microscopy Sciences) and
stained with 2% uranyl acetate immediately before imaging.
4.2.3.3 Cytotoxicity
Fibroblast L929 and Adenocarcinoma Pancreatic PANC-1 cells were
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 1% l-glutamine, and 1% penicillin and
streptomycin. Cells were seeded at 10,000 cells per well in 96 well plates and
incubated for 48 h before testing. For the MTS assay, following 2 h incubation
of cells with nanoparticles, particles were removed and cells were rinsed 2 x
with sterile PBS. Next, the cells were incubated for 3 h with the MTS assay
in DMEM without phenol red with 2% FBS. The supernatant was transferred
to a transparent plate, the 690 nm (background) and 490 nm (MTS assay)
absorbance (A) was measured using a microplate reader (Synergy HT, BioTek
Instruments, Inc.), and relative cell viability (V) was calculated as:
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V = A490, sample − A690, sample − (A490, bleach − A690, bleach)
A490 media − A690, media − (A490, bleach − A690, bleach)
(4.1)
For the CytoTox-ONE Homogeneous Membrane Integrity Assay, L929
cells were incubated with nanoparticles for 1 h, and the assay used according
to the manufacturer’s instructions. The fluorescence was measured using a
microplate reader (Synergy HT, BioTek Instruments, Inc., Winooski, VT) at
530 nm excitation and 590 nm excitation.
4.2.3.4 Hemolysis
Hemolysis at extracellular (pH 7.4) and endosomal (pH 6.5) pH con-
ditions30 was done using sheep blood in 150 mM phosphate buffer. Hemoly-
sis was used to investigate membrane disruption caused by the polycationic
nanoparticles that is relevant for endosomal escape and cytotoxicity. Briefly,
blood was centrifuged, the supernatant removed, and washed 3x with isotonic
sodium chloride. The red blood cells were resuspended in phosphate buffer at
pH 6.5 or 7.4, combined with nanoparticles suspended in phosphate buffer of
the same pH, and incubated for 1 h at 37ºC.
Following centrifugation, the absorbance (A) of the supernatant was
measured at 541 nm as an indicator of hemolytic activity or membrane dis-
ruption (HA), calculated as:
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HA = A541, sample − A541, phosphate buffer
A541, deionized water − A541, phophate buffer
(4.2)
4.2.3.5 Fluorescein loading and release
A 10 ml suspension of 2 mg/ml nanoparticles in 10 mM (1x) PBS at
pH 4.3 was confined to a dialysis bag and submerged in 91 ml of 10.9 μg/ml
fluorescein in PBS at pH 4.3 for 24 h with agitation for loading of the swollen
nanoparticles with fluorescein. 1 N sodium hydroxide was added to increase
the pH of the solution to pH 8.4, and the loaded nanoparticles inside the
dialysis bag were recovered by centrifugation with a Centricon® tube at 3500
rpm for 35 min. The centrifuged particles were recovered, resuspended in 5
ml 10 mM (1x) PBS pH 7.4, and placed in another dialysis bag for the release
study (also with agitation). After 2 h of release at pH 7.4 in 50 ml PBS
at pH 7.4, the pH was decreased to 4.3 using 1 N hydrochloric acid, and the
release study continued. Fluorescence was measured using a microplate reader
(Synergy HT, BioTek Instruments, Inc., Winooski, VT) at excitation 485 nm
and emission 528 nm.
4.3 Results and discussion
Monodisperse polycationic nanoparticles were synthesized using both
ARGET ATRP and UV-initiated polymerization. The best performing for-
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mulations were biocompatible with membrane disruption tuned for endosomal
disruption.
4.3.1 Dynamic light scattering
Dynamic light scattering (DLS) studies were performed using a Malvern
ZetaSizer NanoZS instrument equipped with a 633 MPT-2 Autotitrator. The
values of the z-average diameter and polydispersity index (PDI) of the formu-
lations measured with dynamic light scattering are shown in Table 4.2. It is
clear that diameter increases at lower pH; the diameter at pH 6.5 was greater
than the diameter at pH 7.4. The formulations with a feed ratio of 45 mol
tBMA (per 100 mol DEAEMA in the feed) had poor colloidal stability in 10
mM (1x) PBS at pH 7.4, which was observed as flocculation or aggregation
upon addition of 10x PBS to non-aggregated nanoparticles in water. The AR-
GET ATRP formulations had larger diameters and smaller PDI values than
the corresponding UV-initiated formulations.
The pH-responsive swelling profile of the polymer nanoparticles is
shown in Figure 4.3. The 30ARGET formulation appears to swell more than
the corresponding UV-initiated formulation 30UV. For both 30 mol tBMA
formulations 30ARGET and 30UV, the onset of pH-responsive swelling was
approximately the same pH value. Note that the reported pK a values for
DEAEMA range from 6.6831 to 7.0-7.3.32 The 45UV and 45ARGET formula-
tions were not colloidally stable at high pH values, so as a result, pH-responsive
swelling could not be measuring using DLS.
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The zeta potential values of the four formulations are shown in Table
4.3. All particles have positive surface charge, which will promote complexa-
tion with negatively charged siRNA. The ARGET ATRP formulations have
greater surface charge than the corresponding UV-initiated formulations. Both
45 mol tBMA formulations have low cytotoxicity, but for the 30 mol tBMA
formulations, decreased surface charge correlates with decreased cytotoxicity.
4.3.2 TEM
Dried nanoparticles were suspended in water at 0.02 mg/ml, drop-cast
onto a Formvar-coated 400 mesh copper grid and stained with 2% uranyl
acetate immediately before imaging. Transmission electron microscopy (TEM)
demonstrates that the dried particles are approximately spherical as shown in
Figure 4.4 and that minimal aggregation was observed.
4.3.3 MTS assay
Fibroblast (L929) and Adenocarcinoma Pancreatic (PANC-1) cells were
used to determine biocompatibility of the different types of polycationic
nanoparticles (see Figure 4.5). Cell viability was assessed using MTS assay
after 2 h of incubation with nanoparticles. Both cell lines present similar re-
sponses when exposed to the nanoparticles, and the MTS results correlate with
the LDH assay results. Formulation 45ARGET demonstrates no toxicity at
low concentrations and low toxicity (80% viability for L929 and PANC-1) at
the highest concentration of 5 mg/ml. Formulation 45UV presents no toxicity
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at any of the concentrations studied. Cells incubated with 30UV nanopar-
ticles present toxicity at concentrations greater than 1 mg/ml; cell viability
was reduced to 0% for the highest concentration of 5 mg/ml. Formulation
30ARGET presents toxicity at all the concentrations studied, except for the
lowest concentration of 0.039 mg/ml. For 30ARGET, cell viability was reduced
down to 0% at 2.5 mg/ml. The half maximal inhibitory concentration (IC50)
of 45ARGET and 30UV nanoparticles was found to be approximately 0.625
mg/ml and 2.5 mg/ml, respectively, for both cell lines. Formulations contain-
ing 45 mol tBMA per 100 mol DEAEMA in the feed were less toxic than the
corresponding 30 mol tBMA formulations for both cell lines. ARGET ATRP
synthesized nanoparticles have greater toxicity than UV-initiated formulations
with corresponding feed concentrations. It appears that both tBMA content
and polymerization method affect biocompatibility of the nanoparticles.
4.3.4 Membrane disruption
Hemolysis at endosomal (pH 6.5) and extracellular (pH 7.4) pH values30
was studied using sheep blood in phosphate buffer at various concentrations
exposed to nanoparticles for 1 h. The proposed delivery system for siRNA is
designed for oral administration and so will not come into contact with the
blood. As a result, hemolysis experiments do not have the goal of studying
biocompatibility of the biomaterial with components of the blood, but instead,
hemolysis is used to investigate membrane disruption caused by the polyca-
tionic nanoparticles that is relevant for endosomal escape and cytotoxicity.
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All formulations except for the 30ARGET exhibited pH-dependent
hemolytic activity and strong hemolytic activity at all concentrations at pH
6.5 (Figure 4.6). At endosomal pH of 6.5, the hemolytic activity of 30AR-
GET at concentrations lower than 0.25 mg/ml was lower than that of the
other formulations; however, at pH 7.4, all concentrations of 30ARGET are
more hemolytic. The strong hemolytic activity at endosomal pH (pH 6.5) and
low hemolytic activity at extracellular pH (pH 7.4) was designed to minimize
cytotoxicity while maximizing endosomal escape. The hemolytic activity of
45UV was negligible at all concentrations, while 30UV and 45ARGET each
show some hemolytic activity at the highest concentrations of 2 mg/ml and 1
mg/ml.
The membrane disruption measured using hemolysis correlates with
membrane disruption evaluated using a lactate dehydrogenase (LDH) assay
(see Figure 4.7). For the CytoTox-ONE Homogeneous Membrane Integrity
Assay, L929 cells were incubated with nanoparticles for 1 h, and the assay
used according to the manufacturer’s instructions. Lysis fraction describes the
fraction of dead cells. The 30UV formulation has the greatest lysis fraction
and pH 7.4 hemolytic activity. While the formulations 30UV and 45ARGET
show some hemolytic activity at the highest concentrations of 2 mg/ml and
1 mg/ml, they have negligible lysis fractions. The 45UV formulation also
does not cause lysis. The high membrane integrity functions correlate with
low hemolytic activity at physiological conditions, showing that cytotoxicity
is due to cell membrane disruption.
101
4.3.5 Fluorescein loading and release
Fluorescein has been widely used as a model chemotherapy drug due
to its similarity in molecular weight and hydrophobicity to chemotherapeutic
agents. Fluorescein loading and release using different types of previously
swollen nanoparticles was studied. Such studies may be relevant for using the
polycationic nanoparticles as part of a co-delivery system (siRNA and small
molecule chemotherapeutic) for the treatment of cancer.
Particles were suspended in low pH buffer with fluorescein for 24 h.
Nanoparticles containing 30 mol tBMA (per 100 mol DEAEMA in the feed)
presented a greater loading efficiency compared with nanoparticles containing
45 mol tBMA (see Figure 4.8 and Table 4.4). As a result, the loading efficiency
of fluorescein correlates with the swelling behavior. As previously discussed,
nanoparticles with 30 mol tBMA have greater colloidal stability at high pH and
so present a better swelling profile, regardless of the polymerization method.
Release of fluorescein from nanoparticles was studied at pH 7.4 and at
low pH 4.3 (see Figure 4.9 and Table 4.4). Fluorescein release from ARGET
ATRP formulations is significantly lower than particles polymerized by the
UV-initiated method. Formulation 30UV releases more fluorescein than 30AR-
GET and 45ARGET, probably due to the fact that the loading efficiency and
the swelling were greater. 45UV nanoparticles released a surprising amount
of fluorescein, particularly considering that these particles loaded less fluores-
cein than the 30UV and their swelling profile is worse. This could be due to
altered solubility due to increased hydrophobic content; recall 45UV nanopar-
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ticles have less colloidal stability than 30UV. Surface charge effects could also
play a role in loading and release; the nanoparticles contain DEAEMA which
is protonated at low pH while fluorescein contains carboxyl groups that may
also be affected by pH, hence affecting loading and release.
4.4 Conclusion
This work provides a systemic comparison of ARGET ATRP and UV-
initiated polycationic nanoparticles for drug delivery of hydrophobic drugs to
the cytoplasm. ARGET ATRP nanoparticles present lower biocompatibility
and drug release when compared to the same formulation polymerized by UV,
despite having similar loading profiles. Hydrophobic content of nanoparti-
cles has negative consequences on the swelling and colloidal stability of the
nanoparticles; however, increased hydrophobicity improves biocompatibility.
These results apply to the formulations tested but should not be extended to
a complete range of formulations without additional testing. This work pro-
vides a guide to deciding what type of nanoparticles have the best properties




Table 4.1: Key to formulation nomenclature. UV-initiated and ARGET ATRP
formulations were prepared with 30 and 45 mol tBMA per 100 mol DEAEMA
in the feed. The abbreviations 30UV, 45UV, 30ARGET, and 45ARGET are
used throughout the text to identify the formulations.
UV-initiated ARGET ATRP
30 mol tBMA per 100 mol
DEAEMA in the feed
30UV 30ARGET
45 mol tBMA per 100 mol
DEAEMA in the feed
45UV 45ARGET
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Table 4.2: Z-average diameter and polydispersity index (PDI) for the 30UV,
45UV, 30ARGET, and 45ARGET formulations. Z-average diameter and poly-
dispersity measured using dynamic light scattering with Malvern ZetaSizer
NanoZS instrument in 5mM phosphate buffer (PB) at pH 7.4 and 6.5 as well
as 10 mM (1x) phosphate buffered saline (PBS) at pH 7.4.
Z-average diameter, nm Polydispersity index (PDI)
Formulation PB 7.4 PB 6.5 PBS 7.4 PB 7.4 PB 6.5 PBS 7.4
30UV 71.83 83.09 83.33 0.211 0.185 0.289
45UV 69.68 88.27 74.23 0.233 0.358 0.230
30ARGET 130.2 146.6 147.2 0.148 0.060 0.134
45ARGET 98.29 115.3 106.1 0.212 0.210 0.208
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Table 4.3: Zeta potential measured with Malvern ZetaSizer NanoZS instru-
ment in 5 mM phosphate buffer at pH 7.4 and 6.5 and water.
Zeta potential, mV
Formulation PB 7.4 PB 6.5 water
30UV 6.57 14.4 38.0
45UV 5.54 6.88 40.9
30ARGET 13.3 17.9 42.4
45ARGET 13.2 21.8 45.4
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Table 4.4: Fluorescein loading and release. Polycationic nanoparticles (2
mg/ml) were loaded via equilibrium partitioning with fluorescein (10.9 μg/ml)
while swollen at pH 4.3 for 24 h. Release experiments were conducted in 1x
PBS and at 120 min, pH was decreased from pH 7.4 to pH 4.3.
Formulation Percent loading, % Total release
30UV 65% 14.68 μg
45UV 42% 51.62 μg
30ARGET 56% 5.59 μg
45ARGET 53% 2.04 μg
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Table 4.5: Material properties summary for the 30UV, 45UV, 30ARGET, and
45ARGET formulations. Good swelling is characterized by a colloidal stabil-
ity at high pH values that permits accurate determination of the unswollen
diameter using DLS. Cytotoxicity was evaluated using cancerous (PANC-1
pancreatic adenocarcinoma) and noncancerous (L929 fibroblast) cells using an
MTS assay. Hemolytic activity serves as a measure of membrane disruption.




30UV Good Medium Low High
45UV Poor Good Low High
30ARGET Good Poor High Medium




Figure 4.1: Schematic representation of the polycationic nanoparticle. The
location of PEG, DEAEMA, and tBMA is influenced by hydrophobicity, with
the hydrophilic PEG dominating the surface and the hydrophobic tBMA in
the core. The PEG, DEAEMA, and tBMA do not form three distinct layers, as
represented by the overlapping, spiked cartoon figure. The negatively charged
siRNA complexes with the positively charged DEAEMA, and the hydrophobic
fluorescein associates with the hydrophobic tBMA in the core.
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Figure 4.2: Reagents used in synthesis. Monomers: a) 2-(diethylamino) ethyl
methacrylate (DEAEMA) b) poly(ethylene glycol) methyl ether methacrylate
(PEGMA) (average molecular weight of PEG is 2000), c) tert-butyl methacry-
late (tBMA). Cross-linking agent: d) tetraethylene glycol dimethacrylate
(TEGDMA). Initiator: e) ethyl 2-bromoisobutyrate (EBIB). Ligand: f) tris(2-
pyridylmethyl)amine (TPMA). Reducing agent: g) ascorbic acid.
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(a) Formulations with 30 mol tBMA per 100 mol
DEAEMA in the feed

























(b) Formulations with 45 mol tBMA per 100 mol
DEAEMA in the feed
Figure 4.3: pH-responsive swelling of polycationic nanoparticles (0.5 mg/ml
in water). Nanoparticles were prepared using UV-initiated polymerization or
ARGET ATRP with 30 or 45 mol tBMA with respect to 100 mol DEAEMA in
the feed. Formulations with high feed ratios of tBMA (45UV and 45ARGET)
were not colloidally stable at high pH values; z-average diameters greater than
200 nm at high pH values are not shown. Z-average diameter values measured
using dynamic light scattering with Malvern ZetaSizer NanoZS instrument
equipped with MPT-2 Autotitrator.
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(a) 30UV (b) 30ARGET
(c) 45UV (d) 45ARGET
Figure 4.4: Transmission electron microscopy (TEM) shows spherical dried
polycationic nanoparticles (magnification 26,500 x, FEI Tecnai Transmission
Electron Microscope, 80 kV). A suspension of freeze-dried particles in water
at 0.02 mg/ml was drop-cast onto a Formvar-coated 400 mesh copper grid and






























































Figure 4.5: Cytotoxicity of polycationic nanoparticles for noncancerous (L929
mouse fibroblasts) and cancerous (PANC-1 pancreatic carcinoma) cells evalu-



































































(b) Extracellular: pH 7.4
Figure 4.6: Hemolysis as measure of membrane disruption at endosomal and
extracellular pH values. Sheep blood was washed with isotonic sodium chlo-
ride, resuspended in 150 mM phosphate buffer at pH 6.5 or 7.4, combined with
polycationic nanoparticles suspended in phosphate buffer of the same pH, and
incubated for 1 h. Membrane disruption was determined using absorbance of










































































































































































































Figure 4.7: Increased hemolytic activity at pH 7.4 correlates with increased
fraction of cells with membrane disruption. Hemolytic activity measured using
sheep blood rinsed with isotonic sodium chloride, resuspended in phosphate
buffer, and then exposed to polycationic nanoparticles. The fraction of lysed
cells was determined using a CytoTox-ONE™ Homogeneous Membrane In-
tegrity Assay with L929 cells that were exposed to polycationic nanoparticles
at same concentrations and for same duration as the hemolysis assay. A lysis



















































Figure 4.8: Fluorescein loading into polycationic nanoparticles. 2 mg/ml poly-
cationic nanoparticles were loaded via equilibrium partitioning with 10.9 μg/ml
fluorescein while swollen at pH 4.3 for 24 h. Following loading, the pH was in-
creased and the polycationic nanoparticles recovered using centrifugation with
a Centricon® tube.
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Figure 4.9: Fluorescein release from nanoparticles in 1xPBS. At 120 min,
pH was decreased from pH 7.4 to pH 4.3. Fluorescence measured using a
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Polycationic Nanoparticles for siRNA
Delivery: Comparing ARGET ATRP and
UV-initiated Formulations
5.1 Introduction
Drug delivery systems for siRNA have been extensively studied; how-
ever, the challenges associated with safe and effective delivery continue to
prevent widespread translation of the new technology from the bench to the
clinic.1–9 Oligonucleotides such as siRNA are susceptible to degradation by en-
dogenous nucleases, and as a result, require a protection mechanism. Other de-
livery challenges include effective cellular uptake and endosomal escape; siRNA
must be inside the cytosol (rather than sequestered in a sub-cellular compart-
ment) to have a therapeutic effect.
Some cell types, such as primary cells,10 cells of the central nervous
system,11 and macrophage-type cell lines12 are considered difficult to trans-
fect, while other cell types such as HEK293T are widely used for siRNA screen
experiments. For examples of siRNA knockdown in the literature for represen-
126
tative “easy” and “difficult” cell types see Table 5.1 and Table 5.2 (HEK293T
and RAW264.7, respectively). Note that since a brief search for articles refer-
encing siRNA in a major literature search service reveals 100,000s of articles,
and these articles likely represent 1,000s-10,000s distinct delivery strategies
to 10s-100s of cell types, the types listed in the tables represent only a small
fraction of the siRNA delivery experiments reported in the literature.
Effective drug delivery vehicles must demonstrate siRNA binding,
low cytotoxicity, effective cellular uptake, and most importantly, evidence
of siRNA-induced knockdown. This work evaluates polycationic nanoparti-
cles synthesized by either ARGET ATRP (activators regenerated by electron
transfer atom transfer radical polymerization) or UV-initiated polymerization
and examines their suitability as siRNA delivery vehicles to HEK293T and
RAW264.7 cells.
5.2 Materials and methods
5.2.1 Chemicals
Poly(ethylene glycol) methyl ether methacrylate (PEGMA) solu-
tion (Mn 2000 for PEG chain, 50 wt% in water), 2-(diethylamino)ethyl
methacrylate (DEAEMA), tert-butyl methacrylate (tBMA), tetraethylene gly-
col dimethacrylate (TEGDMA), ethyl 2-bromoisobutyrate (EBIB), tris (2-
pyridylmethyl) amine (TPMA), ascorbic acid (AA), trypsin-EDTA solution,
and Dulbecco’s Phosphate Buffered Saline (DPBS, Sigma-Aldrich) were pur-
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chased from Sigma-Aldrich. 1 N Hydrochloric acid (HCl) was purchased from
Fisher Scientific. Copper(II) bromide was purchased from Acros Organics.
Ultrapure water was used for all studies. All chemicals were used as received.
5.2.2 Nanoparticle synthesis and purification
P(DEAEMA-co-tBMA-co-PEGMA-co-TEGDMA) polycationic
nanoparticles were synthesized using a previously reported activators
regenerated by electron transfer atom transfer radical polymerization
(ARGET ATRP) technique13;14 or a UV-initiated polymerization tech-
nique previously developed by Fisher and colleagues15. Briefly, reagents
DEAEMA:PEGMA:TEGDMA:CuBr2:TPMA:EBIB at molar ratios of
100:10:4:0.5:0.5:4 (with tBMA with a molar ratio of 30 or 45 depending on
the formulation) were combined with 8 mg/ml Brij® 30 (Acros Organics) and
1.35 mg/ml myristyltrimethylammonium bromide (MyTab, Sigma-Aldrich)
in water for a 0.1 weight ratio of monomer to solvent. For the UV-initiated
polymerization, Irgacure® 2959 (Ciba) was added at a 0.005 mass ratio of
initiator to monomer in place of CuBr2:TPMA:EBIB.
Following probe sonication (S-4000 Misonix Ultrasonicator, Misonix
Inc.) and nitrogen purge, the ARGET ATRP and UV-initiated polymeriza-
tions were reacted at ambient temperature for 3 h by the addition of degassed
ascorbic acid solution as a reducing agent (AA: DEAEMA::0.5:100) or for 2.5
h by exposure to UV light (Dymax BlueWave™200 UV), respectively. Purifi-
cation was done by a technique described previously by Fisher and Peppas16
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with repeated precipitation/resuspension with acetone/0.5 N HCl. Following
dialysis (12,000-14,000 molecular weight cut off regenerated cellulose tubing,
Spectra/Por®), polymer was recovered by freeze-drying.
5.2.3 Binding of siRNA
Nanoparticles were loaded with AllStars Negative Control siRNA (Qi-
agen) in 1x PBS pH 5.5 (0.125 mg/ml nanoparticles and 500nM siRNA). Nu-
clease free 10x PBS was prepared by dissolving sodium chloride, potassium
chloride, monosodium phosphate monohydrate, and disodium phosphate hep-
tahydrate (Fisher Scientific) in water, treating with 0.1% v/v diethylpyrocar-
bonate (DEPC, Fisher Scientific) overnight, and then autoclaving to remove
DEPC. The bound siRNA was determined within 10 min of combining the
siRNA with the nanoparticles and then again after 70 min and 160 min in
order to evaluate the effect of loading time. The siRNA binding was also eval-
uated at 0.025 mg/ml nanoparticles and 100 nM siRNA in 0.2x PBS pH 5.5, 1x
PBS pH 5.5, 1x PBS pH 7.4, and Opti-MEM® (Reduced Serum Medium, no
Phenol Red, Life Technologies) at approximately 30 minutes after combining
the siRNA with the nanoparticles in order to evaluate the amount of siRNA
released in conditions prior to uptake by cells.
The fraction of bound siRNA was determined using a Quant-iT™ Ri-
boGreen® RNA Assay Kit (Life Technologies) that was adapted for 384-well
low volume plates. Briefly, a 10 µl sample was combined with 10 µl Ribo-
Green® assay solution (RiboGreen® reagent diluted 200x in 1x TE buffer) in
129
a black 384-well low volume plate. The fluorescence intensity (F) was mea-
sured using a microplate reader (Synergy HT, BioTek Instruments, Inc.) 2-5
min after adding the RiboGreen® assay solution with 485 nm excitation and
528 nm emission. The RiboGreen® reagent is sensitive to components other
than RNA present in the assay (although the importance of these contribu-
tions diminished for increasing siRNA concentrations), so these contributions
to the fluorescence were subtracted from the measured fluorescence signal to
calculate the percent of loading (L) in Equation 5.1:
L=100×
(
1 − Fnanoparticle + siRNA complex − Fnanoparticle only





Human Embryonic Kidney 293T cells (HEK293T) and murine
macrophage RAW264.7 cells (obtained from American Type Culture Col-
lection) were maintained in Dulbecco’s Modified Eagle’s Medium high glu-
cose without L-glutamine (Sigma-Aldrich) supplemented with with 1% L-
glutamine (MediaTech), 1% penicillin (Sigma-Aldrich), 1% streptomycin
(Sigma-Aldrich), and 10% HyClone USDA Tested Fetal Bovine Serum (FBS,
Thermo Scientific). Opti-MEM® Reduced Serum Medium, no Phenol Red
(Life Technologies) was used for all cytotoxicity and transfection experiments.
Lipofectamine and Lipofectamine2000 (Life Technologies) were used as con-
trols in transfection experiments.
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5.2.4.1 Nanoparticle cytotoxicity
HEK293T cells were seeded at 5,000 cells/well on fibronectin (Sigma-
Aldrich) coated 96 well plates (0.4 μg/well in 75 µl/well DPBS for 45 min) and
RAW264.7 cells were seeded at 10,000 cells per well in 96 well plates without
fibronectin coating (Nunc, Thermo Scientific). After 18 h incubation, the
media was replaced with Opti-MEM®. The nanoparticles were prepared at 5x
concentration in 1x PBS pH 5.5 and then added to cells at a final concentration
of 1x in the wells following 1 h incubation with Opti-MEM®.
Following 48 h incubation, media was removed and cells were incu-
bated for 90 min with CellTiter 96® AQueous Non-Radioactive Cell Prolif-
eration Assay (MTS, Promega) with serum-free DMEM without phenol red
(Sigma-Aldrich). The absorbance (A) at 690 nm (background) and 490 nm
(MTS assay) was measured using a microplate reader (Synergy HT, BioTek
Instruments, Inc.), and cell relative viability (V) was calculated as shown in
Equation 5.2:
V = A490, sample − A690, sample − (A490, no cells − A690, no cells)
A490 media − A690, media − (A490, no cells − A690, no cells)
(5.2)
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5.2.4.2 Flow cytometry to quantify uptake of fluorescently-labeled
siRNA
Flow cytometry was used to quantify siRNA internalization. Flow cy-
tometry measurements were collected using a BD Fortessa Flow Cytometer
and analyzed using FACSDiva software (BD Biosciences). 120,000 HEK293T
cells or 240,000 RAW264.7 cells were plated in 6 well plates (Nunc, Thermo
Scientific) and incubated for 40 h. Next, cells were incubated for 2 h with
0.05 mg/ml polycationic nanoparticles or appropriate controls with 200 nM
fluorescently-labeled DY647 siRNA (Thermo Scientific). Controls included
Lipofectamine and Lipofectamine 2000 (5 µl/well) as well as siRNA-only
and untreated controls. Following incubation, cells were rinsed twice with
cold 1xDPBS pH 7.4 prior to treating with trypsin (HEK293T) or scraping
(RAW264.7) to form a cell suspension. The cell suspension was centrifuged,
the supernatant discarded, pellet resuspended in flow cytometry buffer (1%
FBS in DPBS), centrifuged again, supernatant discarded, and finally the pel-
let resuspended in flow cytometry buffer. The samples were stored in darkness
at 4 °C before measurement. The results are reported in two ways: as the
average percent of cells (taken over a large number of cells, typically 10,000)
containing fluorescently-labeled DY647 siRNA and as the mean fluorescence
intensity of the sample normalized to the fluorescence intensity of the blank
control. All results are reported as the average plus/minus the standard devi-
ation of three independent experiments.
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5.2.4.3 Confocal microscopy to verify siRNA internalization
Cover slips (18 mm round, no. 1.5 thickness) were acid washed
overnight with 1 N HCl at 60 °C, rinsed with ethanol/water mixtures with
successively increasing volume ratios of ethanol, and then the cover slips were
placed in a 12 well plate. Prior to plating the HEK293T cells, the acid-washed
cover slips in a 12 well plate were coated with fibronectin (4 μg fibronectin/well
in 750 µl/well DPBS); no fibronectin coating was used for the RAW264.7
cells. HEK293T and RAW264.7 cells were added at 40,000 cells/well and
80,000 cells/well, respectively. Cells were incubated for 40 h prior to 2 h in-
cubation with 0.05 mg/ml polycationic nanoparticles or appropriate controls
with 200 nM siRNA. Controls included Lipofectamine and Lipofectamine 2000
(2.5 µl/well) as well as siRNA-only and untreated controls. Following incu-
bation, cells were rinsed three times with 1xPBS pH 7.4 and fixed with 4%
paraformaldehyde in 1xDPBS for 10 min prior to washing three times with
HBSS (BioWhittaker) and once with DI water (autoclaved). Cover slips were
mounted to glass slides using Prolong® Gold anti-fade reagent with DAPI (Life
Technologies) and stored in the freezer prior to imaging.
Confocal images were acquired using a Zeiss LSM 710 confocal micro-
scope with a 63x objective. The gain and offset for the different channels were
kept constant for the full series of images of each cell type (with the settings
for the HEK293T and RAW264.7 cell types optimized separately) to permit
image comparisons. Images were collected in 16 bit format, and all images un-
derwent identical post-processing (γ=0.45 for red and blue channels, γ=0.1.3
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for brightfield, and brightfield scale adjusted to max/min using ZEN Blue).
5.2.4.4 Transfection with AllStars Death siRNA
Transfection conditions were matched to those used for cytotoxicity.
HEK293T cells were seeded at 5,000 cells/well on fibronectin (Sigma-Aldrich)
coated 96 well plates (0.4 μg/well fibronectin in 75 µl/well DPBS for 45 min)
and RAW264.7 cells were seeded at 10,000 cells per well in 96 well plates with-
out fibronectin coating (Nunc, Thermo Scientific). After 18 h incubation, the
media was replaced with Opti-MEM®. The nanoparticles were combined with
siRNA (AllStars Hs Cell Death siRNA or AllStars Mm/Tn Cell Death siRNA,
Qiagen) in 1xPBS pH 5.5 at 0.125 mg/ml nanoparticles and 5x the final siRNA
concentration. The complexes were added to cells at a final concentration of
0.025 mg/ml in the wells (with 100 nM or 200 nM siRNA) following 1 h incuba-
tion with Opti-MEM®. Lipofectamine and Lipofectamine2000 wells contained
0.25 µl/well Lipofectamine or Lipofectamine2000. Following 48 h incubation,
media was removed and cell death visually confirmed. Viability was evaluated
as for cytotoxicity experiments (cells were incubated for 90 min with MTS
solution, and the absorbance was measured with a plate reader). The results
for viability for the AllStars Death and the Scrambled siRNA were compared
by Student’s t-test (two-tailed, unequal variance) to check for statistically sig-
nificant knockdown. The knockdown efficiency was evaluated using the cell
viability (V) ratio of cells with Death siRNA and cells with scrambled siRNA








5.3 Results and discussion
5.3.1 Binding of siRNA
The loading efficiency of the polycationic nanoparticles is related to
the siRNA binding, and the binding of siRNA to polycationic nanoparticles
was evaluated using the RiboGreen® assay. The siRNA demonstrates efficient
loading even after 10 minutes, with 85-91% loading efficiency for all polyca-
tionic nanoparticle formulations (Figure 5.1). After 70 min incubation, the
loading efficiency demonstrates a nominal increase to 96-98% efficiency for all
polycationic nanoparticle formulations, and this efficiency persists after 160
min. Based on the negligible increase in siRNA from 10 min to 70 min, the
siRNA/nanoparticle complexes were used shortly after preparation (approxi-
mately 10 minutes after adding the siRNA) rather than after a longer incu-
bation. At all time points, there is no significant difference in siRNA binding
among the four formulations.
The siRNA demonstrates very efficient binding (~98% for all formu-
lations) in 0.2x PBS pH 5.5, likely due to positive charge induced by low
pH combined with low ionic strength (Figure 5.2). Across all formulations,
the siRNA binding follows the following decreasing trend: 0.2xPBS pH 5.5 >
1xPBS pH 5.5 > 1xPBS pH 7.4 > Opti-MEM®. For the 1xPBS pH 7.4 and
135
the Opti-MEM®, the 30UV and 30ARGET formulations demonstrate slightly
higher binding efficiencies than the corresponding 45UV and 45ARGET formu-
lations. The 45ARGET formulation demonstrates the lowest binding efficiency
in Opti-MEM® of the four formulations, with 55% of the siRNA bound to the
polymer (compared to 74% for 30UV, 70% for 45UV, and 63% for 30ARGET).
The reduced binding efficiency for 45ARGET compared to the other formula-
tions may be a factor in determining knockdown efficiency; however, it is one
factor among many.
5.3.2 Nanoparticle cytotoxicity
The biocompatibility of the polycationic nanoparticles with HEK293T
cells and RAW264.7 cells was evaluated using an MTS assay following 48 h
incubation with the nanoparticles (see Figure 5.3). Both cell lines demonstrate
high relative viability at low concentrations (greater than 80% viability at
0.025 mg/ml and lower concentrations). In HEK293T cells, formulations 45UV
and 45ARGET show increased biocompatibility compared to the 30UV and
30ARGET formulations; for example, at 0.05 mg/ml, the 45UV and 45ARGET
formulations demonstrate 60% and 78% viability, respectively, while the 30UV
and 30ARGET formulations demonstrate 18% and 21% viability, respectively.
In the RAW264.7 cells, biocompatibility is less dependent on formula-
tion. The biocompatibility of the polycationic nanoparticle formulations with
the RAW264.7 cells is indistinguishable at the upper two (0.2 mg/ml and 0.1
mg/ml) and lower two (0.00313 mg/ml and 0.00156 mg/ml) concentrations.
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Both 30ARGET and 45ARGET show a slightly increased viability compared
to 30UV and 45UV at 0.05 mg/ml and 0.025 mg/ml in RAW264.7 cells. At
0.0625 mg/ml, the 30ARGET shows increased viability compared to the other
three formulations (100% versus 74-82% viability. All formulations demon-
strated low viability in both cell types at the highest concentration tested (0.2
mg/ml).
5.3.3 Flow cytometry to quantify uptake of fluorescently-labeled
siRNA
Flow cytometry was used to evaluate the internalization of
fluorescently-labeled siRNA. The percent of cells associated with fluorescently-
labeled siRNA and the normalized fluorescent intensity for each formulation
are shown in Figure 5.4 and Figure 5.5, respectively, with representative his-
tograms shown in Table 5.3. All polycationic nanoparticles demonstrated ef-
ficient uptake with slight differences among formulations in the percentage of
cells with fluorescently-labeled siRNA. However, the difference between cell
types is more significant. When the siRNA is delivered with polycationic
nanoparticles, a greater percentage of RAW264.7 cells than HEK293T cells
shows fluorescence of DY647 siRNA. For the polycationic nanoparticle for-
mulations with HEK293T cells, 50.8% to 60.8% of cells are associated with
fluorescently-labeled siRNA; likewise, the comparable values for the RAW264.7
cells are 66.0% to 84.5%. In contrast, when the siRNA is delivered with Lipo-
fectamine or Lipofectamine2000, the RAW264.7 cells do not show increased
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association compared to HEK293T. Another important difference between the
cell types is the no-carrier siRNA-only control, which demonstrates strong as-
sociation with the HEK293T cells but not the RAW264.7 cells. The cause of
this association is unclear, as naked siRNA is negatively charged, and thus
tends to resist transport through the negatively charged cell membrane. As
flow cytometry cannot distinguish between surface bound and internalized
fluorescence signal, it is likely the strong siRNA-only signal is membrane-
associated rather than internalized, and this result may be confirmed with
confocal microscopy.
For both cell types, 45UV and 45ARGET demonstrate greater nor-
malized fluorescence intensity than the corresponding 30UV and 30ARGET
formulations. The formulation 45ARGET demonstrates the largest normal-
ized fluorescence intensity of the four polycationic nanoparticle formulations.
Although the difference is slight between the normalized fluorescent intensity
for the polycationic nanoparticle formulations between cell types, as a function
of normalized fluorescence intensity, the Lipofectamine and Lipofectamine2000
have a much larger signal for the HEK293T cells than for the RAW264.7. Also,
the Lipofectamine and Lipofectamine2000 have greater normalized fluorescent
intensities than the polycationic nanoparticle formulations.
5.3.4 Confocal microscopy to verify siRNA internalization
Flow cytometry does not distinguish between surface bound and inter-
nalized fluorescence signal, so confocal microscopy was used to verify siRNA
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internalization. HEK293T cells or RAW264.7 cells were incubated 2 h with
DY647 fluorescently-labeled siRNA complexed with polycationic nanoparti-
cles or controls (200 nM siRNA and 0.05 mg/ml polycationic nanoparticles).
Cells were rinsed, fixed, stained with DAPI nuclear stain, and then mounted to
microscope slides. Settings for image acquisition and processing were kept con-
sistent during the experiment for each cell type to permit direct comparisons
within each cell type.
The trends observed with flow cytometry are supported by confocal mi-
croscopy. Representative images for the HEK293T and RAW 264.7 confocal
microscopy experiments are shown in Figure 5.6 and Figure 5.7, respectively.
For the HEK293T cells, visual inspection confirms greater DY647 fluorescence
for the 45UV and 45ARGET formulations compared to the corresponding
30UV and 30ARGET formulations. Likewise, the Lipofectamine and Lipo-
fectamine2000 images show more DY647 fluorescence than the polycationic
nanoparticles. These microscopy results are consistent with the flow cytom-
etry results. Interestingly, the microscopy results for the 30UV and 45UV
suggest a diffuse fluorescence rather than the punctate fluorescence observed
for the 30ARGET and 45ARGET formulations. The results of the flow cytom-
etry and confocal microscopy experiments using fluorescently-labeled siRNA
indicate evidence of internalization necessary for siRNA-induced knockdown.
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5.3.5 Transfection with AllStars Death siRNA
Knockdown efficiency induced by siRNA was evaluated using AllStars
Hs Cell Death siRNA or AllStars Mm/Tn Cell Death siRNA. HEK293T cells
were transfected for 48 h with 0.025 mg/ml polycationic nanoparticles (or ap-
propriate controls) and 100 nM or 200 nM siRNA following 1 h incubation with
Opti-MEM®. Cell death was confirmed visually and viability was evaluated
using an MTS assay.
The ability of the polycationic nanoparticles to effectively deliver
siRNA was first demonstrated in HEK293T cells with 0.025 mg/ml polyca-
tionic nanoparticles and 200 nM AllStars Hs Cell Death siRNA (see Figure
5.8). All of the siRNA delivery carriers demonstrated knockdown, with the
greatest efficiency demonstrated by the 30UV, 30ARGET, and 45ARGET for-
mulations (78%, 84%, and 75% knockdown efficiency, respectively). Unfortu-
nately, this increased knockdown efficiency is associated with decreased cell
viability.
When the polycationic nanoparticle is kept constant at 0.025 mg/ml
and the siRNA concentration is decreased to 100 nM, the HEK293T cells with
scrambled siRNA demonstrate improved viability; as a result, later studies
used this 100 nM siRNA concentration (see Figure 5.9a and Figure5.10a).
While this change results in increased HEK293T cell viability, it also results
in decreased knockdown efficiency and increased variation. There was statisti-
cally significant knockdown (p<0.05) for the 30UV, 30ARGET, and 45ARGET
formulations (41%, 51%, and 48%, respectively) as well as the Lipofectamine
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commercially available transfection agent (28% knockdown).
Knockdown in RAW264.7 cells using 100 nM AllStars Mm/Tn Cell
Death siRNA was evaluated using the four nanoparticle formulations as well
as two commercially available transfection agents Lipofectamine and Lipofec-
tamine2000 (see Figure 5.9b and Figure5.10b). Statistically significant knock-
down (p<0.05) was observed for all four nanoparticle formulations (knock-
down efficiency of 27%, 34%, 35%, and 25%, respectively) and also for the
Lipofectamine2000 control (41%). The RAW264.7 cells are considered to be
more difficult to transfect than HEK293T cells, and this is supported by the
decreased transfection efficiency and cell viability with the RAW264.7 cells
compared to the HEK293T.
5.4 Conclusion
The purpose of the studies undertaken in this report was to provide
an analysis of four formulations of polycationic nanoparticles and examine
their suitability as siRNA delivery vehicles to HEK293T and RAW264.7 cells.
The polycationic nanoparticles demonstrate effective siRNA loading and good
biocompatibility at low concentrations in vitro. Uptake experiments using
flow cytometry and confocal microscopy confirmed siRNA internalization us-
ing fluorescently-labeled siRNA loaded in polycationic nanoparticles. The per-
cent of cells with fluorescently-labeled siRNA uptake was similar across the
four formulations, with the RAW264.7 cells demonstrating a greater percent
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of cells with fluorescently-labeled siRNA than the HEK293T cells. However,
although all four formulations led to approximately the same percent of cells
with fluorescently-labeled siRNA, the 45ARGET formulation demonstrated a
greater normalized fluorescence intensity than the other polycationic nanopar-
ticle formulations. Knockdown experiments demonstrated knockdown follow-
ing transfection, with the nanoparticle formulations performing on par with
the commercially available carriers. This work indicates that the polycationic
nanoparticles may have utility as siRNA delivery vehicles, but additional re-




Table 5.1: Examples from the literature: transfection of HEK293 cells with
siRNA. DCC: deleted in colorectal cancer, (E)GFP: (enhanced) green fluores-
cent protein, ELISA: enzyme linked immunosorbent assay, mPEG: methoxy-
poly(ethylene glycol), PCL: poly(ε-caprolactone), RT-PCR: reverse transcrip-
tase polymerase chain reaction

















































Table 5.2: Examples from the literature: transfection of RAW264.7 cells with
siRNA. Unfortunately, macrophage-type cells like like RAW264.7 are difficult
to transfect.12 (E)GFP: (enhanced) green fluorescent protein, ELISA: enzyme
linked immunosorbent assay, PEI: polyethylenimine, PLGA: poly(lactide-co-
glycolide), RT-PCR: reverse transcriptase polymerase chain reaction, TNF-α:
tumor necrosis factor-α





































































Table 5.3: Representative flow cytometry histograms for uptake of
fluorescently-labeled siRNA by HEK293T and RAW264.7 cells. Data collected
using a BD Fortessa flow cytometer and analyzed using FACSDiva software.
Cells were incubated for 2 h with 0.05 mg/ml polycationic nanoparticles or






















































Figure 5.1: Binding of siRNA to polycationic nanoparticles. Nanoparticles
were loaded with AllStars Negative Control siRNA in 1x PBS pH 5.5 with
0.125 mg/ml nanoparticles and 500 nM siRNA. Binding of siRNA evaluated

















































0.2x PBS pH 5.5
1x PBS pH 5.5
1x PBS pH 7.4
OptiMEM
Figure 5.2: Binding of siRNA to polycationic nanoparticles in PBS buffers
and Opti-MEM®. Following loading of 0.125 mg/ml nanoparticles with 500
nM siRNA, complexes were diluted 5x in 0.2x PBS pH 5.5, 1x PBS pH 5.5,






































































(b) Biocompatibility of RAW264.7
Figure 5.3: Biocompatibility of polycationic nanoparticle formulations with a)
HEK293T cells or b) RAW264.7 cells at various concentrations (0.02 mg/ml




































































Figure 5.4: HEK293T or RAW264.7 cells associated with fluorescently-labeled
DY647 siRNA. Cells were incubated for 2 h with 0.05 mg/ml polycationic
nanoparticles or appropriate controls with 200 nM fluorescently-labeled DY647
siRNA. Following incubation, cells were rinsed and suspended for flow cytom-
etry analysis with a BD Fortessa Flow Cytometer. Data are expressed as the



























































(a) Normalized fluorescent intensity for fluorescently-


























































(b) Normalized fluorescent intensity for fluorescently-
labeled DY647 siRNA with RAW264.7 cells
Figure 5.5: a) HEK293T or b) RAW264.7 cells associated with fluorescently-
labeled DY647 siRNA. Cells were incubated for 2 h with 0.05 mg/ml polyca-
tionic nanoparticles or appropriate controls with 200 nM fluorescently-labeled
DY647 siRNA. Following incubation, cells were rinsed and suspended for flow
cytometry analysis with a BD Fortessa Flow Cytometer. Data are expressed
as the mean plus or minus the standard deviation of three independent exper-
iments. The data are normalized by dividing by the fluorescence intensity of
the blank PBS-only control. 152
Figure 5.6: Internalization of fluorescently-labeled siRNA in HEK293T cells.
Cells were incubated 2 h with 200 nM DY647 fluorescently-labeled siRNA
complexed with 0.05 mg/ml polycationic nanoparticles or controls prior to
rinsing, fixing, DAPI staining, and mounting. Staining of the cells: blue is
DAPI stained nuclei and red is DY647 fluorescently-labeled siRNA. 5000 nm
scale bars, 63x magnification, γblue=γred=0.45; γbrightfield=1.3.
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Figure 5.7: Internalization of fluorescently-labeled siRNA in RAW264.7 cells.
Cells were incubated 2 h with 200 nM DY647 fluorescently-labeled siRNA
complexed with 0.05 mg/ml polycationic nanoparticles or controls prior to
rinsing, fixing, DAPI staining, and mounting. Staining of the cells: blue is
DAPI stained nuclei and red is DY647 fluorescently-labeled siRNA. 5000 nm











































































































(b) HEK293T knockdown with 200 nM siRNA
Figure 5.8: Delivery of AllStars Death siRNA to HEK293T cells using poly-
cationic nanoparticle carriers. The complexes were added to cells at a final
concentration of 0.025 mg/ml and 200 nM in the wells following 1 h incuba-
tion with Opti-MEM®. The polycationic nanoparticles were evaluated versus
Lipofectamine (0.25 μl/well), Lipofectamine2000 (0.25 μl/well), and no-carrier
controls with an MTS assay following 48 h incubation. Pound signs (#) in (a)







































































































































(b) RAW264.7 knockdown with 100 nM siRNA
Figure 5.9: Delivery of AllStars Death siRNA to a) HEK293T or b) RAW 264.7
cells using polycationic nanoparticle carriers. The complexes were added to
cells at a final concentration of 0.025 mg/ml and 100 nM in the wells following 1
h incubation with Opti-MEM®. The polycationic nanoparticles were evaluated
versus Lipofectamine (0.25 μl/well), Lipofectamine2000 (0.25 μl/well), and no-
carrier controls with an MTS assay following 48 h incubation. Asterisks (*)








































































(b) RAW264.7 knockdown versus viability for 100 nM
siRNA
Figure 5.10: Knockdown efficiency versus viability for a) HEK293T or b) RAW
264.7 cells. Knockdown efficiency was evaluated following 48 h transfection
with 0.025 mg/ml polycationic nanoparticles and 100 nM siRNA following 1 h
incubation with Opti-MEM®. The polycationic nanoparticles were evaluated
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Polymeric Nanocarriers for siRNA Delivery to
Murine Macrophages
6.1 Introduction
Cationic polymers have been investigated as biomaterials for
drug delivery of nucleic acids, and polymers containing DEAEMA
(2-(diethylamino)ethyl methacrylate) or the related DMAEMA (2-
(dimethylamino)ethyl methacrylate) have been investigated by many
groups for the delivery of DNA1–11 as well as siRNA5;12–23 to cells (see Table
6.1 and Table 6.2). Effective siRNA delivery depends on complex interactions
among the siRNA, carrier, and cells of interest. Undesirable cellular toxicity
is a common challenge for polycationic carriers, especially since there seems to
be a trade-off between transfection efficiency and cellular toxicity.24 Another
challenge for researchers working to design improved delivery vehicles is
that the observed transfection efficiency often does not correlate directly
with carrier or siRNA uptake;25 in other words, the carrier with the best
transfection efficiency is not necessarily the one with the most efficient cellular
164
uptake.
This work investigates the interactions of a polycationic nanoparticle
carrier synthesized by activators regenerated ARGET ATRP (activators regen-
erated by electron transfer atom transfer radical polymerization) with siRNA
cargo and RAW264.7 cell delivery sites. The polycationic nanoparticle and
siRNA interactions are probed using a fluorescent assay as well as light scat-
tering techniques, and the polycationic nanoparticle and RAW264.7 cell in-
teractions are investigated using fluorescently-labeled nanoparticles combined
with confocal microscopy or flow cytometry. Finally, the use of these ARGET
ATRP polycationic nanoparticles as siRNA delivery carriers to RAW264.7 cells
is investigated through concentration-dependent transfection experiments.
6.2 Experimental section
6.2.1 Chemicals
Reagents poly(ethylene glycol) methyl ether methacrylate (PEGMA)
solution (Mn 2000 for PEG chain, 50 wt % in water), 2-(diethylamino)ethyl
methacrylate (DEAEMA), tert-butyl methacrylate (tBMA), tetraethylene gly-
col dimethacrylate (TEGDMA), ethyl 2-bromoisobutyrate (EBIB), tris (2-
pyridylmethyl) amine (TPMA), and ascorbic acid (AA) were purchased from
Sigma-Aldrich. Ethanol, 1 N Hydrochloric acid (HCl), sodium chloride, potas-
sium chloride, monosodium phosphate monohydrate, disodium phosphate hep-
tahydrate, and phosphate buffered saline (PBS) were purchased from Fisher
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Scientific. Copper(II) bromide was purchased from Acros Organics. Ultrapure
water was used for all studies. All chemicals were used as received.
6.2.2 Nanoparticle synthesis and purification
The polycationic nanoparticles were synthesized using a previously re-
ported technique.26;27 Monomers (DEAEMA, PEGMA, tBMA), cross-linking
agent (TEGDMA), catalyst (CuBr2), ligand (TPMA), and initiator (EBIB)
were combined at molar ratios of 100:10:45:4:0.5:0.5:4. The reagents were
added to a surfactant solution (8 mg/ml Brij® 30 (Acros Organics) and 1.35
mg/ml myristyltrimethylammonium bromide (MyTab, Sigma-Aldrich) in wa-
ter) at a 0.1 weight ratio of monomer to solvent. An emulsion was formed
using probe sonication (S-4000 Misonix Ultrasonicator, Misonix Inc.) and
then purged with nitrogen. Degassed ascorbic acid solution was added as a
reducing agent (AA:DEAEMA::0.5:100) to start the reaction and the emulsion
was allowed to react for 3 h. Purification was done by a technique described
previously by Fisher and Peppas28 with repeated precipitation/resuspension
with acetone/0.5 N HCl. Following dialysis (12,000-14,000 molecular weight
cut off regenerated cellulose tubing, Spectra/Por®), polymer was recovered by
freeze-drying.
Fluorescently-labeled nanoparticles were synthesized using NBD chlo-
ride (NBD-Cl, 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole, also called 4-chloro7-
nitrobenzofuran, Sigma-Aldrich). Nanoparticles containing primary amines
were synthesized with 2-aminoethyl methacrylate (AEMA, Sigma-Aldrich)
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(AEMA:DEAEMA::32:100). Dried, purified nanoparticles were suspended in
ethanol and combined with an excess of NBD chloride; a typical reaction was
450 mg of dried nanoparticles with 50 mg NBD chloride in 30 ml ethanol. The
mixture was allowed to react overnight to form NBD-labeled nanoparticles
(NBD-NPs) (Figure 6.1). Unreacted NBD-Cl was removed by dialysis and the
fluorescently-labeled nanoparticles were recovered with freeze-drying. Note
that the NBD-Cl becomes strongly fluorescent upon reaction with amines and
that NBD-amines are excited by visible light (464 nm) with emission maximum
of approximately 512 nm.
6.2.3 Binding of siRNA
Nanoparticles were loaded with AllStars Negative Control siRNA (Qi-
agen) in 1x PBS pH 5.5. The final concentration of siRNA was maintained
at 100 nM as the final concentration of polycationic nanoparticles was de-
creased by halves from 0.1 mg/ml to 6.1 ng/ml (g polymer/g siRNA from 80
to 0.00488). The siRNA concentration was maintained constant to minimize
variation associated with the assay at low or high concentrations of siRNA.
Nuclease free 10x PBS was prepared by dissolving sodium chloride, potassium
chloride, monosodium phosphate monohydrate, and disodium phosphate hep-
tahydrate (Fisher Scientific) in water, treating with 0.1% v/v diethylpyrocar-
bonate (DEPC, Fisher Scientific) overnight, and then autoclaving to remove
DEPC.
The fraction of bound siRNA was determined using a Quant-iT™ Ri-
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boGreen® RNA Assay Kit (Life Technologies) that was adapted for 384-well
low volume plates. Briefly, a 10 µl sample was combined with 10 µl Ribo-
Green® assay solution (RiboGreen® reagent diluted 200x in 1x TE buffer) in
a black 384-well low volume plate. The fluorescence intensity (F) was mea-
sured using a microplate reader (Synergy HT, BioTek Instruments, Inc.) 2-5
min after adding the RiboGreen® assay solution with 485 nm excitation and
528 nm emission. The RiboGreen® reagent is sensitive to components other
than RNA present in the assay (although the importance of these contribu-
tions diminished for increasing siRNA concentrations), so these contributions
to the fluorescence were subtracted from the measured fluorescence signal to
calculate the percent loading (L) as calculated in Equation 6.1:
L=100×
(
1 − Fnanoparticle + siRNA complex − Fnanoparticle only




6.2.4 Dynamic light scattering
The z-average diameter and zeta potential were measured using a
Malvern ZetaSizer NanoZS instrument (Malvern Instruments Corp.) equipped
with a 633 nm laser source. Various polymer nanoparticle to siRNA ratios (g
polymer / g siRNA) were prepared in nuclease free 0.1x PBS pH 5.5; the
polymer nanoparticle concentration was fixed at 0.0125 mg/ml and the con-
centration of siRNA varied (0 nM, 12.5 nM, 50 nM, 200 nM, and 800 nM).
The polymer concentration was fixed in order to minimize variation in the light
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scattering results associated with the concentration of polycationic nanopar-
ticles. Concentrations of siRNA greater than 800 nM were not tested due to
the limitations of the stock solution; as a result, the minimum polymer/siRNA
mass ratio tested was 1.25.
6.2.5 Cell culture
Murine macrophage RAW264.7 cells (obtained from American Type
Culture Collection) were maintained in Dulbecco’s Modified Eagle’s Medium
high glucose without L-glutamine (DMEM, Sigma-Aldrich) supplemented with
with 1% L-glutamine (MediaTech), 1% penicillin (Sigma-Aldrich), 1% strepto-
mycin (Sigma-Aldrich), and 10% HyClone USDA Tested Fetal Bovine Serum
(FBS, Thermo Scientific). Opti-MEM® Reduced Serum Medium, no Phenol
Red (Life Technologies) was used for all cytotoxicity and transfection experi-
ments.
6.2.5.1 Flow cytometry
Flow cytometry measurements were collected using a Accuri flow cy-
tometer and analyzed with Accuri software (BD Biosciences) and also with a
BD Fortessa flow cytometer and analyzed using FACSDiva software (BD Bio-
sciences). 240,000 RAW264.7 cells were plated in 6 well plates (Thermo Scien-
tific) and incubated for 50 h. Fluorescently-labeled polycationic nanoparticles
were added at 0.05 mg/ml, 0.025 mg/ml, and 0.0125 mg/ml for incubation
times of 24 h, 2 h, and 30 min at a temperature of 37C and 2 h at a tem-
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perature of 4C. Following incubation, cells were rinsed three times with cold
Dulbecco’s Phosphate-Buffered Saline (DPBS, Sigma-Aldrich) prior to scrap-
ing to form a cell suspension. The cell suspension was centrifuged, the super-
natant discarded, and the pellet was resuspended in FACS buffer (1% FBS
in DPBS). The samples were stored in darkness at 4 °C before measurement.
The results are reported in two ways: as the average percent of cells (taken
over a large number of cells, typically 10,000) containing fluorescently-labeled
NBD-NPs and as the mean fluorescence intensity of the sample normalized to
the fluorescence intensity of the blank control. All results are reported as the
average plus/minus the standard deviation of two replicates as measured us-
ing the Accuri flow cytometer. The results were confirmed in an independent
experiment using the Accuri flow cytometer and an independent experiment
using the BD Fortessa flow cytometer.
6.2.5.2 Confocal microscopy
Cover slips (18 mm round, 1.5 thickness) were acid washed overnight
with 1 N HCl at 60 °C, rinsed with ethanol/water mixtures with successively
increasing volume ratios of ethanol, and then the cover slips were placed in a
12 well plate and UV-sterilized. RAW264.7 cells were plated on the glass cover
slips at 80,000 cells/well. Cells were incubated for 40 h prior to 2 h incubation
with 0.05 mg/ml polycationic nanoparticles. Following incubation, cells were
rinsed three times with 1xPBS pH 7.4 to remove non-internalized nanoparti-
cles. Cells were fixed with 4% para formaldehyde in 1xDPBS for 10 min at
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room temperature prior to washing three times with HBSS (BioWhittaker).
Cells were stained with 1 μg/ml Wheat Germ Agglutinin (WGA) Alexa Fluor
594 conjugate for 10 min at room temperature. Cells were rinsed twice with
cold HBSS and once with DI water (autoclaved). Cover slips were mounted
to glass slides using Prolong® Gold anti-fade reagent with DAPI (Life Tech-
nologies) and stored in the freezer prior to imaging.
Confocal images were acquired using a Zeiss LSM 710 confocal micro-
scope with a 63x objective. The settings for the green laser were adjusted such
that blank cells (no nanoparticles) demonstrated negligible fluorescence. The
step size was maintained at 0.8 μm, while the total stack volume was varied
to match the cell thickness for each field. Images were collected in 16 bit
format, and all images underwent identical post-processing (γ=0.45 for red,
blue, and green channels, γ=1.3 for brightfield, and brightfield scale adjusted
to max/min using ZEN Blue).
6.2.5.3 Transfection with AllStars Death siRNA
RAW264.7 cells were seeded at 10,000 cells per well in 96 well plates
(Nunc, Thermo Scientific). After 18 h incubation, the media was replaced with
Opti-MEM®. The nanoparticles were combined with siRNA (AllStars Mm/Tn
Cell Death or Negative Control siRNA, Qiagen) in 1xPBS pH 5.5 at vari-
ous concentrations of polymer nanoparticles and siRNA. The complexes were
added to cells following 1 h incubation with Opti-MEM®. Lipofectamine wells
contained 0.25 µl/well Lipofectamine. Following 48 h incubation, media was
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removed and cells were incubated for 90 min with CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS, Promega) with serum-free DMEM
without phenol red (Sigma-Aldrich). The absorbance at 690 nm (background)
and 490 nm (MTS assay) was measured using a microplate reader (Synergy
HT, BioTek Instruments, Inc.), and cell viability (V) was calculated as shown
in Equation 6.2:
V = A490, sample − A690, sample − (A490, no cells − A690, no cells)
A490 media − A690, media − (A490, no cells − A690, no cells)
(6.2)
The results for viability for the AllStars Death and the Scrambled
siRNA were compared by Student’s t-test (two-tailed, unequal variance) to
check for statistically significant knockdown. The percent knockdown was cal-
culated from the cell viability for cells transfected with AllStars Death siRNA







6.3 Results and discussion
The polycationic nanoparticles were synthesized using ARGET ATRP.
The interactions between polycationic nanoparticles and siRNA were analyzed
using a fluorescent RiboGreen® assay and using dynamic light scattering. The
interactions between polycationic nanoparticles and murine macrophage cells
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were analyzed using flow cytometry and confocal microscopy. Polycationic
nanoparticles loaded with siRNA were used to transfect RAW264.7 cells in
order to examine the dependence of knockdown efficiency on the concentration
of polycationic nanoparticles and siRNA.
6.3.1 Binding of siRNA
The binding of siRNA was determined from measurements of free
siRNA taken using a RiboGreen® RNA Assay Kit for a range of polymer
to siRNA mass ratios of 80 to 0.0049 (see Figure 6.2). For all measurements,
the siRNA concentration was maintained at 100 nM as the polymer nanopar-
ticle concentration was varied. When the mass ratio of polymer to siRNA
decreases below 1, the binding efficiency decreases sharply. The binding effi-
ciency continues to decrease as the mass ratio of polymer to siRNA decreases
until it begins to level off (reaching 14% binding) near a mass ratio of poly-
mer to siRNA of 0.0195. This binding curve indicates that the polycationic
nanoparticles efficiently bind siRNA at mass ratios of polymer/siRNA greater
than 1. For mass ratios less than one, the polycationic nanoparticles quickly
reach their maximum binding capacity and the binding efficiency decreases
sharply.
6.3.2 Dynamic light scattering
Z-average diameter, polydispersity, and zeta potential were measured
using dynamic light scattering with a Malvern ZetaSizer NanoZS instrument
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(see Figure 6.3). Samples were prepared with a final concentration of 0.0125
mg/ml polymer nanoparticles in 0.1x PBS pH 5.5 with varying concentra-
tions of siRNA. As the concentration of siRNA increases (and the mass ratio
decreases), the diameter of the polycationic nanoparticles decreases from a
maximum of 195.4 nm (mass ratio 80) to a minimum of 170.7 nm (mass ratio
1.25). The decrease in diameter may be associated with binding of anionic
siRNA to the polycationic nanoparticles, resulting in charge neutralization
and a decrease in ion repulsion-driving swelling. If the charge neutralization
is at work, it is not apparent from the surface charge measurements; the zeta
potential was indistinguishable for the five concentrations of siRNA with 0.025
mg/ml polycationic nanoparticles tested (24.2 mV to 25.5 mV).
6.3.3 Flow cytometry to evaluate uptake of polycationic nanopar-
ticles
The uptake of fluorescently-labeled polycationic nanoparticles was eval-
uated using flow cytometry (see Figure 6.3). The percent of cells with nanopar-
ticles increased as the incubation time increased, indicating uptake continues
after 2 h. The percent of cells with nanoparticles also increased as the concen-
tration of nanoparticles increased, although the difference was slight for the
2 h and 30 min incubation times. The maximum percent of cells containing
fluorescently-labeled nanoparticles was 54% for 0.05 mg/ml at 24 h. Likewise,
the normalized fluorescence intensity increased as the incubation time and
nanoparticle concentration increased. Negligible uptake was observed at 30
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min (only 6%, 6%, and 4% for 0.05 mg/ml, 0.025 mg/ml, and 0.0125 mg/ml,
respectively)
The NBD-NPs demonstrate a temperature-dependent uptake profile;
incubation at 37 °C (versus 4 °C) results in a increase in the percent of cells that
have taken-up NBD-NPs (see Figure 6.4). The negligible uptake observed at 4
°C indicates that nanoparticle internalization is dominated by active transport
processes (endocytosis) rather than by a method where the cells were passive
recipients of membrane-disruption by the nanoparticles.
6.3.4 Confocal microscopy to verify internalization of polycationic
nanoparticles
The internalization of nanoparticles was confirmed using confocal mi-
croscopy. Confocal images were acquired with a Zeiss LSM 710 confocal micro-
scope with a 63x objective. Z-stacks were used to gain a more complete 3-D pic-
ture of the cells (see the orthogonal view in Figure 6.5) in addition to 2-D snap-
shots (see Figure 6.6). The confocal images show green fluorescently-labeled
nanoparticles internalized within the red WGA Alexa Fluor 594 conjugate-
stained membrane. Cells without green fluorescently-labeled nanoparticles
show negligible green fluorescence (see Figure 6.7).
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6.3.5 Transfection with AllStars Death siRNA
The dependence of knockdown on the concentration of polycationic
nanoparticles and siRNA was determined by transfection of RAW264.7 cells
with AllStars Death siRNA followed by an MTS assay to evaluate viabil-
ity. RAW264.7 cells were transfected with 0.05 mg/ml, 0.025 mg/ml, 0.0125
mg/ml, and 0 mg/ml polycationic nanoparticles with 200 nM, 100 nM, 50 nM,
10 nM, and 0 nM siRNA (AllStars Death or scrambled). For the two higher
concentrations of polycationic nanoparticles (0.05 mg/ml and 0.025 mg/ml),
knockdown was observed for all four (non-zero) concentrations of siRNA (see
Figure 6.8). Higher concentrations of nanoparticles and siRNA was associated
with increased knockdown.
Knockdown was also observed with 0.0125 mg/ml polycationic
nanoparticles at the siRNA concentrations of 200 nM, 100 nM, and 50 nM
(32%, 35%, 34%, respectively) (see Figure 6.9). Surprisingly, a small but
statistically significant percentage of knockdown (<20% knockdown, p<0.02)
was observed for the highest concentration (200 nM) of naked siRNA. Al-
though surprising because naked siRNA is not efficiently taken-up by cells,
early siRNA experiments and clinical trial attempts used naked siRNA without
a carrier vehicle and saw sufficient knockdown to motivate further studies.29
Transfection with Lipofectamine/siRNA complexes failed to result in statisti-
cally significant knockdown; the polycationic nanoparticles outperformed the
commercially available transfection agent Lipofectamine under the experimen-
tal conditions tested (see Figure 6.10).
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6.4 Conclusions
A polycationic nanoparticle siRNA carrier was investigated for siRNA
delivery to RAW264.7 cell. The polycationic nanoparticle efficiently bound
siRNA for polymer/siRNA mass ratios less than 1. Dynamic light scattering
indicated that siRNA binding was associated with a decreased diameter but
no significant change to the zeta potential. Internalization of fluorescently-
labeled nanoparticles was confirmed using confocal microscopy, and flow cy-
tometry indicated that nanoparticle uptake increased with nanoparticle con-
centration and with incubation time. Knockdown experiments using AllStars
Death siRNA and RAW264.7 cells demonstrated increasing knockdown effi-
ciency for higher concentrations of polycationic nanoparticles and siRNA, and





Table 6.1: Delivery of siRNA using DEAEMA-containing cationic poly-
mers. B16F10: mouse melanoma, BSC-40: primate kidney epithelial, DMF:
dimethylformamide, Dual-Glo: luciferase reporter assay (Promega), EGDMA:
ethylene glycol dimethacrylate, FLuc: firefly luciferase, HuH-7: human liver
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Table 6.2: Delivery of siRNA using DMAEMA-containing polymers. B16F10:
mouse melanoma, Dual-Glo: luciferase reporter assay (Promega), DMF:
dimethylformamide, GFP: green fluorescent protein, HeLa: human cervical
cancer, MDA-MB: human breast cancer, MSN: mesoporous silica nanoparti-
cles, nBA: n-butyl acrylate, PC3: human prostate cancer, PAA: propylacrylic
acid, PEGDMA: PEG dimethacrylate, q-: quaternized with ethyl bromide,
RAFT: reversible addition-fragmentation chain-transfer, RLuc: Renilla lu-
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Table 6.3: Z-average diameter, polydispersity, and zeta potential were mea-
sured using dynamic light scattering with a Malvern ZetaSizer NanoZS instru-
ment. Samples were prepared in 0.1x PBS pH 5.5 with 0.0125 mg/ml polymer













- 0 190.0 25.5 0.270
80 12.5 195.4 25.5 0.277
20 50 193.7 25.2 0.262
5 200 176.3 24.2 0.262




Figure 6.1: Fluorescent labeling of nanoparticles using nanoparticles contain-
ing primary amines reacted with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD
chloride). NBD chloride reacts with primary amines to form fluorescent NBD-
amines. Ethanol was used as the solvent. The fluorescent label is covalently





























Figure 6.2: Binding curve of siRNA electrostatic binding to polycationic
nanoparticles. Free siRNA quantified using a RiboGreen® RNA Assay Kit
(fluorescence-based detection). The concentration of siRNA was maintained
at 100 nM and the concentration of polycationic nanoparticles was varied to



























































































(b) Fluorescence intensity from uptake of
fluorescently-labeled nanoparticles
Figure 6.3: Uptake of fluorescently-labeled polycationic nanoparticles at 37
°C by RAW264.7 cells evaluated using flow cytometry. Fluorescently-labeled
nanoparticles were added at concentrations of 0.05 mg/ml, 0.025 mg/ml, and
0.0125 mg/ml for incubation times of 24 h, 2 h, and 30 min at 37 °C. The flu-
orescence intensity was normalized by the fluorescence intensity of the blank
sample. All results are reported as the average plus/minus the standard de-
viation of two replicates as measured using the Accuri flow cytometer and































































































(b) Fluorescence intensity from uptake of
fluorescently-labeled nanoparticles
Figure 6.4: Uptake of fluorescently-labeled polycationic nanoparticles by
RAW264.7 cells evaluated using flow cytometry. Fluorescently-labeled
nanoparticles were added at concentrations of 0.05 mg/ml, 0.025 mg/ml, and
0.0125 mg/ml for 2 h at 4 °C or 37 °C. The fluorescence intensity was normal-
ized by the fluorescence intensity of the blank sample. All results are reported
as the average plus/minus the standard deviation of two replicates as measured
using the Accuri flow cytometer and analyzed using the Accuri software.
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Figure 6.5: Confocal microscopy image of RAW264.7 cells showing internal-
ization of fluorescently-labeled nanoparticles (NBD-NPs). Orthogonal projec-
tions represent cross-sectional slices, and they are obtained by taking z-stack
images. RAW264.7 cells were incubated with 0.05 mg/ml NBD-NPs for 2 h
prior to rinsing, fixing, staining, and mounting. Confocal images were ac-
quired with a Zeiss LSM 710 confocal microscope with a 63x objective. The
settings for the green laser were adjusted such that blank cells (no nanopar-
ticles) demonstrated negligible fluorescence. Images were collected in 16 bit
format, and all images underwent identical post-processing (γ=0.45 for red,
blue, and green channels, γ=1.3 for brightfield, and brightfield scale adjusted
to max/min using ZEN Blue). Red: cell membrane stained with Wheat Germ
Agglutinin (WGA) Alexa Fluor 594 conjugate, blue: nuclei stained with DAPI,
green: fluorescently-labeled nanoparticles
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DAPI WGA-Alexa Fluor 594
NBD-NPs Fluorescent overlay
Bright eld Overlay
Figure 6.6: Confocal images of cells with fluorescently-labeled nanoparticles
(NBD-NPs). RAW264.7 cells were incubated with 0.05 mg/ml NBD-NPs for
2 h prior to rinsing, fixing, staining, and mounting. Confocal images were
acquired with a Zeiss LSM 710 confocal microscope with a 63x objective. The
settings for the green laser were adjusted such that blank cells (no nanopar-
ticles) demonstrated negligible fluorescence. Images were collected in 16 bit
format, and all images underwent identical post-processing (γ=0.45 for red,
blue, and green channels, γ=1.3 for brightfield, and brightfield scale adjusted
to max/min using ZEN Blue). Red: cell membrane stained with Wheat Germ




(No NBD-NPs) Fluorescent overlay
Bright eld Overlay
Figure 6.7: Confocal images of blank cells without green fluorescently-labeled
nanoparticles (no NBD-NPs) and without red fluorescent membrane stain.
Confocal images were acquired with a Zeiss LSM 710 confocal microscope with
a 63x objective. The settings for the green laser were adjusted such that blank
cells (no nanoparticles) demonstrated negligible fluorescence. Images were
collected in 16 bit format, and all images underwent identical post-processing
(γ=0.45 for red, blue, and green channels, γ=1.3 for brightfield, and brightfield










































































































(b) 0.025 mg/ml polycationic nanoparticles
Figure 6.8: Knockdown dependence on polycationic nanoparticle and siRNA
concentration. Death siRNA (AllStars Mm/Tn Cell Death) and Scrambled
siRNA (negative control) were delivered to RAW264.7 with varying concen-
trations of polycationic nanoparticle carrier. Following 48 incubation, viability
was evaluated using an MTS assay. Asterisk (*) indicates p<0.003 and pound








































































































Figure 6.9: Knockdown dependence on polycationic nanoparticle and siRNA
concentration. Death siRNA (AllStars Mm/Tn Cell Death) and Scrambled
siRNA (negative control) were delivered to RAW264.7 with varying concen-
trations of polycationic nanoparticle carrier (0.0125 mg/ml or 0 mg/ml). Fol-
lowing 48 incubation, viability was evaluated using an MTS assay. Asterisk




















































Figure 6.10: Knockdown dependence on polycationic nanoparticle and siRNA
concentration. Death siRNA (AllStars Mm/Tn Cell Death) and Scrambled
siRNA (negative control) were delivered to RAW264.7 with Lipofectamine.




[1] P. van de Wetering, J. Cherng, H. Talsma, D. J. A. Crommelin, and W. E.
Hennink. 2-(Dimethylamino) ethyl methacrylate based (co) polymers as
gene transfer agents. J. Control. Release, 53(1):145–153, 1998.
[2] X. Jiang, M. C. Lok, and W. E. Hennink. Degradable-brushed pHEMA–
pDMAEMA synthesized via ATRP and click chemistry for gene delivery.
Bioconjugate Chem., 18(6):2077–2084, 2007.
[3] Y. Qiao, Y. Huang, C. Qiu, X. Yue, L. Deng, Y. Wan, J. Xing, C. Zhang,
S. Yuan, A. Dong, and J. Xu. The use of PEGylated poly [2-(N, N-
dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector
and the activation of innate immunity and improvement of HIV-1-specific
immune responses. Biomaterials, 31(1):115–123, 2010.
[4] A. Schallon, V. Jérôme, A. Walther, C.V. Synatschke, A.H.E. Müller, and
R. Freitag. Performance of three PDMAEMA-based polycation architec-
tures as gene delivery agents in comparison to linear and branched PEI.
React. Funct. Polym., 70(1):1–10, 2010.
[5] F. Dai, P. Sun, Y. Liu, and W. Liu. Redox-cleavable star cationic
PDMAEMA by arm-first approach of ATRP as a nonviral vector for gene
delivery. Biomaterials, 31(3):559–569, 2010.
[6] S. Guo, Y. Huang, T. Wei, W. Zhang, W. Wang, D. Lin, X. Zhang,
194
A. Kumar, Q. Du, and J. Xing. Amphiphilic and biodegrad-
able methoxy polyethylene glycol-block-(polycaprolactone-graft-poly(2-
(dimethylamino)ethyl methacrylate)) as an effective gene carrier. Bio-
materials, 32(3):879–889, 2011.
[7] C. V. Synatschke, A. Schallon, V. Jérôme, R. Freitag, and A. H. E.
Müller. Influence of polymer architecture and molecular weight of poly
(2-(dimethylamino) ethyl methacrylate) polycations on transfection ef-
ficiency and cell viability in gene delivery. Biomacromolecules, 12(12):
4247–4255, 2011.
[8] J. H. Tan, N. A. J. McMillan, E. Payne, C. Alexander, F. Heath, A. K.
Whittaker, and K. J. Thurecht. Hyperbranched polymers as delivery
vectors for oligonucleotides. J. Polym. Sci., Part A: Polym. Chem., 50
(13):2585–2595, 2012.
[9] Y. Zhang, M. Zheng, T. Kissel, and S. Agarwal. Design and biophysi-
cal characterization of bioresponsive degradable poly(dimethylaminoethyl
methacrylate) based polymers for in vitro DNA transfection. Biomacro-
molecules, 13:313–322, 2012.
[10] A. P. Majewski, A. Schallon, V. Jérôme, R. Freitag, A. H. E. Müller,
and H. Schmalz. Dual-responsive magnetic core–shell nanoparticles for
nonviral gene delivery and cell separation. Biomacromolecules, 13(3):
857–866, 2012.
195
[11] Yi Zhang, Achim Aigner, and Seema Agarwal. Degradable and biocom-
patible poly (N, N -dimethylaminoethyl methacrylate-co-caprolactone) s
as dna transfection agents. Macromol. Biosci., 13(9):1267–1275, 2013.
[12] A. Tamura, M. Oishi, and Y. Nagasaki. Enhanced cytoplasmic delivery of
siRNA using a stabilized polyion complex based on PEGylated nanogels
with a cross-linked polyamine structure. Biomacromolecules, 10(7):1818–
1827, 2009.
[13] W. Kong, D. Sung, Y. Shim, K. H. Bae, P. Dubois, T. G. Park, J. Kim,
and S. Seo. Efficient intracellular siRNA delivery strategy through rapid
and simple two steps mixing involving noncovalent post-PEGylation. J.
Control. Release, 138(2):141–147, 2009.
[14] Y. Hu, P. U. Atukorale, J. J. Lu, J. J. Moon, S. H. Um, E. C. Cho,
Y. Wang, J. Chen, and D. J. Irvine. Cytosolic delivery mediated via
electrostatic surface binding of protein, virus, or siRNA cargos to pH-
responsive core- shell gel particles. Biomacromolecules, 10(4):756–765,
2009.
[15] A.J. Convertine, D.S.W. Benoit, C.L. Duvall, A.S. Hoffman, and P.S.
Stayton. Development of a novel endosomolytic diblock copolymer for
siRNA delivery. J. Control. Release, 133(3):221–229, 2009.
[16] C. Zhu, S. Jung, S. Luo, F. Meng, X. Zhu, T. G. Park, and Z. Zhong.
Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable
196
cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copoly-
mers. Biomaterials, 31(8):2408–2416, 2010.
[17] A. J. Convertine, C. Diab, M. Prieve, A. Paschal, A. S. Hoffman, P. H.
Johnson, and P. S. Stayton. pH-responsive polymeric micelle carriers for
siRNA drugs. Biomacromolecules, 11(11):2904–2911, 2010.
[18] S. R. Bhattarai, E. Muthuswamy, A. Wani, M. Brichacek, A. L. Cas-
tañeda, S. L. Brock, and D. Oupicky. Enhanced gene and siRNA deliv-
ery by polycation-modified mesoporous silica nanoparticles loaded with
chloroquine. Pharm. Res., 27(12):2556–2568, 2010.
[19] D. J. Gary, H. Lee, R. Sharma, J. Lee, Y. Kim, Z. Y. Cui, D. Jia, V. D.
Bowman, P. R. Chipman, L. Wan, Y. Zou, G. Mao, K. Park, B. Herbert,
S. F. Konieczny, and Y. Y. Won. Influence of nano-carrier architecture on
in vitro siRNA delivery performance and in vivo biodistribution: poly-
plexes vs micelleplexes. ACS Nano, 5(5):3493–3505, 2011.
[20] S.E. Averick, E. Paredes, A. Irastorza, A. Srinivasan, D.J. Siegwart,
A.J.D. Magenau, H.Y. Cho, A.R. Shrivats, E. Hsu, J. Kim, et al. Prepa-
ration of cationic nanogels for nucleic acid delivery. Biomacromolecules,
(11):3445–3449, 2012.
[21] D. J. Gary, J. Min, Y. Kim, K. Park, and Y. Y. Won. The effect of N/P
ratio on the in vitro and in vivo interaction properties of PEGylated Poly
[2-(dimethylamino) ethyl methacrylate]-based siRNA complexes. Macro-
mol. Biosci., 13(8):1059–1071, 2013.
197
[22] C. E. Nelson, J. R. Kintzing, A. Hanna, J. M. Shannon, M. K. Gupta, and
C. L. Duvall. Balancing cationic and hydrophobic content of PEGylated
siRNA polyplexes enhances endosome escape, stability, blood circulation
time, and bioactivity in vivo. ACS Nano, 7(10):8870–8880, 2013.
[23] H. Y. Cho, S. E. Averick, E. Paredes, K. Wegner, A. Averick, S. Jurga,
S. R. Das, and K. Matyjaszewski. Star polymers with a cationic core
prepared by ATRP for cellular nucleic acids delivery. Biomacromolecules,
14(5):1262–1267, 2013.
[24] H. M. Aliabadi, B. Landry, C. Sun, T. Tang, and H. Uludağ. Supramolec-
ular assemblies in functional siRNA delivery: Where do we stand? Bio-
materials, 33(8):2546–2569, 2012.
[25] J. Carralot, T. Kim, B. Lenseigne, A. S. Boese, P. Sommer, A. Genovesio,
and P. Brodin. Automated high-throughput siRNA transfection in raw
264.7 macrophages: a case study for optimization procedure. J. Biomol.
Screen., 14(2):151–160, 2009.
[26] D. C. Forbes, M. Creixell, H. Frizzell, and N. A. Peppas. Polycationic
nanoparticles synthesized using ARGET ATRP for drug delivery. Eur. J.
Pharm. Biopharm., 84(3):472–478, 2013.
[27] D. C. Forbes and N. A. Peppas. Differences in molecular structure in
cross-linked polycationic nanoparticles synthesized using ARGET ATRP
or UV-initiated polymerization. Polymer, 54(17):4486–4492, 2013.
198
[28] O. Z. Fisher and N. A. Peppas. Polybasic nanomatrices prepared by UV-
initiated photopolymerization. Macromolecules, 42(9):3391–3398, 2009.
[29] D. C. Forbes and N. A. Peppas. Oral delivery of small RNA and DNA.
J. Control. Release, 162(2):438–445, 2012.
[30] H. Hayashi, M. Iijima, K. Kataoka, and Y. Nagasaki. pH-sensitive nanogel
possessing reactive PEG tethered chains on the surface. Macromolecules,
37(14):5389–5396, 2004.
[31] Y. Hu, T. Litwin, A. R. Nagaraja, B. Kwong, J. Katz, N. Watson, and
D. J. Irvine. Cytosolic delivery of membrane-impermeable molecules in
dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett.,
7(10):3056–3064, 2007.
[32] S. Pirotton, C. Muller, N. Pantoustier, F. Botteman, S. Collinet,
C. Grandfils, G. Dandrifosse, P. Degée, P. Dubois, and M. Raes. En-
hancement of transfection efficiency through rapid and noncovalent post-
PEGylation of poly (dimethylaminoethyl methacrylate)/DNA complexes.
Pharm. Res., 21(8):1471–1479, 2004.
199
Chapter 7
Differences in Molecular Structure in
Cross-linked Polycationic Nanoparticles
Synthesized using ARGET ATRP or
UV-initiated Polymerization
7.1 Introduction
Hydrogel nanoparticles and microparticles (nanogels and microgels, re-
spectively) are “physically or chemically cross-linked polymer networks.”1 The
increased stability imparted by the cross-linking (compared to self-assembled
systems without cross-linking) is important for applications in complex envi-
ronments (such as physiological fluids with proteins, amino acids, and vita-
mins).2 On a microscopic scale, nanogels and microgels “behave much like a
conventional hydrogel” in that they can be described by their swelling behav-
ior.3 There has been much interest in nanogels and microgels for applications
such as biomaterials for drug delivery,1;4 analyte detection (sensors),5 molecu-
larly imprinted polymers,6 microreactors,7;8 chemical/biological separations,9
200
cosmetics,10–12 food,13;14 and oil recovery.3
The broad range of applications for nanogels and microgels is matched
by a broader range of creative synthesis strategies. In addition to traditional
free radical polymerization, researchers have also pursued controlled polymer-
izations, such as ATRP-based techniques, that make it possible to synthesize
new types of molecular architecture, such as shell cross-linked micelles assem-
bled from block copolymers. Sometimes the advantages of a new polymeriza-
tion technique may not come from a new architecture; sometimes an easier
route can be more valuable than a new destination. Reverse ATRP techniques
such as ARGET ATRP15–17 use copper(II) catalysts, which are less oxygen-
sensitive than the copper(I) catalysts used in forward ATRP techniques such as
traditional ATRP. In applications where it is difficult to remove or control the
quantity of oxygen, such as miniemulsion polymerization where the high shear
mixing (e.g. sonication) tends to entrain air, reverse ATRP can yield better
control than forward ATRP18. Adapting traditional polymerizations to new
controlled techniques may yield advantages in processing while also providing
an opportunity to look at the role of heterogeneity in material properties.
An improved understanding of molecular structure, and its connection
to synthesis techniques and material properties, may facilitate the design of
enhanced materials for a range of applications. Nanoscale heterogeneity, such
as heterogeneity of network cross-linking density, hydrophobic component clus-
tering, or local collapse of thermoresponsive macromolecules,19 is an important
aspect of molecular structure because heterogeneity within particles leads to
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broad transitions. The “continuous” (rather than discontinuous) transition is
a “summation”9 or “convolution of many transitions”20 where each contribu-
tion has its own characteristic transition. Likewise, heterogeneity within the
population of particles also tends to broaden transitions, in the same way that
a polydisperse population of linear PNIPAm has a broad transition.21 Con-
trolled radical polymerizations may reduce heterogeneity compared to tradi-
tional free radical polymerization; for example, assuming equal reactivity of
monomer and cross-linking agent, densely cross-linked regions resulting from
intramolecular cross-linking may form in traditional free radical polymeriza-
tion but not in controlled radical polymerization where the slower reaction
kinetics permit time for chain diffusion and relaxation prior to propagation.7
There is no shortage of reports using complex polymer chemistries
to make advanced materials, such as pH-responsive nanoparticles for thera-
peutic delivery, but there are few reports comparing the new techniques to
well-established UV-initiated polymerizations. A previous report comparing a
panel of polycationic nanoparticles synthesized using ARGET ATRP or UV-
initiated polymerization22 for drug delivery applications prompted interest
in elucidating the underlying molecular structural differences responsible for
differences in material properties. This report examines the effect of poly-
merization method on material properties and the connection to molecular
structure.
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7.2 Materials and methods
7.2.1 Materials
Poly(ethylene glycol) methyl ether methacrylate (PEGMA) solu-
tion (Mn 2000 for PEG chain, 50 wt% in water), 2-(diethylamino)ethyl
methacrylate (DEAEMA), tert-butyl methacrylate (tBMA), tetraethylene
glycol dimethacrylate (TEGDMA), ethyl 2-bromoisobutyrate (EBIB), tris
(2-pyridylmethyl) amine (TPMA), myristyltrimethylammonium bromide
(MyTab), and ascorbic acid (AA) were purchased from Sigma-Aldrich.
1 N Hydrochloric acid (HCl) was purchased from Fisher Scientific; Brij-
30®, copper(II) bromide, and D2O were purchased from Acros Organics; and
Irgacure 2959 was purchased from Ciba Specialty Chemicals Corp. Ultrapure
water was used for all studies. All chemicals were used as received.
7.2.2 Synthesis and purification
P(DEAEMA-co-tBMA-co-PEGMA-co-TEGDMA) cross-linked
polymer nanoparticles were synthesized using a previously reported
ARGET ATRP technique22 or a UV-initiated polymerization pre-
viously developed by Fisher and colleagues.23 Briefly, reagents
DEAEMA:PEGMA:TEGDMA:CuBr2:TPMA:EBIB at molar ratios of
100:10:4:0.5:0.5:4 (with tBMA with a molar ratio of 30 or 45 depending on the
formulation) were combined with 8 mg/ml Brij® 30 and 1.35 mg/ml MyTab
in water for a 0.1 weight ratio of monomer to solvent. For the UV-initiated
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polymerization, Irgacure® 2959 was added at a 0.005 weight ratio initiator
to monomer in place of CuBr2:TPMA:EBIB. Following probe sonication
(S-4000 Misonix Ultrasonicator) and nitrogen purge, the ARGET ATRP
and UV-initiated polymerizations were reacted at ambient temperature for
3 h by the addition of degassed ascorbic acid solution as a reducing agent
(AA:DEAEMA::0.5:100) or for 2.5 h by exposure to UV light (Dymax
BlueWave™200 UV), respectively. Previous work indicates that monomers
like DEAEMA can act as an intrinsic reducing agent, but good control in
the presence of residual air is achieved after addition of an external reducing
agent such as ascorbic acid.24 Purification was done by a technique described
previously by Fisher and Peppas25 with repeated precipitation/resuspension
with acetone/0.5 N HCl. Following dialysis, polymer was recovered by
freeze-drying.
P(DEAEMA-co-tBMA-co-PEGMA) linear polymer chains made with-
out TEGDMA (linear analogs) were synthesized as described previously for
cross-linked polycationic nanoparticles except that TEGDMA was omitted.
The feed ratio of tBMA is identified in the formulation name (e.g. 30UV and
30ARGET have 30 mol tBMA per 100 mol DEAEMA in the feed); likewise,
the synthesis technique (UV or ARGET ATRP) is also indicated in the for-
mulation name. As much as possible, parameters were kept constant across
reactions to permit direct comparison.
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7.2.3 Instrumentation
Cross-linked nanoparticles and linear analogs were characterized with
1H NMR (nuclear magnetic resonance). Dried polymer was dissolved in D2O
at approximately 25-30 mg/ml. Spectra were obtained using a Varian Di-
rectDrive 400 MHz Nuclear Magnetic Resonance Spectrometer equipped with
an automatic sampler and analyzed using SpinWorks 3™ software. The inte-
grated intensity of the DEAEMA 1.17 ppm methyl peak was compared to the
oxyethylene proton peak from PEGMA at 3.55 ppm and the tert-butyl peak
from tBMA at 1.31 ppm. The PEGMA content was corrected by subtracting
the contribution from the unreacted PEGMA estimated from the double bond
peak at 6.02.
The FTIR spectra were recorded using a Nicolet Avatar 360 FTIR. In
all cases, background spectra were subtracted from the sample spectra.
Molecular weight and polydispersity data were collected on an Agilent
1200 Series Iso Pump and Autosampler with an Agilent Technologies 1100 RI
detector. One PLgel 5 µm, 100 Å column and one PLgel 5 µm, 10,000 Å
column were used with 0.01 M lithium bromide (LiBr) in dimethylformamide
(DMF) eluent at 70 °C and a flow rate of 1 ml/min. The elution times were
compared to nine poly(methyl methacrylate) (PMMA) standards (1660, 2200,
4250, 6370, 12600, 23500, 41400, 89300, and 201000 Da), which were used to
calibrate the instrument by refractive index response (conventional calibra-
tion).
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The thermal stability of the samples was determined using thermal
gravimetric analysis (Mettler-Toledo TGA/DSC 1). A 6-8 mg sample of each
polymer was packed tightly into an aluminum oxide crucible. The experiments
were performed under nitrogen or air with a heating rate of 10 °C/min from
40 °C to 600 °C.
Thermal transition temperatures were determined using a differential
scanning calorimeter (DSC) (Mettler-Toledo DSC1). A 5-10 mg sample of
each polymer was packed tightly in an aluminum DSC pan with a 0.1 mm
hole in the lid. The samples were dried overnight in a vacuum oven at 30-
50 °C. Samples were annealed at 130 °C prior to running DSC to erase the
thermal history; the temperature of 130 °C was selected to minimize thermal
cleavage of the tert-butyl ester linkage.26 Samples were then cooled to -65 °C
before heating to 150 °C. All DSC runs were performed under nitrogen gas
atmosphere with 10 °C/min heating rate and 5 °C/min cooling rate.
7.3 Results and discussion
Polycationic nanoparticles (see Figure 7.1) were synthesized with two
different feed ratios of hydrophobic monomer tBMA using both ARGET ATRP
and UV-initiated polymerization (see Table 7.1). P(DEAEMA-co-tBMA-co-
PEGMA-co-TEGDMA) polycationic nanoparticles are statistical copolymers,
which means the composition is a function of the feed, but unlike truly random
copolymers, the polymer composition is not identical to the feed. The four dif-
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ferent formulations demonstrate the effects of composition and synthesis tech-
nique on molecular structure and material properties. Linear P(DEAEMA-
co-tBMA-co-PEGMA) chains (analogs of the polycationic nanoparticles, syn-
thesized by omitting the TEGDMA cross-linking agent) were analyzed with
GPC and NMR . All other characterization was done using the polycationic
nanoparticles.
7.3.1 Polymer composition verified using NMR and FTIR
NMR and FTIR were used to verify that the monomers DEAEMA,
tBMA, and PEGMA were incorporated into the polymerization. The polymer
composition was evaluated using P(DEAEMA-co-tBMA-co-PEGMA) linear
polymer chains made without TEGDMA; see Figure 7.3 for a schematic of
the chemical structure corresponding to peak labeling. NMR spectra indicate
that the UV-initiated formulations have greater incorporation of PEGMA and
tBMA than the corresponding ARGET ATRP formulations (see Figure 7.4a
and Table 7.2). Increased conversion for UV-initiated polymerizations could
explain the difference in PEGMA and tBMA incorporation; the Q-e scheme
predicts a preference for DEAEMA incorporation at low conversions so that
more PEGMA would be incorporated at later times (higher conversion).27
Reactivity ratios r1 and r2 (seem Table 7.3) are calculated using tabulated













exp (−e2 (e2 − e1)) (7.2)
The cross-linking has a significant impact on the spectra; the peaks
are broadened significantly for the polycationic nanoparticles compared to the
linear analogs (see Figure 7.4). The strong peak associated with the PEG
oxyethylene protons in the cross-linked spectra suggests a surface brush layer
of solvated PEG chains. FTIR spectroscopy studies verified the presence of
the methacrylate carboxyl group and the C-N bonds corresponding to the
DEAEMA (see Figure 7.5).
7.3.2 Evaluate molecular weight distribution of linear polymer
chains using GPC
Gel permeation chromatography (GPC) analysis was used to ana-
lyze P(DEAEMA-co-tBMA-co-PEGMA) linear polymer chains made without
TEGDMA to gain insight into the molecular weight distribution of the poly-
mer chains in the cross-linked polycationic nanoparticles (Figure 7.6). The
molecular weight and polydispersity index (PDI) were determined using con-
ventional calibration, so values are reported as PMMA equivalents (Table 7.4).
The ARGET ATRP formulations have a different curve shape than the UV-
initiated formulations; the UV-initiated formulations have a single broad peak
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with a shallow shoulder while the ARGET ATRP formulations have a nar-
row peak with a trailing shoulder. Focusing on the main peak, the PMMA
equivalent PDI of the ARGET ATRP formulations is smaller than for the UV-
initiated formulations. The narrower main peak is the expected result for a
controlled polymerization such as ARGET ATRP rather than an uncontrolled
polymerization such as the UV-initiated polymerization. This result for the
linear chains suggests a narrower distribution of main chain length for the
ARGET ATRP polycationic nanoparticles.
The narrower distribution of molecular weight may explain the pre-
viously reported sharper pH-responsive swelling transition for the ARGET
ATRP formulations compared to the UV-initiated formulations.22 Narrower
molecular weight distributions have been associated with sharper thermore-
sponsive transitions in linear PNIPAm while broad molecular weight distri-
butions result in broad transitions,21 so it seems probable that similar effects
may occur in pH-responsive transitions.
The molecular weight distribution of the linear chains is an incomplete
picture of molecular structure because it does not provide insight into the cross-
linking distribution, which is another important factor in nanoscale hetero-
geneity contributing to broad transitions.19 Oh and associates28 attributed in-
creased swelling ratios of nanogels to increased cross-linking homogeneity with
their poly(oligo(ethylene glycol) monomethyl ether methacrylate) (POEOMA)
nanogels with a disulfide-methacrylate cross-linking agent synthesized using
AGET (activators generated by electron transfer) ATRP or conventional rad-
209
ical polymerization. Oh and associates found that the AGET ATRP nanogels
demonstrated greater swelling (weight swelling ratio of 28.5 in water) than
the conventional radical polymerization nanogels (weight swelling ratio of 16.2
in water). In contrast, the P(DEAEMA-co-tBMA-co-PEGMA-co-TEGDMA)
polycationic nanoparticles synthesized using both methods had comparable
swelling (see Forbes et al.22 for dynamic light scattering and transmission elec-
tron microscopy data), which may indicate the ARGET ATRP did not result
in improved cross-linking homogeneity for the polycationic nanoparticles.
7.3.3 Thermal gravimetric analysis (TGA)
The TGA thermal profile describes the degradation behavior of the
polymer in air and nitrogen and may also give insights into the polymer com-
position. Consideration of degradation behavior is particularly important for
sample handling during analysis and when considering the use of heat-based
processing or sterilization. TGA results in nitrogen atmosphere (Figure 7.7
and Table 7.5) show a small initial weight loss from evaporating water followed
by a first degradation step, and then a temperature range without additional
degradation followed by a final degradation step. The first weight loss (~40%)
occurs from 205 °C - 274 °C, there is negligible weight loss from 274 °C - 402
°C, and the final weight loss (~40%) occurs from 402 °C - 450 °C with negli-
gible additional weight loss at temperatures above 450 °C. The rate of weight
loss is the same for the different formulations.
The observed weight loss following the first degradation step is depen-
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dent on the feed ratio of tBMA; formulations 30UV and 30ARGET have 48.8
wt% and 48.5 wt% remaining following the initial degradation while 45UV and
45ARGET have 51.6 wt% and 51.1 wt% remaining. This two step degrada-
tion is consistent with the two-step degradation profile of methacrylate poly-
mers such as PtBMA29;30 with the first step consisting of the loss of the ester
group,26;31 and at least in the case of the tert-butyl ester, possible formation
of an anhydride cross-linking between deprotected acid groups by removing a
water molecule.26 There are also trends in the final weight percent remaining:
i) all of the ARGET formulations have a higher remaining weight percent than
the UV formulations and ii) increased tBMA content results in a weight per-
cent remaining. Unfortunately, since the range of degradation temperatures
for PDEAEMA and PPEGMA (250 ºC - 500 ºC32 and 75 ºC - 450 ºC33, re-
spectively) overlaps with the region of PtBMA degradation, it is difficult to
translate the curves to quantitative data. Also, since the differences in com-
position are subtle, the resulting differences in the thermal profile are also
subtle.
The differences are even more subtle for the TGA thermogram in air
atmosphere (see Figure 7.8). As for the nitrogen atmosphere, each sample
experiences a small initial weight loss from evaporating water, followed by
a first degradation step. A close look at the derivative plot (rate of weight
loss) indicates at least 4 separate degradation steps for the formulations with
tBMA, compared to 3 degradation steps for the formulation without tBMA.
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7.3.4 Differential scanning calorimeter (DSC)
DSC provides additional information about the thermal properties of
the polymer, and it can also be used to infer details about molecular structure
such as domains or crystallization. The DSC thermograms for the four different
polymer nanoparticle formulations are shown in Figure 7.9. There are two
main differences in the UV and the ARGET formulations: i) the presence of a
melting peak for the UV but not for the ARGET formulations and ii) a sharper
glass transition for the ARGET than for the UV. The glass transition behavior
appears to be strongly influenced by the presence of tBMA; if the tBMA is
eliminated from the formulation (as in 00ARGET), the resulting thermogram
shows a broader, sloping decline in contrast to the clearly defined transition
for 30ARGET and 45ARGET (see Figure 7.10).
The 30UV and 45UV formulation demonstrate an endothermic effect
at 24 °C which can be attributed to the melting of crystallites resulting from
PEG-rich regions containing more than 50% PEG by volume.34 As with other
copolymers,34–36 the melting temperature for the crystalline PEG domains is
less than that of the PEG homopolymer (54 °C34) or the PEGMA macro-
monomer (58 °C from the measured thermal profile of PEGMA, see Figure
7.11). The crystalline regions likely form by segregation rather than by chain
folding since the PEG regions will be distributed statistically rather than in-
corporated as distinct blocks of the polymer backbone.34 Crystalline regions
are not observed for the ARGET formulations, suggesting that the PEG is
incorporated with greater homogeneity that cannot phase-separate. Alterna-
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tively, a lower incorporation of PEGMA into the polymer structure might also
result in an absence of PEG crystallization resulting from insufficient PEG
as NMR indicates that the UV-initiated formulations have more incorporated
PEGMA than the ARGET ATRP formulations.
Estimating the degree of crystallinity, Xc, for a homopolymer is
straightforward; Xc is the ratio between the measured heat of melting and the
reported literature values for heat of melting for the 100% crystalline polymer
(Equation 7.3). Note that for PEG, ÑH0m values range from 166 to 265 J/g






For copolymers or polymer blends, evaluating a degree of crystallinity is
less straightforward because crystallinity may only exists in domains contain-
ing a single component; for the polycationic nanoparticles, the crystallinity is
attributed to regions of PEG that were able to crystallize. As a result, crys-
tallinity is an indicator of heterogeneity in the case of the UV-based formula-
tions. The ratio of crystallized PEG to the total PEG requires an additional
term; namely, an NMR-determined weight composition ratio (45% and 54%









The ARGET formulations have sharper glass transitions than the UV-
initiated formulations. The high glass transition temperature suggests the
presence of tBMA-rich domains since the Tg of PtBMA is 107 °C (compared
to 16 °C - 24 °C for PDEAEMA37;40 and -51 °C for PPEGMA41). Despite
the sharper transition, closer examination of all the glass transition curves
suggests the overall transition is made up of multiple, overlaying glass tran-
sition behavior, perhaps from a range of tBMA domains in the nanoparticle
population (see Figure 7.12). The separately calculated and overall glass tran-
sition temperatures are shown in Table 7.7. The difference in the highest and
lowest individual glass transition temperature can serve as a measure of the
sharpness of the transition, with a small difference corresponding to a sharper
glass transition; UV-initiated formulations have a larger difference in their in-
dividual glass transition temperatures than the ARGET ATRP formulations,
which demonstrates that the UV-initiated formulations have a less sharp glass
transition than the ARGET ATRP formulations.
The sharper glass transition for the ARGET formulations may indicate
a narrower size distribution of tBMA-rich domains in contrast to a broader size
distribution of tBMA-rich domains in the UV formulations. However, studies
using small-angle x-ray scattering of dry and aqueous polycationic nanoparti-
cles to probe molecular structure and orientation did not provide additional
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information. The broader distribution for the UV formulations would be con-
sistent with the uncontrolled polymerization reaction where chains are rapidly
created and then terminated, such that the composition of each chain would
tend to drift with the time of initiation for sufficiently large conversions. In
contrast, ARGET ATRP-based reactions impart control by providing for a
closer approximation to simultaneous initiation (upon addition of the reduc-
ing agent to activate the catalyst), which will result in polymer chains that
may each individually have a gradient composition but individual chains in
the population will be indistinguishable.
7.3.5 SAXS analysis to investigate the structure of polycationic
nanoparticles
SAXS analysis can provide useful information about molecular struc-
ture and orientation for structures with highly ordered domains. The SAXS
pattern of the dry samples at ambient temperature and at 130 ºC, as well as
the aqueous samples, showed scattering at low q values but no distinct peaks
(see Figure 7.6 and Figure 7.14). The change in temperature may change
not only the structure, but also the x-ray contrast;34 however, no peaks are
present for either ambient or elevated (130 ºC) temperature. The absence of
peaks may indicate a) the structure is disordered, b) insufficient x-ray contrast
between the domains, c) the domains are too large (greater than ~500 Å) to
be detected using SAXS, or d) the domains are too small (less than 5 Å) to
be detected using SAXS. Since TEM indicates that dried nanoparticles are on
215
the order of 50 nm in diameter,22 it seems most likely that the structure is
too disordered, that the domains have low x-ray contrast, or that the domains
are too small to detect with SAXS. The crystalline regions compose a small
fraction of the total polymer and there is likely a distribution of tBMA-rich
regions.
7.4 Conclusion
This work considers the connections among polymerization method,
molecular structure, and material properties. Switching from the UV-initiated
polymerization to ARGET ATRP resulted in a narrower molecular weight dis-
tribution. In addition, a sharper glass transition for the cross-linked nanopar-
ticles was observed, which suggests reduced heterogeneity in tBMA-rich do-
mains. Switching to ARGET ATRP also eliminated a melting endotherm
present in the UV-initiated formulations consistent with PEG crystallites. The
reduced heterogeneity may explain the discontinuous pH-responsive transitions
previously reported for the 30ARGET compared to the continuous transition
for 30UV. The sharper transitions present in the ARGET ATRP formulations
motivate additional study in responsive materials using this new and poten-




Table 7.1: Guide to formulation nomenclature for the P(DEAEMA-co-tBMA-
co-PEGMA-co-TEGDMA) polycationic nanoparticles synthesized with AR-
GET ATRP or UV-initiated polymerization with 30 or 45 mol tBMA per 100
mol DEAEMA in the feed.
UV-initiated ARGET ATRP
30 mol tBMA per 100 mol
DEAEMA in the feed
30UV 30ARGET
45 mol tBMA per 100 mol
DEAEMA in the feed
45UV 45ARGET
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Table 7.2: Molar composition of the feed and the polymer. Polymer compo-
sition determined using 1H NMR of the P(DEAEMA-co-tBMA-co-PEGMA)
linear polymer chains made without TEGDMA, which served as linear analogs
of the cross-linked nanoparticles.
mol% in feed mol% in polymer
(from 1H NMR)
Formulation tBMA DEAEMA PEGMA tBMA DEAEMA PEGMA
30UV -
linear
21% 71% 7% 16% 75% 10%
45UV -
linear
29% 65% 6% 18% 66% 16%
30ARGET -
linear
21% 71% 7% 15% 78% 7%
45ARGET -
linear
29% 65% 6% 17% 75% 8%
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Table 7.3: Estimates of reactivity ratios determined using the Q-e scheme.
Monomer 1 fixed as DEAEMA. Glycidyl methacrylate and EGDMA selected
for their resemblance to PEGMA and TEGDMA, respectively, because Q-e
data was unavailable. EGDMA: ethylene glycol dimethacrylate





























0.88 0.24 2.19 0.44
220
Table 7.4: GPC was used to determine the molecular weight and the poly-
dispersity index for the P(DEAEMA-co-tBMA-co-PEGMA) linear polymer
chains made without TEGDMA. Mn and PDI were calculated as the PMMA
equivalent molecular weight and PMMA equivalent PDI from the main poly-
mer peak.
Formulation Elution time Mn PDI
30UV-linear 12.80 min 27,163 Da 2.53
45UV-linear 12.56 min 27,851 Da 2.07
30ARGET-linear 13.01 min 19,829 Da 1.46
45ARGET-linear 12.98 min 20,300 Da 1.52
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Table 7.5: Temperatures associated with the degradation steps of the
P(DEAEMA-co-tBMA-co-PEGMA-co-TEGDMA) polycationic nanoparticles,
where Td represents the temperature at the onset of degradation and Te is the
temperature that marks the end of the degradation step.
Formulation Td,1 Te,1 wt% at
275 ºC
Td,2 Te,2 wt% at
600 ºC
30UV 206 ºC 275 ºC 48.8% 401 ºC 450 ºC 2.8%
45UV 206 ºC 274 ºC 51.6% 401 ºC 449 ºC 3.3%
30ARGET 206 ºC 274 ºC 48.5% 404 ºC 450 ºC 5.7%
45ARGET 203 ºC 273 ºC 51.1% 402 ºC 447 ºC 8.1%
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Table 7.6: Ratio of crystalline PEG to total PEG in the P(DEAEMA-co-
tBMA-co-PEGMA-co-TEGDMA) polycationic nanoparticles calculated using





Table 7.7: Tg,overall describes the overall glass transition value for the multiple
overlapping Tg values, while Tg,1, Tg,2, and Tg,3 are the first, second, and
third (in the case of 45UV) individual Tg values that can be determined from
a careful, closer examination. Tg,n represents the highest individual Tg that
can be determined.
Formulation Tg,overall Tg,1 Tg,2 Tg,3 Tg,n-Tg,1
30UV 124 ºC 114 ºC 125 ºC - 11 ºC
45UV 116 ºC 106 ºC 115 ºC 120 ºC 14 ºC
30ARGET 107 ºC 107 ºC 111 ºC - 5 ºC




Figure 7.1: Schematic representation of the P(DEAEMA-co-tBMA-co-
PEGMA) statistical copolymer nanogels. The nanogels are cross-linked with
TEGDMA. The components tend to segregate based on hydrophobicity, with
the hydrophilic PEG forming a corona and the hydrophobic tBMA tending to
segregate to the core. The DEAEMA is hydrophilic when positively charged


















































Figure 7.2: Reaction scheme for creating P(DEAEMA-co-tBMA-co-PEGMA-
co-TEGDMA) polycationic nanoparticles using ARGET ATRP. EBIB was
used as the initiator and TEGDMA was the cross-linking agent. The reacted
initiator, monomer, and cross-linking agent are represented by i, m, and x,
respectively.
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(b) 1H NMR spectra with labeled peaks
Figure 7.3: Chemical structure of linear chains of P(DEAEMA-co-tBMA-
co-PEGMA) with labeled 1H NMR spectra peaks. Polymers are statistical















(b) 1H NMR spectra with labeled peaks
Figure 7.4: 1H NMR spectra for the four formulations of a) P(DEAEMA-co-
tBMA-co-PEGMA) linear chains and b) P(DEAEMA-co-tBMA-co-PEGMA-
co-TEGDMA) polycationic nanoparticles. Spectra are normalized with respect
to the DEAEMA peak at 1.17 ppm and 3.14 ppm for linear and cross-linked





















Figure 7.5: FTIR spectra for the P(DEAEMA-co-tBMA-co-PEGMA-co-
TEGDMA) polycationic nanoparticles. The spectra were normalized to the
carbonyl peak at 1730 cm-1. Dried polymer and potassium bromide were










Figure 7.6: GPC curve for the P(DEAEMA-co-tBMA-co-PEGMA) linear
polymer chains made without TEGDMA, which served as linear analogs of the
cross-linked nanoparticles. The peak to the right of the polymer peak at 14.61
min is the unreacted macro-monomer PEGMA with molecular weight 2080
that was not removed during purification. The presence of residual unreacted
monomer, particularly for the ARGET ATRP formulations, was confirmed
using NMR.
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(a) TGA thermogram in N2 atmosphere

























(b) Rate of weight loss in N2 atmosphere
Figure 7.7: TGA thermograms of the P(DEAEMA-co-tBMA-co-PEGMA-co-
TEGDMA) polycationic nanoparticles with nitrogen atmosphere. Formulation
00ARGET (no tBMA in the feed) is shown for comparison. Weight, % given
as percent of initial weight. The rate was determined from the derivative of
the weight, % versus temperature data. Additional tBMA appears to slow the
rate of the first degradation step.
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(a) TGA thermogram in air atmosphere

























(b) Rate of weight loss in air atmosphere
Figure 7.8: TGA thermograms of the P(DEAEMA-co-tBMA-co-PEGMA-
co-TEGDMA) polycationic nanoparticles with air atmosphere. Formulation
00ARGET (no tBMA in the feed) is shown for comparison. Weight, % given
as percent of initial weight. The rate was determined from the derivative of
the weight, % versus temperature data. Again, additional tBMA appears to
slow the rate of the first degradation step.
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Figure 7.9: DSC curves for the P(DEAEMA-co-tBMA-co-PEGMA-co-
TEGDMA) polycationic nanoparticles following annealing at 130 ºC to erase
thermal history. Curves are shifted vertically for clarity.
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Figure 7.10: DSC curves for the ARGET formulations of P(DEAEMA-co-
tBMA-co-PEGMA-co-TEGDMA) polycationic nanoparticles following anneal-
ing at 130 ºC to erase thermal history. Note that tBMA strongly influences Tg
behavior. If the tBMA is eliminated from the formulation (as in 00ARGET),
the resulting thermogram shows a broader, sloping decline in contrast to the
clearly defined transition for 30ARGET and 45ARGET.
235

















Figure 7.11: DSC curve showing the melting endotherm of PEGMA monomer
at 58 ºC. The sample was dried in a vacuum oven prior to thermal analysis.
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Figure 7.12: Close-up view of glass transition behavior shows multiple Tg val-
ues for each P(DEAEMA-co-tBMA-co-PEGMA-co-TEGDMA) polycationic
nanoparticle formulation. Curves are shifted vertically for clarity.
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(a) SAXS at ambient temperature















(b) SAXS at 130 ◦C
Figure 7.13: Integrated SAXS patterns of P(DEAEMA-co-tBMA-co-PEGMA-
co-TEGDMA) polycationic nanoparticles collected at ambient temperature or
130 °C after thermal annealing at 130 °C. The patterns are shifted vertically
for clarity.
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Figure 7.14: Integrated SAXS patterns of P(DEAEMA-co-tBMA-co-PEGMA-
co-TEGDMA) polycationic nanoparticles collected at 10 mg/ml polycationic
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Conclusions and Recommendations for Future
Research
8.1 Conclusions
The goal of this research was to create and investigate new polymers
prepared by ARGET ATRP-based (activators regenerated by electron transfer
for atom transfer radical polymerization) reactions in order to understand their
utility as biomaterials for drug delivery. Polycationic nanoparticles were syn-
thesized using a new ARGET ATRP-based technique and evaluated as drug
delivery biomaterials. A panel of polycationic nanoparticles was prepared us-
ing ARGET ATRP or UV-initiated polymerization and characterized in order
to examine the effect of polymerization method on material properties and the
connection to molecular structure.
This work represents the first report in the literature of an ARGET
ATRP-based emulsion in water synthesis method for polycationic nanoparti-
cles.1 The polycationic nanoparticles were composed of 2-(diethylamino)ethyl
methacrylate (DEAEMA) for pH-responsiveness, poly(ethylene glycol) methyl
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ether methacrylate (PEGMA) for improved biocompatibility, tert-butyl
methacrylate (tBMA) to impart hydrophobicity, and a tetraethylene glycol
dimethacrylate (TEGDMA) cross-linking agent for enhanced colloidal stabil-
ity. The polymerization takes 3 h and the reaction takes place at ambient
temperature.
The ARGET ATRP synthesis has advantages over UV-initiated poly-
merizations and traditional ATRP. Avoiding UV-initiation confers advantages
including ease of conducting multiple simultaneous reactions, synthesis pro-
tocols that can be scaled without account for the UV light source intensity
and exposure time, as well as the ability to use photosensitive components
such as dyes or biologically-derived components in the polymerization reac-
tion. Compared to traditional ATRP, ARGET ATRP significantly reduces
the concentration of copper catalyst and is much less oxygen-sensitive.
The ARGET ATRP synthesis method produces monodisperse, pH-
responsive polymer nanoparticles. The polycationic nanoparticles in solution
were analyzed with dynamic light scattering, and pH-responsiveness was con-
firmed. Transmission electron microscopy (TEM) analysis of the dried polyca-
tionic nanoparticles demonstrated that the particles are approximately spher-
ical.
The ARGET ATRP polycationic nanoparticles were investigated for
use as drug delivery vehicles with a central goal of inducing knockdown in cells
through successful siRNA delivery. Prerequisites for successful drug delivery
that are independent of the drug type include biocompatibility and the ability
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to load and release a drug. Drugs such as siRNA and chemotherapeutic agents
require carriers that can be internalized by cells. Effective siRNA delivery also
requires endosomal escape so that the siRNA can be released into the cytosol.
The first stage of evaluating the suitability for drug delivery compared
an array of polycationic nanoparticles synthesized using UV-initiated poly-
merization (similar to the method reported by Fisher et al.2;3) or ARGET
ATRP.1;4 The molar feed ratio of the hydrophobic component tBMA was set
at 30 or 45 mol tBMA per 100 mol DEAEMA in the feed. The four formula-
tions are named based on the synthesis method and the molar feed of tBMA
with respect to 100 mol DEAEMA in the feed: 30UV, 45UV, 30ARGET, and
45ARGET.
The array of polycationic nanoparticles was investigated using an MTS
assay with cancerous and non-cancerous cell lines. MTS assays provide a mea-
sure of relative viability based on the activity of cellular enzymes. For both
cell lines at the conditions tested, the ARGET ATRP formulations were more
toxic that the UV-initiated formulation with a corresponding feed concentra-
tion. Also, formulations containing 45 mol tBMA per 100 mol DEAEMA in
the feed were found to be less toxic than the corresponding 30 mol tBMA for-
mulations for both cell lines. The results of the MTS assay were confirmed with
an LDH (lactase dehydrogenase) assay which provides a measure of relative
viability as a function of the membrane leakage.
Effective siRNA delivery requires cellular internalization as well as en-
dosomal escape, so hemolysis assays were used as a measure of the endoso-
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molytic activity for the array of polycationic nanoparticles. All formulations
except for 30ARGET demonstrated pH-dependent hemolytic activity, with
strong membrane disruption at endosomal conditions (pH 6.5) and small to
negligible membrane disruption for extracellular conditions (pH 7.4). The
hemolysis assay results correlated with the membrane leakage measured using
an LDH assay, providing evidence that the increased toxicity of the 30ARGET
formulation was due to membrane disruption at extracellular conditions (pH
7.4).
The siRNA drug loading capability of the polycationic nanoparticles
was evaluated using a RiboGreen® siRNA binding assay. The array of poly-
cationic nanoparticles demonstrated efficient binding of siRNA (~98% for all
formulations) in 0.2x PBS pH 5.5. The binding efficiency is reduced in Opti-
MEM®, particularly for the 45ARGET formulation with 55% of the siRNA
bound to the polymer (compared to 74% for 30UV, 70% for 45UV, and 63%
for 30ARGET).
Flow cytometry was used to quantify the uptake of fluorescently-labeled
siRNA for the array of polycationic nanoparticles. All formulations demon-
strated efficient uptake with small differences among formulations but large
differences in the percent of cells with siRNA when comparing different cell
types (HEK293T and RAW264.7). The RAW264.7 cells have a higher per-
centage of cells associated with fluorescently-labeled siRNA compared to the
HEK293T cells. For both cell types, the 45ARGET formulation demonstrates
the largest normalized fluorescence intensity of the four polycationic nanopar-
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ticle formulations. The trends observed with flow cytometry were supported
by confocal microscopy.
Knockdown efficiency induced by siRNA was evaluated for the array
of polycationic nanoparticles using AllStars Death siRNA with HEK293T or
RAW264.7 cells. Knockdown was first confirmed in HEK293T cells, with the
greatest efficiency demonstrated by the 30UV, 30ARGET, and 45ARGET
formulations (78%, 84%, and 75% knockdown efficiency, respectively). Un-
fortunately, knockdown with these conditions was associated with decreased
cell viability for control cells with scrambled siRNA. When the siRNA con-
centration was decreased from 200 nM to 100 nM, the HEK293T cells with
scrambled siRNA demonstrate improved viability with decreased knockdown
efficiency. This trade-off between knockdown efficiency and viability is a con-
tinuing challenge of siRNA delivery carriers. Knockdown was also evaluated
in RAW264.7 cells because they are considered to be more difficult to trans-
fect than HEK293T cells. As expected, the RAW264.7 demonstrated lower
knockdown efficiencies than the HEK293T cells when transfected with 100
nM siRNA complexed to polycationic nanoparticles.
The second stage of evaluating the suitability for drug delivery focused
on a single polycationic nanoparticle formulation, 45ARGET, to take a closer
look at the interactions of the polycationic nanoparticles with siRNA and cells
in order to better understand the capabilities and limitations of the carrier. A
RiboGreen® siRNA binding assay was used to evaluate the binding profile for a
range of polymer/siRNA mass ratios, and the polycationic nanoparticles were
252
found to efficiently bind siRNA for polymer/siRNA mass ratios less than 1.
Dynamic light scattering indicated that siRNA binding was associated with
a decreased diameter of the polycationic nanoparticles without a significant
change in zeta potential.
A fluorescently-labeled 45ARGET formulation was prepared to inves-
tigate cellular internalization. Flow cytometry with RAW264.7 cells indicated
that the uptake of fluorescently-labeled nanoparticles increased with nanopar-
ticle concentration and incubation time. Confocal microscopy confirmed in-
ternalization of the fluorescently-labeled nanoparticles.
The dependence of knockdown on the concentration of 45ARGET poly-
cationic nanoparticles and siRNA was investigated in RAW264.7 cells. As ex-
pected, higher concentrations of nanoparticles and siRNA were associated with
increased knockdown. The 45ARGET formulation outperformed the commer-
cially available transfection agent Lipofectamine.
An improved understanding of molecular structure, and its connection
to synthesis techniques and material properties, may facilitate the design of en-
hanced materials. The four formulations of polycationic nanoparticles (30UV,
45UV, 30ARGET, and 45ARGET) were characterized using a variety of tech-
niques designed to probe the molecular structure. Nanoscale heterogeneity is
an important aspect of molecular structure, and the analysis demonstrated
that the ARGET ATRP polycationic nanoparticle formulations had greater
nanoscale homogeneity than the UV-initiated polymerization formulations.
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GPC (gel permeation chromatography) was used to analyze
P(DEAEMA-co-tBMA-co-PEGMA) linear chains to gain insight into the
molecular weight distribution of the polymer chains in the cross-linked polyca-
tionic nanoparticles. The ARGET ATRP linear chains have a narrower main
elution peak than the UV-initiated linear chains, suggesting a narrower distri-
bution of main chain lengths for the ARGET ATRP polycationic nanoparticles.
The narrower distribution of molecular weight may also explain the sharper
pH-responsive swelling transition of the ARGET ATRP polycationic nanopar-
ticles compared to the UV-initiated polycationic nanoparticles observed using
dynamic light scattering.
Thermal analysis using TGA (thermal gravimetric analysis) and DSC
(differential scanning calorimetry) provides additional information about ma-
terial properties. The polycationic nanoparticle formulations demonstrate sub-
tle differences in their TGA profiles in nitrogen and air. The DSC thermograms
show two main differences in the UV and the ARGET ATRP formulations:
i) the presence of a melting peak for the UV but not for the ARGET ATRP
formulations and ii) a sharper glass transition for the ARGET ATRP formu-
lations than for the UV formulations.
The UV-initiated polycationic nanoparticle formulations demonstrate
a melting peak consistent with the melting of crystallites in PEG-rich re-
gions. The ARGET ATRP polycationic nanoparticle formulations do not
demonstrate this melting peak, suggesting that the PEG is incorporated with
greater homogeneity so it cannot phase-separate. Also, the lack of crystallites
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may result from the lower PEGMA incorporation observed for the ARGET
ATRP formulations compared to the UV-initiated formulations as observed us-
ing NMR (nuclear magnetic resonance) of P(DEAEMA-co-tBMA-co-PEGMA)
linear chains.
The ARGET ATRP formulations demonstrate sharper glass transitions
than the UV-initiated formulations. This sharpness is consistent with a nar-
rower size distribution of tBMA-rich region for the ARGET ATRP formula-
tions with a broader size distribution of tBMA-rich regions in the UV-initiated
formulations. Unfortunately, SAXS (small-angle x-ray scattering) analysis to
probe molecular structure did not provide additional information. ARGET
ATRP-based reactions impart greater control than UV-initiated polymeriza-
tions because of the closer approximation to simultaneous initiation. With
simultaneous initiation, individual chains may have a gradient composition,
but individual chains in the population are indistinguishable.
8.2 Recommendations for future research
Future investigations of ARGET ATRP polycationic nanoparticles can
build on this research. Future work can see if ARGET ATRP may be used for
the synthesis of other types of stimuli-responsive nanoparticles composed of
different monomers. With respect to siRNA delivery, future work should seek
to translate the knockdown behavior observed in vitro to a therapeutically rel-
evant in vivo model. RT-qPCR (reverse transcriptase quantitative polymerase
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chain reaction) may provide an alternative method to detect knockdown by
quantifying mRNA expression. Unfortunately, the actual protein expression
may only weakly correlate with the mRNA concentration,5–7 and as a re-
sult, mRNA quantification may be an “inappropriate surrogate for protein
expression evaluation.”8 An in vitro co-culture model may be an important
step toward successful in vivo studies; for example, a recently reported 3D
co-culture model of inflammatory bowel disease may provide a format for ex-
periments that is more therapeutically relevant than mono-culture of epithelial
or macrophage cells alone.9 It is particularly important to account for the role
of culture conditions in transfection efficiency; for example, dramatically in-
creased transfection efficiency has been observed in 3D cell culture models
compared to 2D models.10 Simple 2D cell culture models are often unable to




[1] D. C. Forbes, M. Creixell, H. Frizzell, and N. A. Peppas. Polycationic
nanoparticles synthesized using ARGET ATRP for drug delivery. Eur. J.
Pharm. Biopharm., 84(3):472–478, 2013.
[2] O. Z. Fisher, T. Kim, S. R. Dietz, and N. A. Peppas. Enhanced core hy-
drophobicity, functionalization and cell penetration of polybasic nanoma-
trices. Pharm. Res., 26(1):51–60, 2008.
[3] O. Z. Fisher and N. A. Peppas. Polybasic nanomatrices prepared by UV-
initiated photopolymerization. Macromolecules, 42(9):3391–3398, 2009.
[4] D. C. Forbes and N. A. Peppas. Differences in molecular structure in
cross-linked polycationic nanoparticles synthesized using ARGET ATRP
or UV-initiated polymerization. Polymer, 54(17):4486–4492, 2013.
[5] G. Chen, T. G. Gharib, C. Huang, J. M. G. Taylor, D. E. Misek, S. L. R.
Kardia, T. J. Giordano, M. D. Iannettoni, M. B. Orringer, S. M. Hanash,
and D. G. Beer. Discordant protein and mRNA expression in lung ade-
nocarcinomas. Mol. Cell. Proteomics, 1(4):304–313, 2002.
[6] Q. Tian, S. B. Stepaniants, M. Mao, L. Weng, M. C. Feetham, M. J.
Doyle, C. Y. Eugene, H. Dai, V. Thorsson, J. Eng, D. Goodlett, J. P.
Berger, B. Gunter, P. S. Linseley, R. B. Stoughton, R. Aebersold, S. J.
Collins, W. A. Hanlon, and Hood. L. E. Integrated genomic and proteomic
258
analyses of gene expression in mammalian cells. Mol. Cell. Proteomics, 3
(10):960–969, 2004.
[7] L. Nie, G. Wu, and W. Zhang. Correlation between mRNA and protein
abundance in Desulfovibrio vulgaris: A multiple regression to identify
sources of variations. Biochem. Biophys. Res. Commun., 339(2):603–610,
2006.
[8] J. Carralot, T. Kim, B. Lenseigne, A. S. Boese, P. Sommer, A. Genovesio,
and P. Brodin. Automated high-throughput siRNA transfection in raw
264.7 macrophages: a case study for optimization procedure. J. Biomol.
Screen., 14(2):151–160, 2009.
[9] F. Leonard, E. Collnot, and C. Lehr. A three-dimensional coculture of
enterocytes, monocytes and dendritic cells to model inflamed intestinal
mucosa in vitro. Molecular Pharmaceutics, 7(6):2103–2119, 2010.
[10] J. Zoldan, A. K. R. Lytton-Jean, E. D. Karagiannis, K. Deiorio-Haggar,
L. M. Bellan, R. Langer, and D. G. Anderson. Directing human embryonic






Colon Targeted Delivery Using Nanoparticles
Encapsulated in Alginate
The polycationic nanoparticles may have utility as components of an
oral siRNA delivery system composed of siRNA-loaded nanoparticles encap-
sulated in alginate. This two-part system may be able to provide colon tar-
geted delivery of siRNA to the intestines for the treatment of conditions such
as inflammatory bowel disease (IBD) or colon cancer. Alginates are well-
characterized,1;2 commercially available3 biomaterials.
A.1 Colon targeted delivery
Colon targeted delivery may be advantageous for the treatment of dis-
eases of the large intestine where drug delivered directly to the disease site
may improve treatment effectiveness and reduce side effects associated with
non-specific delivery.4–6 Traditional oral administration results in drug absorp-
tion in the upper part of the gastrointestinal tract, while rectal administration
for colon delivery is subject to a high degree of variability.4 There is an unmet
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need for improved colon targeting systems.7
Approaches for colon targeting include pH-dependent, time-dependent,
pressure-dependent and enzyme-responsive systems, but each system has lim-
itations.4;7 Premature release in the small intestine or no release in the colon
have been reported for pH-dependent colon-targeted systems.8–11 The pH of
the colon (average of 7.0)12 falls within the range of reported values for the
pH of the small intestines: 5-6 as reported by Laroui and colleagues7 and 6.6
to 7.5 in the proximal small intestine (duodenum, see Figure A.1) to terminal
ileum, respectively, as reported by Evans and colleagues12), so a pH-dependent
approach may be inadequate for colon specific delivery. Time-dependent ap-
proaches take advantage of mechanisms such as swelling or erosion that can
be modeled as a function of time.7 However, colon transit may vary from a
few hours to 2 days13 and the system will be susceptible to this variation.4;11
Pressure-dependent systems use the increased intestinal pressure in the colon
from peristalsis to cause rupture of the system resulting in drug release.7
Enzyme-responsive systems are designed with degradable components
that trigger release. Typically, this degradation is caused by digestion of
polysaccharides by colonic bacteria.5;7 An example of such a system would
be using polysaccharide coating to coat a gelatin capsule to favor release in
the colon. The colon contains a very high concentration of microflora, with
typical concentration values of 1011 CFU/ml, compared to typical values of
103 CFU/ml elsewhere in the gastric track13 (note: CFU represents a colony-
forming unit and is a measure of viable microorganisms). These microflora
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in the colon compose about 400 bacterial species, but the main bacteria for
alginate degradation are Bacteroides and Bifidobacteria.5 Poor control over
release kinetics has been reported for some enzyme-responsive polysaccharide
systems that are degraded by microflora in the colon.14;15 The polysaccharides
typically used in enzyme-responsive systems are hydrophilic, and as a result,
may swell and prematurely release loaded drug prior to enzymatic degradation
in the colon.4
Several “di-dependent”4 delivery systems which take advantage of two
of the four targeting strategies (time, pH, pressure, or microflora enzymes)
have been developed including Pulsincap®, OROS®-CT, PORT®, and Time
Clock®.4 These multi-component systems may be highly effective, but the
complexity is a barrier to efficient manufacturing. Defects are an additional
concern; if defects cannot be engineered out of these systems, even low failure
rates may lead to problems in patients resulting from uncontrolled release. In
spite of the challenges, the reported successes of these di-dependent strategies
may motivate the use of a dual-responsive system that makes use of simpler
fabrication strategies.
A.2 Alginate as a biomaterial for oral delivery
Alginate is composed of linear, non-branched polysaccharides that are
copolymers of β-d-mannuronic acid (M) and α-l-guluronic acid (G) linked by
α- or β-1,4 glycosidic bonds (see Figure A.2a).1;16;17 Alginate is a natural an-
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ionic polyelectrolyte18 from brown algae.16;17 Alginate has many properties
that make it attractive for use as a biomaterial. Alginate is biocompatible (al-
though note that ultra-pure grade should be used when biocompatibility is crit-
ical2;17). Since networks are formed under mild conditions in salt solution,2;17
alginate gels can be used as biomaterials for drug delivery for traditional small
molecular drugs as well as fragile macromolecules such as proteins.1 Alginate
microparticles have been used for oral gene delivery of plasmid DNA.19 In the
food industry, alginate is used as a gelling agent, stabilizer, and emulsifier,1
and this accepted use in food is a positive indication supporting the use of
alginate in an oral delivery system.
The network structure of alginate hydrogels is formed when dissolved
alginate is combined with di- or tri-valent metal ions in solution.20 The alginate
is dissolved at 1-8%, with the 1-2% typically used for high molecular weight
alginate and 3-8% used for low molecular weight alginate.21 Large beads (mm
size) can be formed by manually pushing alginate solution through a syringe
needle, but compressed air automated systems can produce smaller (10-120
μm) alginate particles.22 While the particles can be stored in water, freeze-
drying provides a simple solution for storage, and freeze-drying is reported to
produce beads with a smooth surface morphology.21
The “egg-box” model is the most accepted model of network formation;
in the egg-box model, the calcium cations each bind to two G units to cross-
link the alginate chains (see Figure A.2b).20 The chains are cross-linked in a
physical network structure composed of many linear chains stacked together
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along multiple G residues.5
Alginates are pH-responsive and enzyme-responsive. At neutral pH
conditions, the divalent cross-linking cations dissociate and the network dis-
solves;1 particles remain intact at low pH but dissociate at high pH.19;21 Im-
portant parameters that influence erosion and release include particle size, vis-
cosity of the alginate solution, and chemical composition (G/M ratio) of the
alginate.16 Alginate is enzyme-responsive (as well as biodegradable) because
they are degraded by bacteria found at high concentrations in the colon.5
Bodmeier and associates23 reported a technique for the oral delivery of
microparticles and nanoparticles using alginate. Microparticles and nanoparti-
cles are of considerable interest for controlled release, but compression tablet-
ing may damage to particles or may require large concentrations of excipi-
ent fillers and binders.23 The reported technique used by Bodmeier and as-
sociates23 relied upon encapsulation of the microparticles or nanoparticles in
an alginate matrix formed by dropped alginate/particle dispersions into a cal-
cium chloride solution for cross-linking.23 The calcium alginate matrix was pH-
responsive; the matrix remained intact in 0.1 N hydrochloric acid but “rapidly
disintegrated in simulated intestinal fluids” (United States Pharmacopeia XIX,
USP XIX).23 While disintegration may be undesirable for applications where
a constant release rate of a small molecule therapeutic is desired,1 erosion or
disintegration may improve release of nanoparticles over diffusion alone.
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A.3 Materials and methods
A.3.1 Chemicals
Alginic acid from brown algae, pepsin, pancreatin, poly(ethylene gly-
col) methyl ether methacrylate (PEGMA) solution (Mn 2000 for PEG chain,
50 wt % in water), 2-(diethylamino)ethyl methacrylate (DEAEMA), tert-
butyl methacrylate (tBMA), tetraethylene glycol dimethacrylate (TEGDMA),
ethyl 2-bromoisobutyrate (EBIB), tris (2-pyridylmethyl) amine (TPMA), and
ascorbic acid (AA) were purchased from Sigma-Aldrich. Ethanol, phosphate
buffered saline (PBS), 1N hydrochloric acid (HCl), 1N sodium hydroxide
(NaOH), monobasic potassium phosphate, and calcium chloride were pur-
chased from Fisher Scientific. All other chemicals were reagent grade. Ultra-
pure water was used for all experiments. All chemicals were used as received.
A.3.2 Alginate encapsulation of fluorescently-labeled nanoparticles
Fluorescently-labeled nanoparticles were synthesized using NBD chlo-
ride (NBD-Cl, 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole, also called 4-chloro7-
nitrobenzofuran, Sigma-Aldrich). Nanoparticles containing primary amines
were synthesized with 2-aminoethyl methacrylate (AEMA, Sigma-Aldrich)
(AEMA:DEAEMA::32:100). Dried, purified nanoparticles were suspended
in ethanol and combined with an excess of NBD chloride; a typical reac-
tion was 450 mg of dried nanoparticles with 50 mg NBD chloride in 30 ml
ethanol. The mixture was allowed to react overnight to form NBD-labeled
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nanoparticles (NBD-NPs). Unreacted NBD-Cl was removed by dialysis and
the fluorescently-labeled nanoparticles were recovered with freeze-drying. Note
that the NBD-Cl becomes strongly fluorescent upon reaction with amines and
that NBD-amines are excited by visible light (464 nm) with emission maximum
of approximately 512 nm.
The encapsulation technique of Bodmeier and associates23 was adapted
to encapsulate polycationic nanoparticles in alginate beads. The synthesis is
simple and rapid; following dissolution of all components, bead formation takes
less than 10 minutes. The reaction conditions are mild and nontoxic; both
components (alginate and calcium chloride) are permitted for use in food by
the U.S. Food and Drug Administration (FDA).24 A solution with 2% alginic
acid and 1% nanoparticles was prepared and ejected through a 18 gauge syringe
needle dropwise into a stirring solution of 2% calcium chloride. The drops
form beads immediately upon addition to the calcium chloride solution. The
alginate beads loaded with nanoparticles were recovered by filtration, covered
with water, and then freeze-dried.
A.3.3 Alginate encapsulation confirmed using fluorescence mi-
croscopy
Fluorescently-labeled nanoparticles encapsulated in alginate were im-
aged using fluorescence microscopy with a Leica SP2 AOBS confocal micro-
scope or Zeiss Axiovert 200 M microscope. Dry beads where place between a
microscope slide and a cover slip using a spacer.
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A.3.4 Nanoparticle release from alginate matrices
Nanoparticle release from alginate matrices was initially evaluated us-
ing simulated gastric (pH 1.2) and intestinal fluid (pH 7.5) test solutions with
and without enzymes (United States Pharmacopeia (USP) XIX) as well as
in PBS at pH 2 and 7. Drug dissolution in simulated gastrointestinal fluids
is the USP standard for characterizing release for oral delivery systems. The
residence time of an oral system in the mouth and esophagus is very short and
thus not included as part of a USP standard, the system will spend approx-
imately 2.5 h and 3.3 h in the stomach and small bowel, respectively.25 The
proteolytic enzyme pepsin is a major stomach enzyme and pancreatin is repre-
sentative of intestinal enzyme. Pancreatin is a mixture of amylase, lipase, and
trypsin, to degrade starches, triglycerides, and proteins, respectively. Amylase
and lipase are also important enzymes present in saliva.
The simulated gastrointestinal solutions were used for static release ex-
periments and the PBS was used for a dynamic release experiment where there
was a step change in pH at 90 minutes. Alginate beads were added to the test
solutions at 0.5 mg beads/ml test solution and samples were collected (with re-
placement) to measure release over time. Photo-bleaching of the fluorophore
was minimized by avoiding light exposure to the beads, release solution, or
samples. The fluorescence intensity was measured with a plate reader (Syn-
ergy HT, BioTek Instruments, Inc.) with excitation set to a 20 nm filter at
485 nm and emission set to a 20 nm filter at 528 nm.
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A.4 Results and discussion
A.4.1 Alginate encapsulation confirmed using fluorescence mi-
croscopy
Fluorescently-labeled nanoparticles encapsulated in alginate were im-
aged using fluorescence microscopy with a Leica SP2 AOBS confocal micro-
scope (see Figure A.3) or Zeiss Axiovert 200 M microscope (see Figure A.4).
Beads without fluorescently-labeled nanoparticles had negligible autofluores-
cence. The image was used to confirm encapsulation of the nanoparticles by
the alginate as the beads show green fluorescence throughout.
A.4.2 Nanoparticle release from alginate matrices
Nanoparticle release from alginate matrices was initially evaluated us-
ing simulated gastric (pH 1.2) and intestinal fluid (pH 7.5) test solutions with
and without enzymes as well as in PBS at pH 2 and 7. While the limita-
tions of the preliminary calibration curves prevent determination of the exact
concentration (see Figure A.5), the concentration can be approximated us-
ing the linear regression trend line (see Figure A.6). The calibration curves
show scatter at low concentrations; the poor fit to a linear trend line at low
concentrations suggests that accurate concentration measurements at such low
fluorescence intensities will not be possible. The approximation results in some
concentration values that appear negative (although actual concentration val-
ues must be greater than zero). The release plots show release at high and
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neutral pH but no release at low pH. The release behavior is well defined in
simulated gastrointestinal test solutions without enzymes, but the presence of
enzymes results in curves that are less well define.
Images of the beads (dried beads, beads in buffers, and beads in simu-
lated gastric fluids) are shown in Figure A.7. The alginate beads used in the
dynamic release experiment where the pH was increased from pH 2 to pH 7
are swollen but intact. The alginate beads exposed to simulated gastric fluids
(pH 1.2, with and without enzymes) remained intact while the alginate beads
exposed to simulated intestinal fluid (pH 7.5, with and without enzymes) dis-
integrated.
A.5 Conclusion
Alginate encapsulation was investigated as a strategy for oral delivery.
Alginate is a biodegradable biopolymer has been approved for use in food, and
so it is an attractive candidate for an oral delivery system. pH-dependent re-
lease of fluorescently-labeled nanoparticles from the alginate encapsulation was
observed. Unfortunately, accurate quantitation at low concentrations was not
possible. While alginate encapsulation may be a useful oral delivery strategy,
effective translation of this technology would be best achieved by a commercial
partnership with access to a wide variety of alginate types in order to find the




Figure A.1: Gastrointestinal tract, shown from the stomach to the colon. The
pH increase from a value of 1.2-2 in the stomach, to 6.6 in the duodenum, to
an average pH value of 7 in the colon.12
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Figure A.2: Alginate is composed of repeating units of α-l-guluronic acid and
β-d-mannuronic acid.
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Figure A.3: Alginate bead containing polycationic nanoparticles fluorescently-
labeled with NBD. Images taken using the Leica SP2 AOBS confocal micro-
scope and processed using ImageJ software. Alginate does not have detectable
autofluorescence.
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(a) Brightfield of algi-
nate bead with NBD-
NPs
(b) Fluorescence of al-
ginate bead with NBD-
NPs
(c) Fluorescence of algi-
nate bead with NBD-NPs
(d) Fluorescence of algi-
nate bead without NPs,
normal exposure
(e) Fluorescence of algi-
nate bead without NPs,
near maximum exposure
intensity
(f) Fluorescence of algi-
nate bead with NBD-
NPs, medium exposure
intensity
Figure A.4: Alginate bead containing polycationic nanoparticles fluorescently-
labeled with NBD. Fluorescence can be detected at all locations observed on
the exterior of the bead. Images (b) and (c) show how the line of fluorescence
in focus travels up the bead while adjusting focus. Image (d) shows that aut-
ofluorescence of the alginate cannot be detected using the exposure settings
used for imaging the beads containing NBD-NPs, but image (e) shows that
autofluorescence can be detected by greatly increasing exposure up to 10.97
s, 182%. Image (f) shows that for the alginate beads with NBD-NPs, the
fluorescence is saturated at exposures much less than those to detect autoflu-
orescence. Images taken using the Zeiss Axiovert 200 M at 10 x. (a-d 92.82
ms, 98% exposure; e 10.97 s, 182% exposure; f 3s, 97% exposure).
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Linear fit for intestinal
(b) Low concentration range in simulated
gastrointestinal test solutions without en-
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(c) High concentration range in PBS






























(d) Low concentration range in PBS
Figure A.5: Calibration curves for fluorescently-labeled nanoparticles were pre-
pared in the simulated gastrointestinal solutions without enzymes and in PBS.
An additional calibration curve is needed for fluorescently-labeled nanoparti-





























(a) Static release in simulated gastroin-
































(b) Static release in simulated gastroin-
testinal test solutions with enzymes




























(c) Dynamic release in PBS
Figure A.6: Release of fluorescently-labeled nanoparticles from alginate ma-
trix. The concentration of nanoparticles was determined using a calibration
curve as a function of fluorescence intensity. The release with enzymes was
approximated using the calibration curve for solutions without enzymes. a)
Simulated gastric fluid at pH 1.2 and simulated intestinal fluid at pH 7.5 (USP
XIX), prepared without enzymes. b) Simulated gastric fluid at pH 1.2 with
pepsin and simulated intestinal fluid at pH 7.5 with pancreatin (amylase, li-
pase, and protease) (USP XIX). c) Release in PBS buffer at pH 2 and then
increased to pH 7 after 90 minutes.
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(c) Static release insimulated gastrointestinal fluids (gastric without
enzymes, gastric with enzymes, intestinal without enzymes, intestinal
with enzymes)
Figure A.7: Alginate beads after nanoparticle release experiment. From left to
right: simulated gastric fluid at pH 1.2 without enzymes, simulated intestinal
solution at pH 7.5 without enzymes, and PBS at pH 7. Alginate beads remain
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Appendix B
TNF-α Knockdown as a Strategy for the
Treatment of Inflammatory Bowel Disease
B.1 Introduction
RNAi-based therapeutics may offer improved treatment strategies to
treat and prevent inflammation. Inflammatory bowel disease, a disease char-
acterized by inflammation of the gastrointestinal tract, may benefit from a
treatment strategy designed to deliver anti-inflammatory siRNA to the in-
testines. There are an estimated 1.4 million people in the United States with
inflammatory bowel disease (IBD).1;2 The burden of the disease has been de-
scribed as “More Than Pain and Diarrhea”;3 the disease has a profound impact
on the individual as well as a heavy economic burden ($15.5 billion in direct
and indirect costs4) for the United States. The disease accounts for an esti-
mated 100,000 hospitalizations per year, and there are an estimated 119,000
people who are disabled and unable to work as a result of inflammatory bowel
disease.1
Inflammatory bowel disease in children is a huge challenge for physi-
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cians; both the disease and the therapeutics used to treat it can interfere with
growth and development, and some of the medications are associated with
serious or life-threatening cancers in children. There are an estimated 140,000
people under the age of eighteen with inflammatory bowel disease,1 and the
incidence rate in children is increasing.5
As its name suggests, inflammatory bowel disease is characterized by
inflammation in the gastrointestinal (GI) tract. Symptoms include diarrhea,
abdominal pain, GI bleeding, weight loss, fatigue, and fever (see Figure B.1).1
The exact cause is unknown but is believed to result from a combination
of genetic and environmental factors.6 It is a lifelong disease with periods
of remission and relapse. The symptoms of IBD do more than just affect
the patient’s quality of life; they can also lead to serious and life-threatening
complications.
The most common types of inflammatory bowel disease are ulcerative
colitis (UC) and Crohn’s disease (CD). The most important differences be-
tween the types are the location and the extent of the inflammation; for UC,
inflammation is restricted to the epithelial lining in the colon and the rectum,
and for CD, inflammation may occur anywhere in the gastrointestinal tract
(although it most commonly occurs in the intestine) and the inflammation
may spread deep into bowel tissue.7
There is no curative drug treatment for IBD; instead, treatment is
intended to induce and maintain remission. Each of the therapeutics used for
the treatment of IBD has limitations (see Table B.1) and for many patients,
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medications are not enough and surgery becomes necessary when symptoms
are uncontrolled or complications develop. Approximately 30% of people with
ulcerative colitis and 70% of people with Crohn’s disease will require surgery
at some point.8 Recall that in ulcerative colitis, inflammation is restricted to
the colorectal tissue, and so removing all of this tissue will “cure” the patient
whereas in the case of Crohn’s disease, the inflammation can occur throughout
the length of the GI tract and so cannot be “cured” with surgery.
The main focus of both biological and RNA interference (RNAi)-based
therapeutics for the treatment of inflammatory bowel disease has been anti-
tumor necrosis factor (TNF)-α functionality. Although the pathogenesis of
IBD is not well understood, it is acknowledged that TNF-α plays an impor-
tant role as a pro-inflammatory cytokine.9 Biological therapeutics that block
TNF-α include infliximab (Remicade®, Janssen Biotech, Inc.), adalimumab
(Humira®, Abbott Laboratories), and certolizumab (Cimzia®, UCB, Inc.),
and etanercept (Enbrel®, Pfizer), and all but etanercept are recommended
treatments for Crohn’s disease.10 These biological therapeutics lead to sys-
temic TNF-α repression that can lead to serious side effects; adverse events
such as mycobacterial infections (tuberculosis) or allergic responses (anaphy-
laxis) have been reported.11 Perhaps even more concerning is the potential
carcinogenicity of the treatments, but there is insufficient data to conclude if
the reported cases of cancer following infliximab treatment were caused by the
infliximab.11 Unfortunately, up to a third of patients in clinical trials have been
unresponsive to infliximab treatment.4;11 Natalizumab (Tysabri®, Elan Phar-
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maceuticals, Inc) is distinct from other biologic treatments for Crohn’s disease
because it is not an anti-TNF-α antibody but instead is an antibody against
the cellular adhesion molecule α4-integrin.12 Therapeutic siRNAs investigated
with oral delivery systems include anti-TNF-α siRNA used by Wilson and as-
sociates13 and Amiji and Kriegel14 as well as Cyclin D1 (regulates cell cycle
progression) used by Amiji and colleagues14 and Map4k4 (facilitates TNF-α
signaling) used by Aouadi and associates.15
B.2 Experimental section
B.2.1 Chemicals
Reagents poly(ethylene glycol) methyl ether methacrylate (PEGMA)
solution (Mn 2000 for PEG chain, 50 wt% in water), 2-(diethylamino)ethyl
methacrylate (DEAEMA), tert-butyl methacrylate (tBMA), tetraethylene
glycol dimethacrylate (TEGDMA), ethyl 2-bromoisobutyrate (EBIB), tris
(2-pyridylmethyl) amine (TPMA), ascorbic acid (AA), and Dulbecco’s
Phosphate-Buffered Saline (DPBS) were purchased from Sigma-Aldrich. 1
N Hydrochloric acid (HCl) and phosphate buffered saline (PBS) were pur-
chased from Fisher Scientific. Copper(II) bromide was purchased from Acros
Organics. Ultrapure water was used for all studies. All chemicals were used
as received.
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B.2.2 Nanoparticle synthesis and purification
The P(DEAEMA-co-PEGMA-co-tBMA-co-TEGDMA) polycationic
nanoparticles were prepared as described previously16;17 with an ARGET
ATRP catalyst/ligand/initiator system (CuBr2/TPMA/EBIB) and 45 mol
tBMA and 10 mol PEGMA with respect to 100 mol DEAEMA in the feed.
The monomer-in-water emulsion was stabilized with 8 mg/ml Brij® 30 (Acros
Organics) and 1.35 mg/ml myristyltrimethylammonium bromide (MyTab,
Sigma-Aldrich) at a 0.1 weight ratio monomer to solvent. The mixture
was probe sonicated (S-4000 Misonix Ultrasonicator Misonix Inc.) and de-
gassing with nitrogen prior to adding degassed ascorbic acid solution as a
reducing agent (AA:DEAEMA::0.5:100) to start the reaction. The reaction
was allowed to continue for 3 h and the nanoparticles were purified using a
technique described previously by Fisher and Peppas18 with repeated pre-
cipitation/resuspension with acetone/0.5 N HCl followed by dialysis (12,000-
14,000 molecular weight cut off regenerated cellulose tubing, Spectra/Por®)
and freeze-drying.
Fluorescently-labeled nanoparticles were synthesized using NBD chlo-
ride (NBD-Cl, 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole, also called 4-chloro7-
nitrobenzofuran, Sigma-Aldrich). Nanoparticles containing primary amines
were synthesized with 2-aminoethyl methacrylate (AEMA, Sigma-Aldrich)
(AEMA:DEAEMA::32:100). Dried, purified nanoparticles were suspended
in ethanol and combined with an excess of NBD chloride; a typical reac-
tion was 450 mg of dried nanoparticles with 50 mg NBD chloride in 30 ml
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ethanol. The mixture was allowed to react overnight to form NBD-labeled
nanoparticles (NBD-NPs). Unreacted NBD-Cl was removed by dialysis and
the fluorescently-labeled nanoparticles were recovered with freeze-drying. Note
that the NBD-Cl becomes strongly fluorescent upon reaction with amines and
that NBD-amines are excited by visible light (464 nm) with emission maximum
of approximately 512 nm.
B.2.3 Cell culture
Murine macrophage RAW264.7 cells (obtained from American Type
Culture Collection) were maintained in Dulbecco’s Modified Eagle’s Medium
high glucose without L-glutamine (DMEM, Sigma-Aldrich) supplemented with
with 1% L-glutamine (MediaTech), 1% penicillin (Sigma-Aldrich), 1% strepto-
mycin (Sigma-Aldrich), and 10% HyClone USDA Tested Fetal Bovine Serum
(FBS, Thermo Scientific). Cells were plated in 2% FBS complete media
(no phenol red) or 10% FBS complete media. Opti-MEM® Reduced Serum
Medium, no Phenol Red (Life Technologies) was used for transfection experi-
ments.
B.2.4 Internalization of fluorescently-labeled nanoparticles evalu-
ated using flow cytometry and confocal microscopy
Flow cytometry was used to quantify internalization of fluorescently-
labeled nanoparticles. Flow cytometry measurements were collected using a
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BD Fortessa Flow Cytometer and analyzed using FACSDiva software (BD Bio-
sciences). 1 million RAW264.7 cells were plated in a flask (T25) in 2 % FBS
media (complete, no phenol red) and incubated for 18 h. Next, cells were incu-
bated for 2 h with 0.25 mg/ml fluorescently-labeled polycationic nanoparticles
in 2 % FBS media. Following this 2 h incubation, cells were rinsed three times
with cold DPBS pH 7.4 prior to scraping (RAW264.7) to form a cell suspen-
sion. The cell suspension was centrifuged, the supernatant discarded, and the
pellet resuspended in flow cytometry buffer (1% FBS in DPBS). The samples
were stored in darkness at 4 °C before measurement. The results are reported
in two ways: as the average percent of cells (taken over a large number of cells,
typically 10,000) containing fluorescently-labeled DY647 siRNA.
Flow cytometry does not distinguish between surface bound and inter-
nalized fluorescence signal, so confocal microscopy was used to verify internal-
ization of the fluorescently-labeled nanoparticles. RAW 264.7 cells were seeded
at 95,000 cells/well on acid-wash glass cover slips in a 12 well plate. Cells
were incubated for 18 h prior to 2 h incubation with 0.25 mg/ml fluorescently-
labeled nanoparticles in 2% FBS media. Following incubation, cells were rinsed
three times with 1xPBS pH 7.4. Cells were fixed with 4% para formaldehyde
in 1xDPBS for 10 min at room temperature prior to washing three times with
HBSS (BioWhittaker). Cells were stained with 1 μg/ml Wheat Germ Agglu-
tinin (WGA) Alexa Fluor 594 conjugate for 10 min at room temperature. Cells
were rinsed twice with cold HBSS and once with DI water (autoclaved). Cover
slips were mounted to glass slides using Prolong® Gold anti-fade reagent with
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DAPI (Life Technologies) and stored in the freezer prior to imaging.
Confocal images were acquired using a Zeiss LSM 710 confocal micro-
scope with a 63x objective. The gain and offset for the different channels
were kept constant for the full series of images to permit image comparisons.
Images were collected in 16 bit format, and all images underwent identical
post-processing (γ=0.45 for red and blue channels, γ=0.1.3 for brightfield,
and brightfield scale adjusted to max/min using ZEN Blue).
B.2.5 Induce inflammation with LPS in RAW264.7 cells
RAW264.7 cells were seeded at 240,000 cells/well in 6 well plates (Nunc,
Thermo Scientific) in 2% FBS complete media (no phenol red). After 18 h
incubation, the media was replaced with 2% FBS complete media (no phenol
red) or solutions (200 to 3.125 ng/ml in dilutions by halves) of lipopolysaccha-
ride (LPS, Sigma-Aldrich) to induce inflammation. Samples of the supernatant
were removed at various times (0 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h, and 48
h) and stored at -80 °C prior to analysis of the TNF-α expression.
The TNF-α expression in the RAW264.7 cell supernatant was evaluated
by TNF-α-induced killing of L929 cells.19;20 The relative viability of the L929
following incubation with the TNF-α-containing supernatant is correlated with
the concentration of the TNF-α. L929 cells were seeded at 35,000 cells per
well in 96 well plates (Nunc, Thermo Scientific) in 100 µl of 2% FBS complete
media (no phenol red). After 18 h incubation, 50 µl of supernatant sample (or
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control) and 50 µl of 8 µg/ml Actinomycin D were added to each well. After
24 h incubation, the media was removed and cells were rinsed once with 100
µl PBS and cells were incubated for 2.5 h with CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS, Promega) with serum-free DMEM
without phenol red (Sigma-Aldrich). The absorbance at 690 nm (background)
and 490 nm (MTS assay) was measured using a microplate reader (Synergy
HT, BioTek Instruments, Inc.), and cell viability (V) was calculated as shown
in Equation B.1:
V = A490, sample − A690, sample − (A490, no cells − A690, no cells)
A490 media − A690, media − (A490, no cells − A690, no cells)
(B.1)
B.2.6 Transfect RAW264.7 cells with anti-TNF-α siRNA and in-
duce inflammation with LPS
RAW264.7 cells were transfected with anti-TNF-α siRNA prior to treat-
ment with LPS to induce inflammation to check for knockdown of TNF-α
expression. Three different conditions were tested, varying in cell seeding con-
ditions, transfection conditions, transfection incubation time, and LPS treat-
ment incubation time (see Table B.2). The Student’s t-test (two-tailed, un-
equal variance) was used to determine statistical significance. Knockdown was








Condition 1: RAW264.7 cells were seeded at 95,000 cells per well in 12
well plates in 2% FBS complete media (no phenol red) and incubated for
18 h prior to adding fresh media (2% FBS, complete, no phenol red). After
1 h incubation with fresh media, complexes of polycationic nanoparticles or
Lipofectamine2000 with siRNA were added.
The polycationic nanoparticle/siRNA complexes were prepared ahead
of time using anti-TNF-α or negative control siRNA (Life Technologies). To
prepare the complexes, 1.5 mg/ml polycationic nanoparticles with 150 nM
siRNA in 1x PBS pH 5.5 were incubated for 1 h in nuclease-free low-adhesion
tubes. Next, acetone was added and the tubes were centrifuged for 15 min at
14,500 rpm to form a pellet. The supernatant was discarded and the tubes
allowed to dry for ~20 min in a laminar flow hood so residual acetone could
evaporate. The pellets were resuspended and added to cells at 1/6 the concen-
tration of the preparation. Lipofectamine2000/siRNA complexes were added
to wells for 0.25 µl/well Lipofectamine2000 with 25 nM siRNA.
The RAW264.7 cells were incubated with the complexes for 4 h prior
to removal and replacement with fresh media (2% FBS, complete, no phenol
red). After 20 h incubation with the fresh media, samples of supernatant were
removed (0 h time point) and cells were incubated with 200 ng/ml LPS in
media. Supernatant samples were removed at 1 h and 24 h and the TNF-α
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concentration was evaluated using a TNF-α ELISA (eBioscience) according to
the manufacturers instructions.
Condition 2: RAW264.7 cells were seeded at 10,000 cells per well in 96
well plates in 10% FBS complete media. After 18 h incubation, the media was
replaced with Opti-MEM®. The nanoparticles were combined with siRNA
(anti-TNF-α or negative control siRNA) in 1xPBS pH 5.5. The complexes
were added to cells following 1 h incubation with Opti-MEM®. The final con-
centration of polycationic nanoparticles in the wells was 0.025 mg/ml with 100
nM or 200 nM siRNA. Lipofectamine2000 wells contained 0.25 µl/well Lipo-
fectamine2000. Following 42 h incubation, media was removed and cells were
incubated with Opti-MEM® or 200 ng/ml LPS in Opti-MEM®. Following 7
h incubation, the supernatant was removed and the TNF-α concentration was
evaluated using a TNF-α ELISA (eBioscience) according to the manufacturers
instructions.
Condition 3: Condition 3 varies from Condition 2 only in the incubation
times for transfection and LPS treatment. In Condition 3, the RAW264.7 cells
are incubated with the complexes for 26 h and with 200 ng/ml LPS for 16 h.
B.3 Results and discussion
The ability of polycationic nanoparticles to reduce TNF-α expression
in inflamed RAW264.7 cells was evaluated. LPS was used to induce inflam-
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mation in RAW264.7 cells. TNF-α is an important target for the treatment of
inflammatory diseases, such as inflammatory bowel disease and arthritis.
B.3.1 Internalization of fluorescently-labeled nanoparticles evalu-
ated using flow cytometry and confocal microscopy
The internalization of fluorescently-labeled nanoparticles by RAW264.7
cells was evaluated using flow cytometry. RAW264.7 cells were incubated for
2 h with 0.25 mg/ml fluorescently-labeled nanoparticles. The fluorescently-
labeled nanoparticles are efficiently internalized by the RAW264.7 cells, with
~88% of cells associated with fluorescently-labeled nanoparticles (representa-
tive histogram shown in Figure B.2). Confocal microscopy confirmed internal-
ization of the fluorescently-labeled nanoparticles (see Figure B.3 and Figure
B.4).
B.3.2 Induce inflammation with LPS in RAW264.7 cells
Inflammation was induced in RAW264.7 cells with LPS at various con-
centrations. The inflammation profile of the RAW264.7 cells for various con-
centrations of LPS over time was determined using TNF-α-induced killing of
L929 cells because the relative viability of the L929 cells can be correlated
with the TNF-α expression of the RAW264.7 (see Figure B.5); increased vi-
ability is associated with decreased TNF-α. After 1 h of incubation of LPS
with RAW264.7 cells, the different concentrations of LPS all produce signifi-
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cant TNF-α (see Figure B.6). The 200 ng/ml LPS concentration was selected
for future experiments.
B.3.3 Transfect RAW264.7 cells with anti-TNF-α siRNA and in-
duce inflammation with LPS
RAW264.7 cells were transfected with anti-TNF-α siRNA prior to treat-
ment with LPS to induce inflammation. Three different conditions were tested,
varying in cell seeding density, transfection conditions, transfection incubation
time, and LPS treatment incubation time. The transfection with anti-TNF-
α siRNA was intended to induce knockdown of TNF-α expression. Unfor-
tunately, the knockdown of TNF-α was highly variable within and between
experiments, and it also dependent on the incubation times used in the exper-
iment.
Some statistically significant knockdown was observed in RAW264.7
cells that had been transfected with Condition 1. The cells had been incubated
for 4 h with complexes and then the media was changed. After 20 h, inflam-
mation was induced using 200 ng/ml LPS and samples were analyzed from 0 h,
1 h, and 24 h. The 0 h samples demonstrate that the 45ARGET polycationic
nanoparticles induce TNF-α expression while the Lipofectamine2000 TNF-α
expression is indistinguishable from the no-carrier control (see Figure B.7).
As a result, although the 45ARGET formulation induces TNF-α knockdown
at 0 h (14-16%), the TNF-α expression of the RAW264.7 cells treated with
45ARGET/anti-TNF-α siRNA still exceeded that of the no-carrier control.
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For cells treated with LPS for 1 h or 24 h, the Lipofectamine2000 outper-
formed the 45ARGET polycationic nanoparticles (see Figure B.8 and Figure
B.9). There was 17% knockdown with Lipofectamine2000 for both 1 h and 24
h and 11% knockdown with the 45ARGET for 24 h. Unfortunately, neither the
45ARGET nor the Lipofectamine2000 was able reduce the TNF-α expression
to a value comparable to that of the no LPS, no-carrier control.
Some knockdown was observed in RAW264.7 cells that had been trans-
fected 42 h prior to 7 h treatment with LPS (Condition 2). In one experiment,
statistically significant knockdown was only observed after LPS treatment of
cells that had been transfected with 100 nM anti-TNF-α siRNA complexed
with 0.025 mg/ml polycationic nanoparticles (69% knockdown, see Figure
B.10). Unfortunately, when the experiment was repeated, statistically signifi-
cant knockdown was only observed for 100 nM anti-TNF-α siRNA complexed
with Lipofectamine2000 (25% knockdown) and increased TNF-α expression
was observed for cells transfected with 45ARGET with 100 nM or 200 nM
anti-TNF-α siRNA (see Figure B.11).
No knockdown was observed for RAW264.7 cells that had been trans-
fected with Condition 3 (see Figure B.12). The cells had been incubated for 26
h with complexes followed by 16 h incubation with 200 ng/ml LPS to induce
inflammation. The lack of knockdown observed may be a result of the reduced




The proinflammatory cytokine TNF-α is an important target for
the treatment of inflammatory diseases, such as inflammatory bowel dis-
ease and arthritis. RAW264.7 cells were pre-treated with polycationic
nanoparticle/anti-TNF-α siRNA complexes prior to LPS-stimulation to in-
duce inflammation. Unfortunately, the knockdown of TNF-α expression was
low in magnitude and highly variable depending on the transfection conditions.
Problems with in vitro transfection for 2D cell cultures have been reported in
the literature, with improved knockdown observed in 3D cell culture models
that are better able to represent complex biological systems.21 As a result,
the knockdown may be improved in a more complex model that better repre-
sents the inflammatory process. Alternatively, the anti-TNF-α-siRNA delivery
strategy with the 45ARGET polycationic nanoparticles may not be sufficient





Table B.1: Medications used to treat IBD and their disadvantages. Improved






Frequent (3-4 x) daily dosing





Risks: steroid dependence, infection,
osteoporosis












Table B.2: Conditions for RAW264.7 transfection with anti-TNF-α siRNA.
FBS: fetal bovine serum, NPs: polycationic nanoparticles
Parameter Condition 1 Condition 2 Condition 3
Plate 12-well 96-well 96-well






































































4 h (20 h with
fresh media)








Figure B.1: Comparison of Ulcerative Colitis (UC) and Crohn’s Disease (CD),
the two main types of inflammatory bowel disease. Many of the symptoms are




(b) RAW264.7 cells with fluorescently-
labeled nanoparticles
Figure B.2: Representative histograms for flow cytometry to quantify uptake
of fluorescently-labeled nanoparticles. a) Blank b) RAW264.7 cells incubated
for 2 h with 0.25 mg/ml fluorescently-labeled nanoparticles.
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Figure B.3: Confocal microscopy to image internalization of fluorescently-
labeled nanoparticles: orthogonal view. Orthogonal projections repre-
sent cross-sectional slices, and they are obtained by taking z-stack images.
RAW264.7 cells incubated for 2 h with 0.25 mg/ml fluorescently-labeled
nanoparticles prior to rinsing, fixing, staining, and mounting. Confocal images
were acquired with a Zeiss LSM 710 confocal microscope with a 63x objec-
tive. The settings for the green laser were adjusted such that blank cells (no
nanoparticles) demonstrated negligible fluorescence. Images were collected in
16 bit format, and all images underwent identical post-processing (γ=0.45 for
red, blue, and green channels, γ=1.3 for brightfield, and brightfield scale ad-
justed to max/min using ZEN Blue). Red: cell membrane stained with Wheat
Germ Agglutinin (WGA) Alexa Fluor 594 conjugate, blue: nuclei stained with
DAPI, green: fluorescently-labeled nanoparticles
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Figure B.4: Confocal microscopy to image internalization of fluorescently-
labeled nanoparticles: RAW264.7 cells without fluorescently-labeled nanopar-
ticles. Confocal images were acquired with a Zeiss LSM 710 confocal micro-
scope with a 63x objective. The settings for the green laser were adjusted
such that blank cells (no nanoparticles) demonstrated negligible fluorescence.
Images were collected in 16 bit format, and all images underwent identical post-
processing (γ=0.45 for red, blue, and green channels, γ=1.3 for brightfield, and
brightfield scale adjusted to max/min using ZEN Blue). Red: cell membrane
stained with Wheat Germ Agglutinin (WGA) Alexa Fluor 594 conjugate, blue:






















Figure B.5: The relative viability of L929 cells following TNF-α killing is
correlated to the concentration of TNF-α. L929 cells were incubated with
TNF-α dilutions. Data are represented as the mean plus/minus the standard
deviation (n=3). For large concentrations of TNF-α, the standard deviations






































































(b) LPS to induce inflammation
Figure B.6: Inflammation profile of RAW264.7 cells following incubation with
LPS plotted versus a) concentration of LPS, ng/ml and b) incubation time,
h. The relative viability of L929 cells following TNF-α killing is correlated to
the concentration of TNF-α. L929 cells were incubated with supernatant from
RAW264.7 cells following incubation with LPS. Data are represented as the






















































































(b) LPS to induce inflammation
Figure B.7: TNF-α expression by RAW264.7 cells a) without LPS and b) with
LPS (Condition 1, 0 h). RAW264.7 cells are incubated for 4 h with polycationic
nanoparticle/siRNA complexes (acetone precipitate and re-suspend) and then
20 h with fresh media prior to removing supernatant for analysis of TNF-α with
ELISA. Data is plotted as the mean plus/minus the standard deviation for n=2
biological replicates and n=2 technical ELISA replicates for each biological






















































































(b) LPS to induce inflammation
Figure B.8: TNF-α expression by RAW264.7 cells a) without LPS and b) with
LPS (Condition 1, 1 h). RAW264.7 cells are incubated for 4 h with polycationic
nanoparticle/siRNA complexes (acetone precipitate and re-suspend) and then
20 h with fresh media. Next, cells are incubated for 1 h with 200 ng/ml
LPS prior to removing supernatant for analysis of TNF-α with ELISA. Data
is plotted as the mean plus/minus the standard deviation for n=2 biological
replicates and n=2 technical ELISA replicates for each biological replicate.





















































































(b) LPS to induce inflammation
Figure B.9: TNF-α expression by RAW264.7 cells a) without LPS and b) with
LPS (Condition 1, 24 h). RAW264.7 cells are incubated for 4 h with poly-
cationic nanoparticle/siRNA complexes (acetone precipitate and re-suspend)
and then 20 h with fresh media. Next, cells are incubated for 24 h with 200
ng/ml LPS prior to removing supernatant for analysis of TNF-α with ELISA.
Data is plotted as the mean plus/minus the standard deviation for n=2 biolog-
ical replicates and n=2 technical ELISA replicates for each biological replicate.

































































































































(b) LPS to induce inflammation
Figure B.10: Relative expression of TNF-α by RAW264.7 cells a) without LPS
and b) with LPS (Condition 2, experiment 1). RAW264.7 cells are incubated
for 42 h with 0.025 mg/ml polycationic nanoparticles with 100 nM or 200 nM
siRNA or 0.25 µl/well Lipofectamine2000 (Lipo2000) with 100 nM siRNA.
Following this incubation, cells were incubated for 7 h with Opti-MEM® or
200 ng/ml LPS in Opti-MEM®. TNF-α concentration was determined using
a TNF-α ELISA. Data is plotted as the mean plus/minus the standard de-
viation for n=2 biological replicates and n=2 technical ELISA replicates for




















































































































(b) LPS to induce inflammation
Figure B.11: Relative expression of TNF-α by RAW264.7 cells a) without LPS
and b) with LPS (Condition 2, experiment 2). RAW264.7 cells are incubated
for 42 h with 0.025 mg/ml polycationic nanoparticles with 100 nM or 200 nM
siRNA or 0.25 µl/well Lipofectamine2000 (Lipo2000) with 100 nM siRNA.
Following this incubation, cells were incubated for 7 h with Opti-MEM® or
200 ng/ml LPS in Opti-MEM®. TNF-α concentration was determined using
a TNF-α ELISA. Data is plotted as the mean plus/minus the standard de-
viation for n=3 biological replicates and n=2 technical ELISA replicates for






























































































(b) LPS to induce inflammation
Figure B.12: Relative expression of TNF-α by RAW264.7 cells a) without
LPS and b) with LPS (Condition 3). RAW264.7 cells are incubated for 26 h
with 0.025 mg/ml polycationic nanoparticles with 100 nM or 200 nM siRNA
or 0.25 µl/well Lipofectamine2000 (Lipo2000) with 100 nM siRNA. Following
this incubation, cells were incubated for 16 h with Opti-MEM® or 200 ng/ml
LPS in Opti-MEM®. TNF-α concentration was determined using a TNF-α
ELISA. Data is plotted as the mean plus/minus the standard deviation for n=6
biological replicates and n=2 technical ELISA replicates for each biological
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Block copolymers are macromolecules composed of “two or more chem-
ically distinct polymer blocks.”1 Block copolymers, as well as certain types of
graft copolymers, can combine properties of the constituent polymers. If the
polymer blocks are thermodynamically incompatible, they may phase segre-
gate to form complex nanostructures. In solution, amphiphilic block copoly-
mers can self assemble to form structures like micelles with a hydrophobic core
and a hydrophilic corona.2–4 These self-assembled structures formed from block
copolymers are of great interest to researchers designing drug delivery vehi-
cles.5 The hydrophobic core may be loaded with hydrophobic chemotherapeu-
tic agents6–8 and stimuli-responsive components that are pH-responsive,9–11
photo-responsive,12 temperature-responsive,13 or multi-responsive14 may be
incorporated in order to achieve controlled drug release. Advanced struc-
tures such as core or shell cross-linked micelles may represent an improvement





Reagents poly(ethylene glycol) methyl ether methacrylate (PEGMA)
(Mn 300 for PEG chain), 2-(dimethylamino)ethyl methacrylate (DMAEMA),
ethyl 2-bromoisobutyrate (EBIB), tris (2-pyridylmethyl) amine (TPMA),
ascorbic acid (AA), and tin(II) 2-ethylhexanoate were purchased from Sigma-
Aldrich. 2-Propanol (IPA) was purchased from Fisher Scientific. Copper(II)
bromide was purchased from Acros Organics. Ultrapure water was used for
all studies. All chemicals were used as received.
C.2.2 Synthesis
PPEGMA and PPEGMA-b-PDMAEMA linear polymer chains
were synthesized in a two-step ARGET ATRP synthesis reac-
tion. In the first step, reagents were combined at molar ratios of
CuBr2:TPMA:EBIB:PEGMA::0.04:0.4:1:50 in a mixed solvent of 95/5
v/v IPA/W at a ratio of 1.75 v/v solvent/monomer. After a nitrogen
purge, the reaction was started by adding a reducing agent solution of
tin(II) 2-ethylhexanoate in IPA (10 mg/ml) at a molar ratio of EBIB:tin(II)
2-ethylhexanoate::1:0.25. The mixture was allowed to react overnight and
then 25% of the reaction volume was removed for analysis. In the second
step, DMAEMA was added at molar ratios PEGMA:DMAEMA::50:60, the
mixture was purged with nitrogen, and the reaction was started by adding
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a reducing agent solution of tin(II) 2-ethylhexanoate in IPA (10 mg/ml) at
a molar ratio of EBIB:tin(II) 2-ethylhexanoate::1:0.25. The mixture was
allowed to react overnight.
C.2.3 Instrumentation
Molecular weight and polydispersity data were collected on an Agilent
1200 Series Iso Pump and Autosampler with an Agilent Technologies 1100 RI
detector. One PLgel 5 µm, 100 Å column and one PLgel 5 µm, 10,000 Å
column were used with 0.01 M lithium bromide (LiBr) in dimethylformamide
(DMF) eluent at 70 °C and a flow rate of 1 ml/min. The elution times were
compared to nine poly(methyl methacrylate) (PMMA) standards (1660, 2200,
4250, 6370, 12600, 23500, 41400, 89300, and 201000 Da), which were used to
calibrate the instrument by refractive index response (conventional calibra-
tion).
The polymers were characterized with 1H NMR (nuclear magnetic res-
onance). Dried polymer was dissolved in deuterated chloroform (CDCl3) at
approximately 15 mg/ml. Spectra were obtained using a Varian DirectDrive
400 MHz Nuclear Magnetic Resonance Spectrometer equipped with an auto-
matic sampler and analyzed using SpinWorks 3™ software. The molar ratio of
the PEGMA and the DMAEMA was determined by comparing the integrated
intensity of the methoxy proton peak of PEGMA at 3.32 ppm and to that of
the methyl proton peak of DMAEMA at 2.23 ppm.
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C.3 Results and discussion
The linear homopolymers were analyzed with GPC to determine molec-
ular weight distribution and with NMR to determine the composition. Chain
extension of the first block confirmed with GPC combined with NMR data to
confirm the addition of monomers in the second block is needed to demonstrate
the synthesis of a block copolymer.
C.3.1 Analysis of molecular weight distribution with GPC
Gel permeation chromatography (GPC) analysis was used to analyze
PPEGMA and PPEGMA-b-PDMAEMA linear polymer chains to determine
the molecular weight distribution (see Figure C.1). The molecular weight and
polydispersity index (PDI) were determined using conventional calibration, so
values are reported as PMMA equivalents (see Table C.1). A comparison of
the molecular weight of the first block (15,900 Da) to the molecular weight
of the diblock (19,400 Da) confirms chain extension. The polydispersity of
the linear chains increases upon chain extension (1.58 to 1.99), and these
polydispersity values indicate incomplete control over termination reactions in
the polymerization.
C.3.2 Analysis of polymer composition with NMR
NMR (nuclear magnetic resonance) was used to evaluate the polymer
composition (see Figure C.2). As expected, the NMR spectra for the first
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block showed peaks characteristic of PPEGMA, and the NMR spectra for the
diblock showed peaks characteristic for both PPEGMA and PDMAEMA. The
relative molar quantities of the PEGMA and DMAEMA can be determined
by comparing the relative peak integrations (see Table C.2). In both the
feed and the diblock copolymer, PEGMA and DMAEMA are present in near
equal-molar quantities.
C.4 Conclusions
Diblock PPEGMA-b-PDMAEMA copolymers were synthesized using
ARGET ATRP. GPC confirmed an increased molecular weight following chain
extension of PPEGMA with DMAEMA. NMR confirmed the presence of func-
tional groups from both the PEGMA and DMAEMA in the final diblock
copolymer. Unfortunately, the method did not produce tight control over




Table C.1: GPC was used to determine the molecular weight and the polydis-
persity index for the PPEGMA-b-PDMAEMA linear polymer chains. Mn and
PDI were calculated as the PMMA equivalent molecular weight and PMMA
equivalent PDI from the main polymer peak.
Polymer Mn, Da PDI
Block 1: PPEGMA homopolymer 15,900 1.58
Block 2: PPEGMA-b-PDMAEMA 19,400 1.99
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Table C.2: The molar composition of the feed versus the molar composition
of the polymer as determined by 1H NMR. The molar ratio of the PEGMA
and the DMAEMA was determined by comparing the integrated intensity of
the methoxy proton peak of PEGMA at 3.32 ppm and to that of the methyl
proton peak of DMAEMA at 2.23 ppm.
Polymer PEGMA DMAEMA
mol % in feed 45% 55%











Figure C.1: Chain extension was confirmed with GPC. GPC was used to deter-
mine the molecular weight and the polydispersity index for the PPEGMA-b-
PDMAEMA linear polymer chains. Mn and PDI were calculated as the PMMA
equivalent molecular weight and PMMA equivalent PDI from the main poly-
mer peak.
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Figure C.2: H NMR spectra for the PPEGMA block and the PPEGMA-b-
PDMAEMA diblock copolymer chains.
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Figure C.3: Chemical structure of the PPEGMA-b-PDMAEMA diblock
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Hydrophobic components incorporated into cationic polymer drug de-
livery carriers for gene delivery may enhance gene delivery efficiency1 by tun-
ing pH-responsive properties and by enhancing membrane disruption for en-
dosomal escape.2;3 Various hydrophobic structures including lipids,1 choles-
terol,1 and hydrophobic amino acids such as l-valine, l-leucine, and l-
phenylalanine4 have been incorporated into polymer carriers. Unfortunately,
many of these hydrophobic components lack the functionality to be incor-
porated during a vinyl polymerization reaction, and vinyl-modified versions
are not commercially available. The hydrophobic amino acid derivative 2-
methacryloylamidophenylalanine (MAPA) was synthesized for future investi-




Anhydrous triethylamine, methacryloyl chloride, and l-phenylalanine
methyl ester hydrochloric acid were purchased from Sigma-Aldrich. Sodium
hydroxide solution (NaOH, 1 N), hydrochloric acid solution (HCl, 1 N), methy-
lene chloride, hexanes, and ethyl acetate were purchased from Fisher Scientific.
Ultrapure water was used for all experiments.
D.2.2 Synthesis and purification
The 2-methacryloylamidophenylalanine (MAPA) was synthesized by
conjugating a methacrylate group to the amine site of the amino acid ester to
form a l-phenylalanine-based methacrylamide (see Figure D.1). The synthesis
method was based on a technique reported by Sandra et al.5 (although there
are other related methods reported in the literature6–8). The l-phenylalanine
methyl ester hydrochloric acid was dissolved in 1 N NaOH and extracted into
methylene chloride. The solution was cooled in an ice bath, and 2 molar
equivalents of triethylamine were added. Methacryloyl chloride was added
dropwise to the stirring mixture under nitrogen. The reaction continued under
nitrogen for 4 h, and then the vessel was sealed and the reaction continued
overnight at room temperature.
The reaction mixture was purified using successive acid, base, and salt
washes (1 N HCl, 1 N NaOH, and saturated NaCl solutions). The organic
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phase was concentrated by rotary evaporation and purified using a Companion
Automated Flash Chromatography Instrument equipped with a 100 g silica
column and 254 nm absorbance detector. The flow rate was set to 35 ml/min
and the column was equilibrated with 500-1500 ml hexanes before injecting 1
ml of the concentrated organic phase product from the synthesis reaction. A
gradient elution was used to separate the MAPA product (Solvent A: hexanes
and Solvent B: ethyl acetate). For the first 25 min, the fraction of Solvent
B was increased from 0 to 0.4 and then held constant for 10 min during the
collection of the MAPA fractions. To clear the column, the fraction of Solvent
B was increased from 0.4 to 1 for the last 10 min. The collected MAPA
fractions were combined and concentrated by rotary evaporation. Vacuum
oven drying produced a crystalline, white powder.
D.2.3 Verify product using 1H NMR
The MAPA product was characterized using 1H NMR (nuclear mag-
netic resonance). Dried sample was dissolved in deuterated chloroform
(CDCl3) with tetramethylsilane (TMS) internal standard. Spectra were ob-
tained using a Varian DirectDrive 400 MHz Nuclear Magnetic Resonance Spec-
trometer equipped with an automatic sampler and analyzed using SpinWorks
3™ software.
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D.3 Results and discussion
The 2-methacryloylamidophenylalanine (MAPA) was synthesized and
purified, and the product was verified using 1H NMR.
D.3.1 Synthesis and purification
The 2-methacryloylamidophenylalanine (MAPA) is an l-phenylalanine-
based methacrylamide that was synthesized by conjugating a methacrylate
group to the amine site of l-phenylalanine methyl ester (see Figure D.1). Side
reactions with the unprotected carboxyl group of an amino acid were prevented
by using a methyl ester analog. The concentrated reaction product was puri-
fied using a Companion Automated Flash Chromatography Instrument, and
a sample chromatogram is shown in Figure D.2.
D.3.2 Verify product using 1H NMR
The MAPA product was characterized using 1H NMR. The spectra is
shown in Figure D.3 with labeled peaks, and the relative peak integration is
shown in Table D.1.
D.4 Conclusions
A hydrophobic l-phenylalanine-based methacrylamide was synthesized
and purified, and the chemical structure confirmed with 1H NMR. Amino acid-
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derived monomers such as 2-methacryloylamidophenylalanine (MAPA) may
have utility for the design of new polycationic nanoparticles with enhanced
gene delivery efficiency.
Acknowledgments The MAPA synthesis and purification was completed




Table D.1: Peak integrations for 2-methacryloylamidophenylalanine (MAPA)
1H NMR. Dried sample was dissolved in deuterated chloroform (CDCl3) with
tetramethylsilane internal standard. Spectra were obtained using a Varian
DirectDrive 400 MHz Nuclear Magnetic Resonance Spectrometer equipped







a 3 7.28 3.38
b 2 7.09 2.09
c 1 6.22 1.00
d 1 5.66 1.00
d 1 5.34 0.98
e 1 4.93 1.01
f 3 3.75 3.09
g 2 3.18 2.11




Figure D.1: Reaction scheme for the synthesis of 2-
methacryloylamidophenylalanine (MAPA).
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Figure D.2: Purification of 2-methacryloylamidophenylalanine (MAPA) us-
ing automated flash chromatography. The organic phase was concentrated by
rotary evaporation and purified using a Companion Automated Flash Chro-
matography Instrument equipped with a 100 g silica column and 254 nm ab-
sorbance detector. The flow rate was set to 35 ml/min and the column was
equilibrated with 500-1500 ml hexanes before injecting the concentrated or-
ganic phase product from the synthesis reaction. A gradient elution was used
to separate the MAPA product using Solvent A: hexanes and Solvent B: ethyl
acetate. For the first 25 min, the fraction of Solvent B was increased from 0
to 0.4 and then held constant for 10 min during the collection of the MAPA
fractions. To clear the column, the fraction of Solvent B was increased from
0.4 to 1 for the last 10 min.
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(b) 1H NMR spectra with labeled peaks
Figure D.3: Chemical structure of 2-methacryloylamidophenylalanine
(MAPA) with labeled 1H NMR spectra peaks. Dried sample was dissolved
in deuterated chloroform (CDCl3) with tetramethylsilane internal standard.
Spectra were obtained using a Varian DirectDrive 400 MHz Nuclear Magnetic
Resonance Spectrometer equipped with an automatic sampler and analyzed
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30ARGET: polycationic nanoparticle formulation synthesized by ARGET
ATRP with 30 mol tBMA per 100 mol DEAEMA in the feed
45ARGET: polycationic nanoparticle formulation synthesized by ARGET
ATRP with 45 mol tBMA per 100 mol DEAEMA in the feed
30UV: polycationic nanoparticle formulation synthesized by UV-initiated
polymerization with 30 mol tBMA per 100 mol DEAEMA in the feed
45UV: polycationic nanoparticle formulation synthesized by UV-initiated
polymerization with 45 mol tBMA per 100 mol DEAEMA in the feed
AA: ascorbic acid
AEMA: amino ethyl methacrylate
AGET ATRP: activator generated by electron transfer atom-transfer radical
polymerization





ATCC: American Type Culture Collection
ATRP: atom-transfer radical polymerization
B16F10: mouse melanoma cell line
BMA: butyl methacrylate
bp: base pairs
BSA: bovine serum albumin





CRP: controlled radical polymerization
cSCKs: cationic shell cross-linked knedel-like nanoparticles







DCC: deleted in colorectal cancer
DEAEMA: 2-(diethylamino)ethyl methacrylate
DLS: dynamic light scattering
DMAEMA: 2-(dimethylamino)ethyl methacrylate




DPBS: Dulbecco’s Phosphate Buffered Saline
DSC: dynamic scanning calorimetry
dsRNA: double-stranded RNA
DSS: dextran sulfate sodium




EGDMA: ethylene glycol dimethacrylate
EGFP: enhanced green fluorescent protein
ELISA: enzyme linked immunosorbent assay
EPA: Environmental Protection Agency
ESD: emulsion solvent diffusion method
FACS: fluorescence-activated cell sorting, flow cytometry
FBS: fetal bovine serum
FDA: U.S. Food and Drug Administration
FLuc: firefly luciferase
FTIR: Fourier transform infrared spectroscopy
G: α-l-guluronic acid
GALT: gut-associated lymphatic tissue
GAPDH: glyceraldehyde-3-phospate dehydrogenase
GFP: green fluorescent protein
GI: gastrointestinal
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GeRPs: β1,3-D-glucan-encapsulated siRNA particles
GPC: gel permeation chromatography
GTC: galactosylated trimethyl chitosan-cysteine
HBSS: Hank’s balanced salt solution
HCl: hydrochloric acid
HEK293T: human embryonic kidney cell line
HeLa: human cervical cancer cell line
HTCC: N -((2-hydroxy-3-trimethylammonium) propyl) chitosan chloride
HMIS: hazardous materials identification system
1H NMR: proton nuclear magnetic resonance
HuH-7: human liver cancer cell line
IAA: Imidazole-4-acetic acid
IBD: inflammatory bowel disease





IUPAC: International Union of Pure and Applied Chemistry
L: ligand







Map4k4: mitogen-activated protein kinase kinase kinase kinase 4
MAPA: 2-methacryloylamidophenylalanine
MCLG: maximum contaminant level goal
MDA-MB: human breast cancer cell line
Me6TREN: tris[2-(dimethylamino)ethyl]amine
miRNA: microRNA
mPEG: methoxypoly( ethylene glycol)
mRNA: messenger RNA
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MSN: mesoporous silica nanoparticles
Mt: transition metal catalyst
MTC: mannose-modified trimethyl chitosan-cysteine
mTERT: mouse telomerase reverse transcriptase
MTS: [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-







NBD-NPs: fluorescently-labeled polycationic nanoparticles
NiMOS: nanoparticles-in-microsphere oral system
NCT: national clinical trial
NFPA: National Fire Protection Association





PBS: phosphate buffered saline
PC3: human prostate cancer cell line
PCL: poly(ε-caprolactone)
PCR: polymerase chain reaction
PDI: polydispersity index
PDMAEMA: poly(2-(dimethylamino) ethyl methacrylate)
PDEAEMA: poly(2-(diethylamino) ethyl meth, Winooski, VTacrylate)
PEG: polyethylene glycol
PEGDMA: PEG dimethacrylate
PEGMA: poly(ethylene glycol) methyl ether methacrylate
PEI: polyethylenimine





POEOMA: poly(oligo(ethylene glycol) monomethyl ether methacrylate)
PPADT: poly(1,4-phenyleneacetone dimethylene thioketal)
PPGDA: poly(propylene glycol) diacrylate
PtBMA: poly(tert-butyl methacrylate)
PVA: polyvinyl alcohol
qPCR: quantitative polymerase chain reaction
RA: reducing agent
RAFT: reversible addition−fragmentation chain-transfer polymerization
RAW264.7: murine macrophage cell line
RDRP: reversible-deactivation radical polymerization




ROS: reactive oxygen species
RT-PCR: reverse transcriptase polymerase chain reaction
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RVG-9dR: Rabies virus glycoprotein conjugated nona-d-arginine residues
S2: Drosophila (fruit fly) Schneider 2 cell line
SAXS: small-angle X-ray scattering
SCL: shell cross-linked
SCVCP: self-condensing vinyl copolymerization
shRNA: short hairpin siRNA




TEGDMA: tetraethylene glycol dimethacrylate
TEM: transmission electron microscopy
TGA: thermogravimetric analysis
TMS: tetramethylsilane








VEGF: vascular endothelial growth factor
W: water




CHE381N Fluid Flow and Heat Transfer
CHE381P Adv Analysis for Chem Engineer
CHE387K Advanced Thermodynamics
CHE392 Polymer Science
CH392N Phys Chem of Macromolec System
CHE384 Adv Engineering Biomaterials
CHE384 Mass Transfer in Polymers
362
Appendix G
List of Presentations and Publications
G.1 Publications
1. D. C. Forbes and N. A. Peppas, Differences in molecular structure in
cross-linked polycationic nanoparticles synthesized using ARGET ATRP
or UV-initiated polymerization, Polymer 54 (17) (2013) 4486-4492.
2. D. C. Forbes, M. Creixell, H. Frizzell, and N.A. Peppas, Polycationic
nanoparticles synthesized using ARGET ATRP for drug delivery, Eu-
ropean Journal of Pharmaceutics and Biopharmaceutics, 84 (3) (2013)
472-478.
3. D. C. Forbes and N. A. Peppas, Oral delivery of small RNA and DNA,
Journal of Controlled Release 162 (2) (2012) 438-445.
4. M. Mouton-Johnston and D. C. Forbes, Controlled release using an
oral drug delivery system designed to improve treatment of conditions




1. D. C. Forbes and N. A. Peppas, Therapeutic siRNA delivery using
pH-responsive polymer nanoparticles, 2013 AAPS Annual Meeting, San
Antonio, Texas, November 2013 (poster).
2. D. C. Forbes, H. Frizzell, B. Carillo-Conde, and N. A. Peppas, pH-
Responsive polymer nanoparticles synthesized using ARGET ATRP for
therapeutic siRNA delivery, Biomaterial’s Day, Austin, Texas, May 31,
2013 (poster).
3. D. C. Forbes, H. Frizzell, B. Carillo-Conde, and N. A. Peppas, Poly-
cationic Hydrogel Nanoparticles for siRNA Delivery, Society for Bio-
materials 2013 Annual Meeting, Boston, Massachusetts, April 11, 2013
(poster).
4. D. C. Forbes, M. Creixell, H. Frizzell, and N. A. Peppas, Oral siRNA
delivery system for the treatment of colon cancer, CPRIT: Cancer Pre-
vention & Research Institute of Texas Annual Conference, Austin, Texas,
October 24, 2012 (poster).
5. D. C. Forbes and N. A. Peppas, pH-Responsive, Polycationic Nanopar-
ticles Designed for Intracellular siRNA Delivery, American Institute of
Chemical Engineers (AICHE) Annual Meeting, Pittsburgh, Pennsylva-
nia, October 30, 2012 (oral presentation, given by colleague J. Knipe).
364
6. D. C. Forbes, H. Frizzell, and N. A. Peppas, Comparing ARGET ATRP
with Traditional Free Radical Polymerization for Versatile Polycationic
Hydrogel Nanoparticles, Biomaterial’s Day, Houston, Texas, July 27,
2012 (poster).
7. H. Frizzell, D. C. Forbes, and N. A. Peppas, Oral Delivery of siRNA
Using pH-Responsive Hydrogel Nanoparticles, Biomedical Engineering
Society (BMES) Annual Meeting, Seattle, Washington, September 25,
2013 (poster).
8. H. Frizzell, D. C. Forbes, and N. A. Peppas, Oral delivery of siRNA
using pH-responsive hydrogel nanoparticles, Biomaterial’s Day, Austin,
Texas, May 31, 2013 (poster).
9. M. Creixell, D. C. Forbes, and N. A. Peppas, Nanohydrogels as deliv-
ery systems of antineoplastic drugs and siRNA to overcome multidrug
resistance in cancer treatment, CPRIT: Cancer Prevention & Research
Institute of Texas Annual Conference, Austin, Texas, October 24, 2012
(poster).
10. M. Creixell, D. C. Forbes, and N. A. Peppas, Responsive polycationic
nanoparticles for co-delivery of siRNA and chemotherapeutical agents
to overcome multidrug resistance in cancer therapy, Biomaterial’s Day,
Houston, Texas, July 27, 2012 (poster).
11. H. Frizzell, D. C. Forbes, and N. A. Peppas, Two-part Oral siRNA De-
365
livery Systems: Polycationic Hydrogel Nanoparticles and Alginate Ma-
trices, Biomaterial’s Day, Houston, Texas, July 27, 2012 (poster).
12. D. C. Brown, G. Sander, and J. V. Shanks. Alkaloid Extraction and
Purification from Catharanthus roseus Hairy Root Tissue,
(a) 5th Annual Research in the Capitol presented by the Iowa Regent
Universities, Des Moines, Iowa, March 25, 2010 (poster).
(b) American Institute of Chemical Engineers (AIChE) Undergradu-
ate Poster Competition, National Convention, Nashville, Tennessee,
November 9, 2009 (poster).
(c) Iowa State University Undergraduate Research Symposium, Ames,
Iowa, April 21, 2009 (oral presentation).
(d) Iowa State University Honors Poster Presentation, Ames, Iowa,
April 15, 2009 (poster).
13. D. C. Brown, Maize in Mexico, World Food Prize Global Youth In-
stitute, Des Moines, Iowa, October 21, 2006 (paper, poster, and oral
presentation).
14. D. C. Brown, Students in Asia and Latin America: Making a Differ-
ence, Iowa Public Television hosted ICN Video Classroom for middle




[1] W. Abramovits, P. Granowski, and P. Arrazola. Applications of
nanomedicine in dermatology: use of nanoparticles in various therapies
and imaging. J. Cosmet. Dermatol., 9(2):154–159, 2010.
[2] M. L. Adams, A. Lavasanifar, and G. S. Kwon. Amphiphilic block
copolymers for drug delivery. J. Pharm. Sci., 92(7):1343–1355, 2003.
[3] S. Agrawal. Antisense Therapeutics. Humana Press, Totowa, NJ, 1996.
[4] P. Agulhon, V. Markova, M. Robitzer, F. Quignard, and T. Mineva.
Structure of alginate gels: Interaction of diuronate units with diva-
lent cations from density functional calculations. Biomacromolecules,
13(6):1899–1907, 2012.
[5] A. Aigner. Cellular delivery in vivo of siRNA-based therapeutics. Curr.
Pharm. Des., 14(34):3603–3619, 2008.
[6] S. Akhtar. Oral delivery of siRNA and antisense oligonucleotides. J.
Drug Targeting, 17(7):491–495, 2009.
367
[7] S. Akhtar and I. Benter. Toxicogenomics of non-viral drug delivery sys-
tems for RNAi: Potential impact on siRNA-mediated gene silencing ac-
tivity and specificity. Adv. Drug Deliver. Rev., 59(2-3):164–182, 2007.
[8] H. M. Aliabadi, B. Landry, C. Sun, T. Tang, and H. Uludağ. Supramolec-
ular assemblies in functional siRNA delivery: Where do we stand? Bio-
materials, 33(8):2546–2569, 2012.
[9] J. I. Amalvy, E. J. Wanless, Y. Li, V. Michailidou, S. P. Armes, and
Y. Duccini. Synthesis and characterization of novel pH-responsive mi-
crogels based on tertiary amine methacrylates. Langmuir, 20(21):8992–
8999, 2004.
[10] E. K. Anderberg, T. Lindmark, and P. Artursson. Sodium caprate elic-
its dilatations in human intestinal tight junctions and enhances drug
absorption by the paracellular route. Pharm. Res., 10(6):857–864, 1993.
[11] M. Aouadi, G. J. Tesz, S. M. Nicoloro, M. Wang, M. Chouinard,
E. Soto, G. R. Ostroff, and M. P. Czech. Orally delivered siRNA tar-
geting macrophage Map4k4 suppresses systemic inflammation. Nature,
458(7242):1180–1184, 2009.
[12] M. Ashford, J. Fell, D. Attwood, H. Sharma, and P. Woodhead. An
in vivo investigation into the suitability of pH dependent polymers for
colonic targeting. Int. J. Pharm., 95(1-3):193–199, 1993.
368
[13] A. D. Augst, H. J. Kong, and D. J. Mooney. Alginate hydrogels as
biomaterials. Macromol. Biosci., 6(8):623–633, 2006.
[14] S. Averick, E. Paredes, A. Irastorza, A. Srinivasan, D. Siegwart, A. Ma-
genau, H. Cho, A. Shrivats, E. Hsu, J. Kim, et al. Preparation of cationic
nanogels for nucleic acid delivery. Biomacromolecules, (11):3445–3449,
2012.
[15] N. Ayres. Atom transfer radical polymerization: a robust and versatile
route for polymer synthesis. Polym. Rev., 51(2):138–162, 2011.
B
[16] M. J. Baarsch, M. J. Wannemuehler, T. W. Molitor, and M. P. Mur-
taugh. Detection of tumor necrosis factor α from porcine alveolar
macrophages using an L929 fibroblast bioassay. J. Immunol. Methods,
140(1):15–22, 1991.
[17] A. K. Bajpai, J. Bajpai, R. Saini, and R. Gupta. Responsive polymers
in biology and technology. Polym. Rev., 51(1):53–97, 2011.
[18] B. Ballarín-González, F. Dagnaes-Hansen, R. A. Fenton, S. Gao, S. Hein,
M. Dong, J. Kjems, and K. A. Howard. Protection and systemic
translocation of siRNA following oral administration of chitosan/siRNA
nanoparticles. Mol. Ther. Nucleic Acids, 2(3):e76, 2013.
369
[19] B. Ballarín-González and K. A. Howard. Polycation-based nanoparticle
delivery of {RNAi} therapeutics: Adverse effects and solutions. Adv.
Drug Deliver. Rev., 64(15):1717–1729, 2012.
[20] S. C. Balmert and S. R. Little. Biomimetic delivery with micro-and
nanoparticles. Adv. Mater., 24(28):3757–3778, 2012.
[21] R. Barbalat, S. E. Ewald, M. L. Mouchess, and G. M. Barton. Nucleic
acid recognition by the innate immune system. Annu. Rev. Immunol.,
29(1):185–214, 2011.
[22] F. S. Bates and G. H. Fredrickson. Block copolymers-designer soft ma-
terials. Phys. Today., 38:32–38, 1999.
[23] D. C. Baumgart and W. J. Sandborn. Inflammatory bowel dis-
ease: clinical aspects and established and evolving therapies. Lancet,
369(9573):1641–1657, 2007.
[24] C. L. Bayer, É. P. Herrero, and N. A. Peppas. Alginate films as
macromolecular imprinted matrices. J. Biomater. Sci., Polym. Ed.,
22(11):1523–1534, 2011.
[25] S. A. Bencherif, D. J. Siegwart, A. Srinivasan, F. Horkay, J. O. Hollinger,
N. R. Washburn, and K. Matyjaszewski. Nanostructured hybrid hydro-
gels prepared by a combination of atom transfer radical polymerization
and free radical polymerization. Biomaterials, 30(29):5270–5278, 2009.
370
[26] C. E. Beneke, A. M. Viljoen, and J. H. Hamman. Polymeric plant-
derived excipients in drug delivery. Molecules, 14(7):2602–2620, 2009.
[27] C. F. Bennett and E. E. Swayze. RNA targeting therapeutics: Molecu-
lar mechanisms of antisense oligonucleotides as a therapeutic platform.
Annu. Rev. Pharmacol. Toxicol., 50(1):259–293, 2010.
[28] S. Y. Berezhna. siRNA in human cells selectively localizes to target RNA
sites. P. Natl. Acad. Sci., 103(20):7682–7687, 2006.
[29] B. Bertram, S. Wiese, and A. von Holst. High-efficiency transfection and
survival rates of embryonic and adult mouse neural stem cells achieved
by electroporation. J. Neurosci. Meth., 209(2):420–427, 2012.
[30] S. R. Bhattarai, E. Muthuswamy, A. Wani, M. Brichacek, A. L. Cas-
tañeda, S. L. Brock, and D. Oupicky. Enhanced gene and siRNA deliv-
ery by polycation-modified mesoporous silica nanoparticles loaded with
chloroquine. Pharm. Res., 27(12):2556–2568, 2010.
[31] M. Bhavsar and M. Amiji. Polymeric nano- and microparticle technolo-
gies for oral gene delivery. Expert Opin. Drug Del., 4(3):197–213, 2007.
[32] M. D. Bhavsar and M. M. Amiji. Gastrointestinal distribution and in
vivo gene transfection studies with nanoparticles-in-microsphere oral sys-
tem (NiMOS). J. Control. Release, 119(3):339–348, 2007.
[33] M. D. Bhavsar and M. M. Amiji. Development of novel biodegrad-
able polymeric nanoparticles-in-microsphere formulation for local plas-
371
mid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech,
9(1):288–294, 2008.
[34] M. D. Bhavsar and M. M. Amiji. Oral IL-10 gene delivery in a
microsphere-based formulation for local transfection and therapeutic ef-
ficacy in inflammatory bowel disease. Gene Ther., 15(17):1200–1209,
2008.
[35] P. Bielli and L. Calabrese. Structure to function relationships in cerulo-
plasmin: a ’moonlighting’ protein. Cell. Mol. Life Sci., 59(9):1413–1427,
2002.
[36] K. Bodger. Cost effectiveness of treatments for inflammatory bowel dis-
ease. Pharmacoeconomics, 29(5):387–401, 2011.
[37] R. Bodmeier, H. Chen, and O. Paeratakul. A novel approach to the oral
delivery of micro-or nanoparticles. Pharm. Res., 6(5):413–417, 1989.
[38] N. Bodyak, A. Borrelli, J. Fruehauf, J. Harborth, M. B. Vaze, C. Grillot-
Courvalin, and A. Silva. Ind-enabling studies for CEQ508 targeting beta-
Catenin of GI polyps: First oral RNAi drug. Gastroenterology (Supple-
ment 1), 138(5):S–79, 2010.
[39] L. Bonetta. RNA-based therapeutics: Ready for delivery? Cell,
136(4):581–584, 2009.
[40] A. Bouchie. Companies in footrace to deliver RNAi. Nat. Biotechnol.,
30(12):1154–1157, 2012.
372
[41] M. C. Branco and J. P. Schneider. Self-assembling materials for thera-
peutic delivery. Acta. Biomater., 5(3):817–831, 2009.
[42] J. Brandrup, E. H. Immergut, E. A. Grulke, A. Abe, and D. R. Bloch.
Polymer Handbook. Wiley New York, 1999.
[43] K. Bruno. Using drug-excipient interactions for siRNA delivery. Adv.
Drug Deliver. Rev., 63(13):1210–1226, 2011.
[44] D. Bumcrot, M. Manoharan, V. Koteliansky, and D. W. Y. Sah. RNAi
therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem.
Biol., 2(12):711–719, 2006.
[45] J. Burnett, J. Rossi, and K. Tiemann. Current progress of
siRNA/shRNA therapeutics in clinical trials. Biotechnol. J., 6(9):1130–
1146, 2011.
C
[46] G. Cai, H. Zhang, P. Liu, L. Wang, and H. Jiang. Triggered disassembly
of hierarchically assembled onion-like micelles into the pristine core–shell
micelles via a small change in pH. Acta. Biomater., 7(10):3729–3737,
2011.
[47] M. Caldorera-Moore and N. Peppas. Micro- and nanotechnologies for
intelligent and responsive biomaterial-based medical systems. Adv. Drug
Deliver. Rev., 61(15):1391–1401, 2009.
373
[48] L. Cao, T. Man, J. Zhuang, and M. Kruk. Poly (N -isopropylacrylamide)
and poly (2-(dimethylamino) ethyl methacrylate) grafted on an ordered
mesoporous silica surface using atom transfer radical polymerization
with activators regenerated by electron transfer. J. Mater. Chem.,
22:6939–6946, 2012.
[49] J. Carralot, T. Kim, B. Lenseigne, A. S. Boese, P. Sommer, A. Genovesio,
and P. Brodin. Automated high-throughput siRNA transfection in raw
264.7 macrophages: a case study for optimization procedure. J. Biomol.
Screen., 14(2):151–160, 2009.
[50] D. Castanotto and J. J. Rossi. The promises and pitfalls of RNA-
interference-based therapeutics. Nature, 457(7228):426–433, 2009.
[51] D. Cejka, D. Losert, and V. Wacheck. Short interfering RNA (siRNA):
tool or therapeutic? Clin. Sci., 110(1):47, 2006.
[52] Centers for Disease Control and Prevention (CDC). Inflammatory bowel
disease, 2011. http://www.cdc.gov/ibd/.
[53] D. Chang, J. Lei, H. Cui, N. Lu, Y. Sun, X. Zhang, C. Gao, H. Zheng,
and Y. Yin. Disulfide cross-linked nanospheres from sodium alginate
derivative for inflammatory bowel disease: Preparation, characteriza-
tion, and in vitro drug release behavior. Carbohydr. Polym., 88(2):663–
669, 2012.
374
[54] N. Charlaftis, D. T. Fearon, A. Schoenemeyer, and P. J. Morley. siRNA
high-throughput kinase library screen identifies protein kinase, DNA-
activated catalytic polypeptide to play a role in MyD88-induced IFNA2
activation and IL-8 secretion. Biotechnol. Appl. Biochem., 59(1):6–14,
2012.
[55] B. T. Cheesman, A. J. G. Neilson, J. D. Willott, G. B. Webber, S. Ed-
mondson, and E. J. Wanless. Effect of colloidal substrate curvature
on pH-responsive polyelectrolyte brush growth. Langmuir, 29(20):6131–
6140, 2013.
[56] C. J. Chen, G. Y. Liu, Y. T. Shi, C. S. Zhu, S. P. Pang, X. S. Liu, and
J. Ji. Biocompatible micelles based on comb-like PEG derivates: For-
mation, characterization, and photo-responsiveness. Macromol. Rapid
Commun., 32(14):1077–1081, 2011.
[57] G. Chen, T. G. Gharib, C. Huang, J. M. G. Taylor, D. E. Misek, S. L. R.
Kardia, T. J. Giordano, M. D. Iannettoni, M. B. Orringer, S. M. Hanash,
and D. G. Beer. Discordant protein and mRNA expression in lung ade-
nocarcinomas. Mol. Cell. Proteomics, 1(4):304–313, 2002.
[58] M. Chen, H. M. Cooper, J. Z. Zhou, P. F. Bartlett, and Z. P. Xu.
Reduction in the size of layered double hydroxide nanoparticles enhances
the efficiency of siRNA delivery. J. Colloid Interface Sci., 390(1):275–
281, 2013.
375
[59] R. Chen, M. E. Eccleston, Z. Yue, and N. K. H. Slater. Synthesis and pH-
responsive properties of pseudo-peptides containing hydrophobic amino
acid grafts. J. Mater. Chem., 19(24):4217–4224, 2009.
[60] R. Chen, S. Khormaee, M. E. Eccleston, and N. K. H. Slater. The
role of hydrophobic amino acid grafts in the enhancement of membrane-
disruptive activity of pH-responsive pseudo-peptides. Biomaterials,
30(10):1954–1961, 2009.
[61] K. Cheng and R. I. Mahato. Biological and therapeutic applications of
small RNAs. Pharm. Res., 28(12):2961–2965, 2011.
[62] H. Y. Cho, S. E. Averick, E. Paredes, K. Wegner, A. Averick, S. Jurga,
S. R. Das, and K. Matyjaszewski. Star polymers with a cationic core
prepared by ATRP for cellular nucleic acids delivery. Biomacromolecules,
14(5):1262–1267, 2013.
[63] D. S. H. Chu, J. G. Schellinger, J. Shi, A. J. Convertine, P. S. Stayton,
and S. H. Pun. Application of living free radical polymerization for
nucleic acid delivery. Acc. Chem. Res., 45(7):1089–1099, 2012.
[64] J. E. Chung, M. Yokoyama, M. Yamato, T. Aoyagi, Y. Sakurai, and
T. Okano. Thermo-responsive drug delivery from polymeric micelles
constructed using block copolymers of poly (N -isopropylacrylamide) and
poly (butylmethacrylate). J. Control. Release, 62(1):115–127, 1999.
376
[65] D. Cohn and A. Hotovely-Salomon. Biodegradable multiblock
PEO/PLA thermoplastic elastomers: molecular design and properties.
Polymer, 46(7):2068–2075, 2005.
[66] A. Convertine, D. Benoit, C. Duvall, A. Hoffman, and P. Stayton. Devel-
opment of a novel endosomolytic diblock copolymer for siRNA delivery.
J. Control. Release, 133(3):221–229, 2009.
[67] A. J. Convertine, C. Diab, M. Prieve, A. Paschal, A. S. Hoffman, P. H.
Johnson, and P. S. Stayton. pH-responsive polymeric micelle carriers for
siRNA drugs. Biomacromolecules, 11(11):2904–2911, 2010.
[68] J. M. Cornejo-Bravo and R. A. Siegel. Water vapour sorption be-
haviour of copolymers of N, N -diethylaminoethyl methacrylate and
methyl methacrylate. Biomaterials, 17(12):1187–1193, 1996.
[69] M. Cortizo and M. Lorenzo de Mele. Cytotoxicity of copper ions released
from metal. Biol. Trace Elem. Res., 102(1):129–141, 2004.
[70] P. Couvreur. Nanoparticles in drug delivery: Past, present and future.
Adv. Drug Deliver. Rev., 65(1):21–23, 2013.
[71] M. Creixell and N. A. Peppas. Co-delivery of siRNA and therapeutic
agents using nanocarriers to overcome cancer resistance. Nano Today,
7(4):367–379, 2012.
377
[72] G. Crisponi, V. M. Nurchi, D. Fanni, C. Gerosa, S. Nemolato, and
G. Faa. Copper-related diseases: from chemistry to molecular pathology.
Coord. Chem. Rev., 254(7-8):876–889, 2010.
[73] S. Crunkhorn. Trial watch: Pioneering RNAi therapy shows antitumour
activity in humans. Nat. Rev. Drug Discovery, 12(3):178–178cru, 2013.
D
[74] F. Dai, P. Sun, Y. Liu, and W. Liu. Redox-cleavable star cationic
PDMAEMA by arm-first approach of ATRP as a nonviral vector for
gene delivery. Biomaterials, 31(3):559–569, 2010.
[75] F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and
V. Préat. PLGA-based nanoparticles: An overview of biomedical ap-
plications. J. Control. Release, 161(2 (Special Issue: Drug Delivery Re-
search in Europe)):505–522, 2012.
[76] B. L. Davidson and P. B. McCray. Current prospects for RNA
interference-based therapies. Nat. Rev. Genet., 12(5):329–340, 2011.
[77] M. E. Davis, J. E. Zuckerman, C. H. J. Choi, D. Seligson, A. Tolcher,
C. A. Alabi, Y. Yen, J. D. Heidel, and A. Ribas. Evidence of RNAi in hu-
mans from systemically administered siRNA via targeted nanoparticles.
Nature, 464(7291):1067–1070, 2010.
[78] S. Davis. Improved targeting of miRNA with antisense oligonucleotides.
Nucleic Acids Res., 34(8):2294–2304, 2006.
378
[79] L. P. Degen and S. F. Phillips. Variability of gastrointestinal transit in
healthy women and men. Gut, 39(2):299–305, 1996.
[80] G. D’Haens. Anti-TNF therapy for Crohn’s disease. Curr. Pharm. Des.,
9(4):289–294, 2003.
[81] T. L. Doane and C. Burda. The unique role of nanoparticles in
nanomedicine: imaging, drug delivery and therapy. Chem. Soc. Rev.,
41(7):2885–2911, 2012.
[82] M. Dominska and D. M. Dykxhoorn. Breaking down the barriers: siRNA
delivery and endosome escape. J. Cell Sci., 123(8):1183–1189, 2010.
[83] H. Dong and K. Matyjaszewski. ARGET ATRP of 2-(dimethylamino)
ethyl methacrylate as an intrinsic reducing agent. Macromolecules,
41(19):6868–6870, 2008.
[84] V. Dubois, S. Breton, M. Linder, J. Fanni, and M. Parmentier. Fatty
acid profiles of 80 vegetable oils with regard to their nutritional potential.
Eur. J. Lipid Sci. Technol., 109(7):710–732, 2007.
[85] M. Dufresne and J. Leroux. Study of the micellization behavior of differ-




[86] A. M. Elsen, J. Burdynska, S. Park, and K. Matyjaszewski. Activators
regenerated by electron transfer atom transfer radical polymerization
in miniemulsion with 50 ppm of copper catalyst. ACS Macro Lett.,
2(9):822–825, 2013.
[87] M. L. Etheridge, S. A. Campbell, A. G. Erdman, C. L. Haynes, S. M.
Wolf, and J. McCullough. The big picture on nanomedicine: the state of
investigational and approved nanomedicine products. Nanomed.: Nan-
otechnol., 9(1):1–14, 2013.
[88] D. F. Evans, G. Pye, R. Bramley, A. G. Clark, T. J. Dyson, and J. D.
Hardcastle. Measurement of gastrointestinal pH profiles in normal am-
bulant human subjects. Gut, 29(8):1035–1041, 1988.










[91] G. Faa, C. Liguori, A. Columbano, and G. Diaz. Uneven copper distri-
bution in the human newborn liver. Hepatology, 7(5):838–842, 1987.
[92] E. Fattal and A. Bochot. State of the art and perspectives for the delivery
of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int.
J. Pharm., 364(2):237–248, 2008.
[93] M. G. Ferreiro, L. G. Tillman, G. Hardee, and R. Bodmeier.
Alginate/poly-L-lysine microparticles for the intestinal delivery of an-
tisense oligonucleotides. Pharm. Res., 19(6):755–764, 2002.
[94] M. C. Filion and N. C. Phillips. Toxicity and immunomodulatory activity
of liposomal vectors formulated with cationic lipids toward immune ef-
fector cells. Biochim. Biophys. Acta, Biomembr., 1329(2):345–356, 1997.
[95] A. Fire, S. Q. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and
C. C. Mello. Potent and specific genetic interference by double-stranded
RNA in Caenorhabditis elegans. Nature, 391(6669):806–811, 1998.
[96] O. Z. Fisher, T. Kim, S. R. Dietz, and N. A. Peppas. Enhanced
core hydrophobicity, functionalization and cell penetration of polybasic
nanomatrices. Pharm. Res., 26(1):51–60, 2008.
[97] O. Z. Fisher and N. A. Peppas. Polybasic nanomatrices prepared by UV-
initiated photopolymerization. Macromolecules, 42(9):3391–3398, 2009.
[98] FMCBiopolymer. Alginate, 2012. http://www.fmcbiopolymer.com/ oth-
ermarkets/OtherMarkets/Products/Alginate.aspx.
381
[99] D. C. Forbes, M. Creixell, H. Frizzell, and N. A. Peppas. Polycationic
nanoparticles synthesized using ARGET ATRP for drug delivery. Eur.
J. Pharm. Biopharm., 84(3):472–478, 2013.
[100] D. C. Forbes and N. A. Peppas. Oral delivery of small RNA and DNA.
J. Control. Release, 162(2):438–445, 2012.
[101] D. C. Forbes and N. A. Peppas. Differences in molecular structure in
cross-linked polycationic nanoparticles synthesized using ARGET ATRP
or UV-initiated polymerization. Polymer, 54(17):4486–4492, 2013.
[102] C. J. Fristrup, K. Jankova, and S. Hvilsted. Hydrophilization of poly
(ether ether ketone) films by surface-initiated atom transfer radical poly-
merization. Polym. Chem., 1(10):1696–1701, 2010.
[103] J. Fruehauf, M. Vaze, F. Laroux, and J. Sexton. E. coli mediated gene
silencing of beta-catenin. US Patent 2010/0189691 A1, 2010.
[104] G. Fundueanu, C. Nastruzzi, A. Carpov, J. Desbrieres, and M. Rin-
audo. Physico-chemical characterization of Ca-alginate microparticles
produced with different methods. Biomaterials, 20(15):1427–1435, 1999.
G
[105] D. Gan and L. A. Lyon. Interfacial nonradiative energy transfer
in responsive core-shell hydrogel nanoparticles. J. Am. Chem. Soc.,
123(34):8203–8209, 2001.
382
[106] S. Ganta, H. Devalapally, A. Shahiwala, and M. Amiji. A review of
stimuli-responsive nanocarriers for drug and gene delivery. J. Control.
Release, 126(3):187–204, 2008.
[107] W. Gao, J. M. Chan, and O. C. Farokhzad. pH-responsive nanoparticles
for drug delivery. Mol. Pharm., 7(6):1913–1920, 2010.
[108] D. J. Gary, H. Lee, R. Sharma, J. Lee, Y. Kim, Z. Y. Cui, D. Jia, V. D.
Bowman, P. R. Chipman, L. Wan, Y. Zou, G. Mao, K. Park, B. Herbert,
S. F. Konieczny, and Y. Y. Won. Influence of nano-carrier architecture on
in vitro siRNA delivery performance and in vivo biodistribution: poly-
plexes vs micelleplexes. ACS Nano, 5(5):3493–3505, 2011.
[109] D. J. Gary, J. Min, Y. Kim, K. Park, and Y. Y. Won. The effect of N/P
ratio on the in vitro and in vivo interaction properties of PEGylated
Poly [2-(dimethylamino) ethyl methacrylate]-based siRNA complexes.
Macromol. Biosci., 13(8):1059–1071, 2013.
[110] D. J. Gary, N. Puri, and Y. Y. Won. Polymer-based siRNA delivery:
Perspectives on the fundamental and phenomenological distinctions from
polymer-based DNA delivery. J. Control. Release, 121(1-2):64–73, 2007.
[111] B. Ghosn, S. P. Kasturi, and K. Roy. Enhancing polysaccharide-
mediated delivery of nucleic acids through functionalization with sec-
ondary and tertiary amines. Curr. Top. Med. Chem., 8(4):331–340, 2008.
383
[112] D. Gitlin, W. Hughes, and C. Janeway. Absorption and excretion of
copper in mice. Nature, 188(4745):150–151, 1960.
[113] A. Gregory and M. Stenzel. The use of reversible addition fragmentation
chain transfer polymerization for drug delivery systems. Expert Opin.
Drug Del., 8(2):237–269, 2011.
[114] H. Guo, J. Zhang, and C. Inal. Targeting tumor gene by shRNA-
expressing Salmonella-mediated RNAi. Gene Ther., 18(1):95–105, 2010.
[115] S. Guo, Y. Huang, T. Wei, W. Zhang, W. Wang, D. Lin, X. Zhang,
A. Kumar, Q. Du, and J. Xing. Amphiphilic and biodegrad-
able methoxy polyethylene glycol-block-(polycaprolactone-graft-poly(2-
(dimethylamino)ethyl methacrylate)) as an effective gene carrier. Bio-
materials, 32(3):879–889, 2011.
[116] D. Guzman-Villanueva, I. M. El-Sherbiny, D. Herrera-Ruiz, A. V.
Vlassov, and H. D. C. Smyth. Formulation approaches to short interfer-
ing RNA and MicroRNA: Challenges and implications. J. Pharm. Sci.,
101(11):4046–4066, 2012.
H
[117] G. Ham. Copolymerization. Interscience Publishers, 1964.
[118] S. M. Hammond. MicroRNA therapeutics: a new niche for antisense
nucleic acids. Trends Mol. Med., 12(3):99–101, 2006.
384
[119] S. Hanauer. Positioning biologic agents in the treatment of Crohn’s
disease. Inflamm. Bowel Dis., 15(10):1570–1582, 2009.
[120] H. Hayashi, M. Iijima, K. Kataoka, and Y. Nagasaki. pH-sensitive
nanogel possessing reactive PEG tethered chains on the surface. Macro-
molecules, 37(14):5389–5396, 2004.
[121] C. He, L. Yin, C. Tang, and C. Yin. Multifunctional polymeric nanopar-
ticles for oral delivery of TNF-alpha siRNA to macrophages. Biomate-
rials, 34(11):2843–2854, 2013.
[122] C. He, L. Yin, C. Tang, and C. Yin. Trimethyl chitosan-cysteine
nanoparticles for systemic delivery of TNF-α siRNA via oral and in-
traperitoneal routes. Pharm. Res., 30(10):2596–2606, 2013.
[123] T. He, F. Di Lena, K. C. Neo, and C. L. L. Chai. Direct synthesis of
pH-responsive polymer nanoparticles based on living radical polymeriza-
tion and traditional radical polymerization. Soft Matter, 7(7):3358–3365,
2011.
[124] W. He, L. Zhang, J. Miao, Z. Cheng, and X. Zhu. Facile iron-mediated
AGET ATRP for water-soluble poly (ethylene glycol) monomethyl ether
methacrylate in water. Macromol. Rapid Commun., 33(12):1067–1073,
2012.
[125] N. Hellman and J. Gitlin. Ceruloplasmin metabolism and function.
Annu. Rev. Nutr., 22(1):439–458, 2002.
385
[126] P. C. Hiemenz and T. P. Lodge. Polymer Chemistry, 2nd. Boca Raton:
CRC Press, 2007.
[127] T. Hoare and R. Pelton. Functional group distributions in carboxylic
acid containing poly (N -isopropylacrylamide) microgels. Langmuir,
20(6):2123–2133, 2004.
[128] A. S. Hoffman. Stimuli-responsive polymers: Biomedical applications
and challenges for clinical translation. Adv. Drug Deliver. Rev., 65(1):10–
16, 2012.
[129] S. J. Holder, N. A. A. Rossi, C. T. Yeoh, G. G. Durand, M. J. Boerakker,
and N. A. J. M. Sommerdijk. ABA triblock copolymers: from controlled
synthesis to controlled function. J. Mater. Chem., 13(11):2771–2778,
2003.
[130] Y. Hu, P. U. Atukorale, J. J. Lu, J. J. Moon, S. H. Um, E. C. Cho,
Y. Wang, J. Chen, and D. J. Irvine. Cytosolic delivery mediated via
electrostatic surface binding of protein, virus, or siRNA cargos to pH-
responsive core- shell gel particles. Biomacromolecules, 10(4):756–765,
2009.
[131] Y. Hu, T. Litwin, A. R. Nagaraja, B. Kwong, J. Katz, N. Watson, and
D. J. Irvine. Cytosolic delivery of membrane-impermeable molecules in
dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett.,
7(10):3056–3064, 2007.
386
[132] L. Huang and Y. Liu. In vivo delivery of RNAi with lipid-based nanopar-
ticles. Annu. Rev. Biomed. Eng., 13(1):507–530, 2011.
[133] X. Huang, D. Appelhans, P. Formanek, F. Simon, and B. Voit. Tai-
lored synthesis of intelligent polymer nanocapsules: An investigation of
controlled permeability and pH-dependent degradability. ACS Nano,
6(11):9718–9726, 2012.
J
[134] A. Jain, Y. Gupta, and S. K. Jain. Perspectives of biodegradable natural
polysaccharides for site-specific drug delivery to the colon. J. Pharm.
Pharm. Sci., 10(1):86–128, 2007.
[135] S. K. Jain and N. K. Jain. Multiparticulate carriers for sun-screening
agents. Int. J. Cosmet. Sci., 32(2):89–98, 2010.
[136] W. Jakubowski and K. Matyjaszewski. Activators regenerated by elec-
tron transfer for atom-transfer radical polymerization of (meth)acrylates
and related block copolymers. Angew. Chem., 118(27):4594–4598, 2006.
[137] W. Jakubowski, K. Min, and K. Matyjaszewski. Activators regenerated
by electron transfer for atom transfer radical polymerization of styrene.
Macromolecules, 39(1):39–45, 2006.
[138] A. D. Jenkins, R. G. Jones, and G. Moad. Terminology for reversible-
deactivation radical polymerization previously called "controlled" radi-
387
cal or "living" radical polymerization (IUPAC Recommendations 2010).
Pure Appl. Chem., 82(2):483–491, 2010.
[139] C. Ji, H. Xu, and W. Wu. In vitro evaluation and pharmacokinetics in
dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of
indomethacin. J. Drug Targeting, 15(2):123–131, 2007.
[140] X. Jiang, M. C. Lok, and W. E. Hennink. Degradable-brushed pHEMA–
pDMAEMA synthesized via ATRP and click chemistry for gene delivery.
Bioconjugate Chem., 18(6):2077–2084, 2007.
[141] R. Juliano, M. Alam, V. Dixit, and H. Kang. Mechanisms and strategies
for effective delivery of antisense and siRNA oligonucleotides. Nucleic
Acids Res., 36(12):4158–4171, 2008.
[142] R. L. Juliano. The future of nanomedicine: Promises and limitations.
Sci. Publ. Policy, 39(1):99–104, 2012.
K
[143] A. V. Kabanov and S. V. Vinogradov. Nanogels as pharmaceutical car-
riers: finite networks of infinite capabilities. Angew. Chem., Int. Ed.,
48(30):5418–5429, 2009.
[144] H. C. Kang, K. M. Huh, and Y. H. Bae. Polymeric nucleic acid car-
riers: current issues and novel design approaches. J. Control. Release,
164(3):256–264, 2012.
388
[145] A. A. Khan, D. Betel, M. L. Miller, C. Sander, C. S. Leslie, and D. S.
Marks. Transfection of small RNAs globally perturbs gene regulation by
endogenous microRNAs. Nat. Biotechnol., 27:549–555, 2009.
[146] J. Kim, N. Singh, and L. A. Lyon. Label-free biosensing with hydrogel
microlenses. Angew. Chem., Int. Ed., 45(9):1446–1449, 2006.
[147] J. B. Kim and H. Kim. Effect of acid structure on deprotection of poly (2-
trimethylsilyl-2-propyl methacrylate). Polymer, 40(14):4055–4061, 1999.
[148] S. Kim, C. Ye, P. Kumar, I. Chiu, S. Subramanya, H. Wu, P. Shankar,
and N. Manjunath. Targeted delivery of siRNA to macrophages for anti-
inflammatory treatment. Mol. Ther., 18(5):993–1001, 2010.
[149] Y. Kim, M. H. Pourgholami, D. L. Morris, and M. H. Stenzel. Effect of
cross-linking on the performance of micelles as drug delivery carriers: A
cell uptake study. Biomacromolecules, 13(3):814–825, 2012.
[150] J. Klein, J. Stock, and K. D. Vorlop. Pore size and properties of spher-
ical Ca-alginate biocatalysts. Appl. Microbiol. Biotechnol., 18(2):86–91,
1983.
[151] W. Kong, D. Sung, Y. Shim, K. H. Bae, P. Dubois, T. G. Park, J. Kim,
and S. Seo. Efficient intracellular siRNA delivery strategy through rapid
and simple two steps mixing involving noncovalent post-PEGylation. J.
Control. Release, 138(2):141–147, 2009.
389
[152] C. Kriegel and M. M. Amiji. Dual TNF-α/Cyclin D1 gene silencing
with an oral polymeric microparticle system as a novel strategy for the
treatment of inflammatory bowel disease. Clin. Transl. Gastroenterol.,
2(3):e2, 2011.
[153] C. Kriegel and M. M. Amiji. Oral TNF-α gene silencing using a poly-
meric microsphere-based delivery system for the treatment of inflamma-
tory bowel disease. J. Control. Release, 150(1):77–86, 2011.
[154] C. Kriegel, H. Attarwala, and M. Amiji. Multi-compartmental oral de-
livery systems for nucleic acid therapy in the gastrointestinal tract. Adv.
Drug Deliver. Rev., 65(6):891–901, 2013.
[155] D. Kurzbach, M. J. N. Junk, and D. Hinderberger. Nanoscale inho-
mogeneities in thermoresponsive polymers. Macromol. Rapid Commun.,
34(2):119–134, 2013.
[156] Y. Kwak, A. J. D. Magenau, and K. Matyjaszewski. ARGET ATRP
of methyl acrylate with inexpensive ligands and ppm concentrations of
catalyst. Macromolecules, 44(4):811–819, 2011.
[157] G. S. Kwon and T. Okano. Polymeric micelles as new drug carriers. Adv.
Drug Deliver. Rev., 21(2):107–116, 1996.
L
390
[158] Y. H. La, E. W. Edwards, S. M. Park, and P. F. Nealey. Directed as-
sembly of cylinder-forming block copolymer films and thermochemically
induced cylinder to sphere transition: a hierarchical route to linear ar-
rays of nanodots. Nano Lett., 5(7):1379–1384, 2005.
[159] L. Langmead and P. Irving. Inflammatory bowel disease: The Facts.
Oxford University Press, Oxford, UK, 2008.
[160] M. R. Lares, J. J. Rossi, and D. L. Ouellet. RNAi and small interfering
RNAs in human disease therapeutic applications. Trends Biotechnol.,
28(11):570–579, 2010.
[161] H. Laroui, G. Dalmasso, H. T. T. Nguyen, Y. Yan, S. V. Sitaraman,
and D. Merlin. Drug-loaded nanoparticles targeted to the colon with
polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterol-
ogy, 138(3):843–853.e2, 2010.
[162] H. Laroui, A. L. Theiss, Y. Yan, G. Dalmasso, H. T. T. Nguyen, S. V.
Sitaraman, and D. Merlin. Functional TNFα gene silencing mediated
by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon.
Biomaterials, 32(4):1218–1228, 2011.
[163] H. Laroui, D. S. Wilson, G. Dalmasso, K. Salaita, N. Murthy, S. V.
Sitaraman, and D. Merlin. Nanomedicine in GI. Am. J. Physiol. Gas-
trointest. Liver Physiol., 300(3):G371–G383, 2011.
391
[164] F. Leonard, E. Collnot, and C. Lehr. A three-dimensional coculture of
enterocytes, monocytes and dendritic cells to model inflamed intestinal
mucosa in vitro. Molecular Pharmaceutics, 7(6):2103–2119, 2010.
[165] Y. Li, H. J. Heo, G. H. Gao, S. W. Kang, C. T. Huynh, M. S. Kim,
J. W. Lee, J. H. Lee, and D. S. Lee. Synthesis and characterization of
an amphiphilic graft polymer and its potential as a pH-sensitive drug
carrier. Polymer, 52(15):3304–3310, 2011.
[166] W. Liechty, M. Caldorera-Moore, M. Phillips, C. Schoener, and N. Pep-
pas. Advanced molecular design of biopolymers for transmucosal and
intracellular delivery of chemotherapeutic agents and biological thera-
peutics. J. Control. Release, 155(2):119–127, 2011.
[167] W. Liechty, D. Kryscio, B. Slaughter, and N. Peppas. Polymers for drug
delivery systems. Annu. Rev. Chem. Biomol., 1(1):149–173, 2010.
[168] W. Liechty and N. Peppas. Expert opinion: Responsive polymer
nanoparticles in cancer therapy. Eur. J. Pharm. Biopharm., 80:241–246,
2012.
[169] W. B. Liechty. Multi-responsive nanoscale hydrogels for intracellular de-
livery of siRNA. Preliminary Oral Examination, Department of Chemical
Engineering, The University of Texas at Austin, 2012.
[170] W. B. Liechty, R. Chen, F. Farzaneh, M. Tavassoli, and N. K. H. Slater.
392
Synthetic pH-responsive polymers for protein transduction. Adv. Mater.,
21:3910–3914, 2009.
[171] W. B. Liechty, R. L. Scheuerle, and N. A. Peppas. Tunable, respon-
sive nanogels containing t-butyl methacrylate and 2-(t-butylamino)ethyl
methacrylate. Polymer, 54(15):3784–3795, 2013.
[172] M. C. Linder, L. Wooten, P. Cerveza, S. Cotton, R. Shulze, and
N. Lomeli. Copper transport. Am. J. Clin. Nutr., 67(5):965S–971S,
1998.
[173] M. Lindow, H. Vornlocher, D. Riley, D. J. Kornbrust, J. Burchard, L. O.
Whiteley, J. Kamens, J. D. Thompson, S. Nochur, H. Younis, S. Bartz,
J. Parry, N. Ferrari, S. P. Henry, and A. A. Levin. Assessing unin-
tended hybridization-induced biological effects of oligonucleotides. Nat.
Biotechnol., 30(10):920–923, 2012.
[174] H. Liu, X. Jiang, J. Fan, G. Wang, and S. Liu. Aldehyde surface-
functionalized shell cross-linked micelles with pH-tunable core swella-
bility and their bioconjugation with lysozyme. Macromolecules,
40(25):9074–9083, 2007.
[175] Q. Liu and Z. Paroo. Biochemical principles of small RNA pathways.
Annu. Rev. Biochem., 79(1):295–319, 2010.
[176] S. Liu, J. V. M. Weaver, Y. Tang, N. C. Billingham, S. P. Armes, and
K. Tribe. Synthesis of shell cross-linked micelles with pH-responsive
393
cores using ABC triblock copolymers. Macromolecules, 35(16):6121–
6131, 2002.
[177] Z. Liu, Z. Zhang, C. Zhou, and Y. Jiao. Hydrophobic modifications of
cationic polymers for gene delivery. Prog. Polym. Sci., 35(9):1144–1162,
2010.
[178] C. Lo, C. Huang, K. Lin, and G. Hsiue. Mixed micelles formed from graft
and diblock copolymers for application in intracellular drug delivery.
Biomaterials, 28(6):1225–1235, 2007.
[179] E. V. Loftus. Clinical epidemiology of inflammatory bowel disease: in-
cidence, prevalence, and environmental influences. Gastroenterology,
126(6):1504–1517, 2004.
[180] X. J. Loh, J. del Barrio, P. P. C. Toh, T. Lee, D. Jiao, U. Rauwald, E. A.
Appel, and O. A. Scherman. Triply triggered doxorubicin release from
supramolecular nanocontainers. Biomacromolecules, 13(1):84–91, 2011.
[181] Q. Lou and D. A. Shipp. Recent developments in atom transfer radical
polymerization (ATRP): Methods to reduce metal catalyst concentra-
tions. ChemPhysChem, 13(14):3257–3261, 2012.
[182] Y. Lu and A. Bousvaros. Healthcare burden of inflammatory bowel
disease in the United States: More than pain and diarrhea. Inflamm.
Bowel Dis., 15(11):1767–1768, 2009.
394
M
[183] G. Mack. MicroRNA gets down to business. Nat. Biotechnol., 25(6):631–
638, 2007.
[184] S. Maher, T. W. Leonard, J. Jacobsen, and D. J. Brayden. Safety and
efficacy of sodium caprate in promoting oral drug absorption: from in
vitro to the clinic. Adv. Drug Deliver. Rev., 61(15):1427–1449, 2009.
[185] A. P. Majewski, A. Schallon, V. Jérôme, R. Freitag, A. H. E. Müller, and
H. Schmalz. Dual-responsive magnetic core–shell nanoparticles for nonvi-
ral gene delivery and cell separation. Biomacromolecules, 13(3):857–866,
2012.
[186] H. M. Malaty, X. Fan, A. R. Opekun, C. Thibodeaux, and G. D. Ferry.
Rising incidence of inflammatory bowel disease among children: a 12-
year study. J. Pediatr. Gastr. Nutr., 50(1):27–31, 2010.
[187] A. Malek, O. Merkel, L. Fink, F. Czubayko, T. Kissel, and A. Aigner. In
vivo pharmacokinetics, tissue distribution and underlying mechanisms
of various PEI (-PEG)/siRNA complexes. Toxicol. Appl. Pharmacol.,
236(1):97–108, 2009.
[188] M. J. Mann and V. J. Dzau. Therapeutic applications of transcription
factor decoy oligonucleotides. J. Clin. Invest., 106(9):1071–1076, 2000.
[189] B. Mao, L. Gan, Y. Gan, X. Li, P. Ravi, and K. Tam. Controlled
polymerizations of 2-(dialkylamino)ethyl methacrylates and their block
395
copolymers in protic solvents at ambient temperature via atrp. J. Polym.
Sci., Part A: Polym. Chem., 42(20):5161–5169, 2004.
[190] S. Marine, J. Freeman, A. Riccio, M. Axenborg, J. Pihl, R. Ketteler, and
S. Aspengren. High-throughput transfection of differentiated primary
neurons from rat forebrain. J. Biomol. Screen., 17(5):692–696, 2012.
[191] P. R. Mark, N. S. Murthy, S. Weigand, K. Breitenkamp, M. Kade, and
T. Emrick. Microphase separated structures in the solid and molten
states of double-crystal graft copolymers of polyethylene and poly (ethy-
lene oxide). Polymer, 49(13):3116–3124, 2008.
[192] K. Matyjaszewski. Atom transfer radical polymerization (ATRP): cur-
rent status and future perspectives. Macromolecules, 45(10):4015–4039,
2012.
[193] K. Matyjaszewski, H. Dong, W. Jakubowski, J. Pietrasik, and
A. Kusumo. Grafting from surfaces for everyone: ARGET ATRP in
the presence of air. Langmuir, 23(8):4528–4531, 2007.
[194] K. Matyjaszewski, W. Jakubowski, K. Min, W. Tang, J. Huang, W. A.
Braunecker, and N. V. Tsarevsky. Diminishing catalyst concentration
in atom transfer radical polymerization with reducing agents. P. Natl.
Acad. Sci., 103(42):15,309–15,314, 2006.
[195] K. Matyjaszewski and J. Xia. Atom transfer radical polymerization.
Chem. Rev., 101(9):2921–2990, 2001.
396
[196] Mayo Clinic. Prednisone and other corticosteroids: Balance the risks and
benefits, 2011. http://www.mayoclinic.com/health/steroids/HQ01431.
[197] J. McCarthy, M. O’Neill, L. Bourre, D. Walsh, A. Quinlan, G. Hurley,
J. Ogier, F. Shanahan, S. Melgar, R. Darcy, and C. O’Driscoll. Gene si-
lencing of TNF-alpha in a murine model of acute colitis using a modified
cyclodextrin delivery system. J. Control. Release, 168(1):28–34, 2013.
[198] E. L. McConnell, M. D. Short, and A. W. Basit. An in vivo comparison
of intestinal pH and bacteria as physiological trigger mechanisms for
colonic targeting in man. J. Control. Release, 130(2):154–160, 2008.
[199] G. Meister. RNA interference in the nucleus. Science, 321(5888):496–
497, 2008.
[200] J. Miao, W. He, L. Zhang, Y. Wang, Z. Cheng, and X. Zhu. AGET
ATRP of water-soluble PEGMA: Fast living radical polymerization
mediated by iron catalyst. J. Polym. Sci., Part A: Polym. Chem.,
50(11):2194–2200, 2012.
[201] K. Min, H. Gao, and K. Matyjaszewski. Use of ascorbic acid as re-
ducing agent for synthesis of well-defined polymers by ARGET ATRP.
Macromolecules, 40(6):1789–1791, 2007.
[202] K. Min, W. Jakubowski, and K. Matyjaszewski. AGET ATRP in the
presence of air in miniemulsion and in bulk. Macromol. Rapid Commun.,
27(8):594–598, 2006.
397
[203] S. Moghimi, P. Symonds, J. Murray, A. Hunter, G. Debska, and
A. Szewczyk. A two-stage poly(ethylenimine)-mediated cytotoxicity: im-
plications for gene transfer/therapy. Mol. Ther., 11(6):990–995, 2005.
[204] M. J. Monteiro and M. F. Cunningham. Polymer nanoparticles via living
radical polymerization in aqueous dispersions: Design and applications.
Macromolecules, 45(12):4939–4957, 2012.
[205] H. Mori, A. Walther, X. André, M. G. Lanzendörfer, and A. H. E. Müller.
Synthesis of highly branched cationic polyelectrolytes via self-condensing
atom transfer radical copolymerization with 2-(diethylamino) ethyl
methacrylate. Macromolecules, 37(6):2054–2066, 2004.
[206] M. Morille, C. Passirani, A. Vonarbourg, A. Clavreul, and J. P. Benoit.
Progress in developing cationic vectors for non-viral systemic gene ther-
apy against cancer. Biomaterials, 29(24-25):3477–3496, 2008.
[207] R. Morishita, G. H. Gibbons, M. Horiuchi, K. E. Ellison, M. Nakama,
L. Zhang, Y. Kaneda, T. Ogihara, and V. J. Dzau. A gene therapy strat-
egy using a transcription factor decoy of the E2F binding site inhibits
smooth muscle proliferation in vivo. P. Natl. Acad. Sci., 92(13):5855,
1995.
[208] N. S. Murthy, W. Wang, and J. Kohn. Microphase separation in copoly-
mers of hydrophilic PEG blocks and hydrophobic tyrosine-derived seg-




[209] M. R. Nabid, S. J. Tabatabaei Rezaei, R. Sedghi, H. Niknejad, A. A.
Entezami, H. A. Oskooie, and M. M. Heravi. Self-assembled micelles
of well-defined pentaerythritol-centered amphiphilic A4 B8 star-block
copolymers based on PCL and PEG for hydrophobic drug delivery. Poly-
mer, 52(13):2799–2809, 2011.
[210] National Center for Biotechnology Information
(NCBI), MedlinePlus. Wilson disease, 2012.
http://www.nlm.nih.gov/medlineplus/wilsondisease.html.
[211] National Center for Biotechnology Information
(NCBI), PubMed Health. Azathioprine, 2011.
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000602.
[212] National Center for Biotechnology Information
(NCBI), PubMed Health. Infliximab, 2011.
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000267.
[213] National Center for Biotechnology Information (NCBI),
PubMed Health. Methylprednisolone oral, 2011.
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000776/.
[214] National Center for Biotechnology Information
(NCBI), PubMed Health. Prednisone, 2011.
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000091/.
399
[215] National Center for Biotechnology Information
(NCBI), PubMed Health. Sulfasalazine, 2011.
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000610.
[216] National Center for Biotechnology Information
(NCBI), PubMed Health. Crohn’s disease, 2012.
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001295/.
[217] National Center for Biotechnology Information
(NCBI), PubMed Health. Mesalamine, 2012.
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000880.
[218] S. Nayak and L. A. Lyon. Soft nanotechnology with soft nanoparticles.
Angew. Chem., Int. Ed., 44(47):7686–7708, 2005.
[219] C. E. Nelson, J. R. Kintzing, A. Hanna, J. M. Shannon, M. K. Gupta,
and C. L. Duvall. Balancing cationic and hydrophobic content of PE-
Gylated siRNA polyplexes enhances endosome escape, stability, blood
circulation time, and bioactivity in vivo. ACS Nano, 7(10):8870–8880,
2013.
[220] Y. H. Ng, F. di Lena, and C. L. L. Chai. Metalloenzymatic radical
polymerization using alkyl halides as initiators. Polym. Chem., 2(3):589–
594, 2011.
[221] Y. H. Ng, F. di Lina, and C. L. L. Chai. PolyPEGA with predeter-
400
mined molecular weights from enzyme-mediated radical polymerization
in water. Chem. Commun., 47(22):6464–6466, 2011.
[222] R. Nicolaÿ and Y. Kwak. ATRP with alkyl pseudohalides acting as initia-
tors and chain transfer agents: When ATRP and RAFT polymerization
become one. Isr. J. Chem., 52(3-4):288–305, 2012.
[223] L. Nie, G. Wu, and W. Zhang. Correlation between mRNA and protein
abundance in Desulfovibrio vulgaris: A multiple regression to identify
sources of variations. Biochem. Biophys. Res. Commun., 339(2):603–
610, 2006.
[224] N. Nograles, S. Abdullah, M. N. Shamsudin, N. Billa, and R. Rosli.
Formation and characterization of pDNA-loaded alginate microspheres
for oral administration in mice. J. Biosci. Bioeng., 113(2):133–140, 2012.
O
[225] G. Odian. Principles of Polymerization. John Wiley and Sons, Hoboken,
NJ, 2004.
[226] J. K. Oh, S. A. Bencherif, and K. Matyjaszewski. Atom transfer radical
polymerization in inverse miniemulsion: A versatile route toward prepa-
ration and functionalization of microgels/nanogels for targeted drug de-
livery applications. Polymer, 50(19):4407–4423, 2009.
401
[227] J. K. Oh, H. Dong, R. Zhang, K. Matyjaszewski, and H. Schlaad.
Preparation of nanoparticles of double-hydrophilic PEO-PHEMA block
copolymers by AGET ATRP in inverse miniemulsion. J. Polym. Sci.,
Part A: Polym. Chem., 45(21):4764–4772, 2007.
[228] J. K. Oh, R. Drumright, D. J. Siegwart, and K. Matyjaszewski. The
development of microgels/nanogels for drug delivery applications. Prog.
Polym. Sci., 33(4):448–477, 2008.
[229] J. K. Oh, K. Min, and K. Matyjaszewski. Preparation of poly (oligo
(ethylene glycol) monomethyl ether methacrylate) by homogeneous
aqueous AGET ATRP. Macromolecules, 39(9):3161–3167, 2006.
[230] J. K. Oh, F. Perineau, B. Charleux, and K. Matyjaszewski. AGET
ATRP in water and inverse miniemulsion: A facile route for preparation
of high-molecular-weight biocompatible brush-like polymers. J. Polym.
Sci., Part A: Polym. Chem., 47(7):1771–1781, 2009.
[231] J. K. Oh, F. Perineau, and K. Matyjaszewski. Preparation of nanoparti-
cles of well-controlled water-soluble homopolymers and block copolymers
using an inverse miniemulsion ATRP. Macromolecules, 39(23):8003–
8010, 2006.
[232] J. K. Oh, D. J. Siegwart, H. Lee, G. Sherwood, L. Peteanu, J. O.
Hollinger, K. Kataoka, and K. Matyjaszewski. Biodegradable nanogels
402
prepared by atom transfer radical polymerization as potential drug de-
livery carriers: synthesis, biodegradation, in vitro release, and bioconju-
gation. J. Am. Chem. Soc., 129(18):5939–5945, 2007.
[233] J. K. Oh, C. Tang, H. Gao, N. V. Tsarevsky, and K. Matyjaszewski.
Inverse miniemulsion ATRP: a new method for synthesis and function-
alization of well-defined water-soluble/cross-linked polymeric particles.
J. Am. Chem. Soc., 128(16):5578–5584, 2006.
[234] Y. K. Oh and T. G. Park. siRNA delivery systems for cancer treatment.
Adv. Drug Deliver. Rev., 61(10):850–862, 2009.
[235] N. Öztürk, S. Akgöl, M. Arısoy, and A. Denizli. Reversible adsorption of
lipase on novel hydrophobic nanospheres. Sep. Purif. Technol., 58(1):83–
90, 2007.
P
[236] D. W. Pack, A. S. Hoffman, S. Pun, and P. S. Stayton. Design and
development of polymers for gene delivery. Nat. Rev. Drug Discov.,
4(7):581–593, 2005.
[237] D. Palioura, S. P. Armes, S. H. Anastasiadis, and M. Vamvakaki.
Metal nanocrystals incorporated within pH-responsive microgel parti-
cles. Langmuir, 23(10):5761–5768, 2007.
403
[238] N. Pantoustier, S. Moins, M. Wautier, P. Degée, and P. Dubois. Solvent-
free synthesis and purification of poly[2-(dimethylamino)ethyl methacry-
late] by atom transfer radical polymerization. Chem. Commun., (3):340–
341, 2003.
[239] T. Park, J. Jeong, and S. Kim. Current status of polymeric gene delivery
systems. Adv. Drug Deliver. Rev., 58(4):467–486, 2006.
[240] M. M. Patel. Cutting-edge technologies in colon-targeted drug delivery
systems. Expert Opin. Drug Del., 8(10):1247–1258, 2011.
[241] M. M. Patel and A. F. Amin. Design and optimization of colon-targeted
system of theophylline for chronotherapy of nocturnal asthma. J. Pharm.
Sci., 100(5):1760–1772, 2011.
[242] M. M. Patel and A. F. Amin. Process, optimization and characterization
of mebeverine hydrochloride loaded guar gum microspheres for irritable
bowel syndrome. Carbohydr. Polym., 86(2):536–545, 2011.
[243] S. M. Paterson, D. H. Brown, T. V. Chirila, I. Keen, A. K. Whittaker,
and M. V. Baker. The synthesis of water-soluble phema via arget atrp in
protic media. J. Polym. Sci., Part A: Polym. Chem., 48(18):4084–4092,
2010.
[244] V. B. Patravale and S. D. Mandawgade. Novel cosmetic delivery systems:
an application update. Int. J. Cosmet. Sci., 30(1):19–33, 2008.
404
[245] K. A. Payne, D. R. D’hooge, P. H. M. Van Steenberge, M. Reyniers,
M. F. Cunningham, R. A. Hutchinson, and G. B. Marin. ARGET ATRP
of butyl methacrylate: Utilizing kinetic modeling to understand experi-
mental trends. Macromolecules, 46(10):3828–3840, 2013.
[246] C. V. Pecot, G. A. Calin, R. L. Coleman, G. Lopez-Berestein, and A. K.
Sood. RNA interference in the clinic: challenges and future directions.
Nat. Rev. Cancer, 11(1):59–67, 2011.
[247] N. A. Peppas. Intelligent therapeutics: biomimetic systems and nan-
otechnology in drug delivery. Adv. Drug Deliver. Rev., 56(11):1529–1531,
2004.
[248] N. A. Peppas, P. Bures, W. Leobandung, and H. Ichikawa. Hydrogels in
pharmaceutical formulations. Eur. J. Pharm. Biopharm., 50(1):27–46,
2000.
[249] N. A. Peppas, J. Z. Hilt, A. Khademhosseini, and R. Langer. Hydrogels
in biology and medicine: From molecular principles to bionanotechnol-
ogy. Adv. Mater., 18(11):1345–1360, 2006.
[250] J. Perkel. RNAi therapeutics: A two-year update. Science,
326(5951):454, 2009.
[251] M. Phillips. Antisense therapeutics. Springer, Totowa, NJ, 2005.
405
[252] M. V. A. Pichai and L. R. Ferguson. Potential prospects of nanomedicine
for targeted therapeutics in inflammatory bowel diseases. World J. Gas-
troenterol., 18(23):2895–2901, 2012.
[253] K. Pielichowski and K. Flejtuch. Differential scanning calorimetry stud-
ies on poly (ethylene glycol) with different molecular weights for ther-
mal energy storage materials. Polym. Adv. Technol., 13(10-12):690–696,
2003.
[254] T. Pintauer and K. Matyjaszewski. Atom transfer radical addition and
polymerization reactions catalyzed by ppm amounts of copper com-
plexes. Chem. Soc. Rev., 37(6):1087, 2008.
[255] S. Pirotton, C. Muller, N. Pantoustier, F. Botteman, S. Collinet,
C. Grandfils, G. Dandrifosse, P. Degée, P. Dubois, and M. Raes. En-
hancement of transfection efficiency through rapid and noncovalent
post-PEGylation of poly (dimethylaminoethyl methacrylate)/DNA com-
plexes. Pharm. Res., 21(8):1471–1479, 2004.
Q
[256] Y. Qiao, Y. Huang, C. Qiu, X. Yue, L. Deng, Y. Wan, J. Xing, C. Zhang,
S. Yuan, A. Dong, and J. Xu. The use of PEGylated poly [2-(N, N-
dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vec-
tor and the activation of innate immunity and improvement of HIV-1-
specific immune responses. Biomaterials, 31(1):115–123, 2010.
406
[257] J. Qiu, B. Charleux, and K. Matyjaszewski. Controlled/living radical
polymerization in aqueous media: homogeneous and heterogeneous sys-
tems. Prog. Polym. Sci., 26(10):2083–2134, 2001.
R
[258] C. Ramireddy, Z. Tuzar, K. Prochazka, S. E. Webber, and
P. Munk. Styrene-tert-butyl methacrylate and styrene-methacrylic acid
block copolymers: synthesis and characterization. Macromolecules,
25(9):2541–2545, 1992.
[259] M. Ranger, M. Jones, M. Yessine, and J. Leroux. From well-defined
diblock copolymers prepared by a versatile atom transfer radical poly-
merization method to supramolecular assemblies. J. Polym. Sci., Part
A: Polym. Chem., 39(22):3861–3874, 2001.
[260] D. D. Rao, J. S. Vorhies, N. Senzer, and J. Nemunaitis. siRNA vs.
shRNA: Similarities and differences. Adv. Drug Deliver. Rev., 61(9):746–
759, 2009.
[261] A. A. Raoof, P. Chiu, Z. Ramtoola, I. K. Cumming, C. Teng, S. P. Wein-
bach, G. E. Hardee, A. A. Levin, and R. S. Geary. Oral bioavailability
and multiple dose tolerability of an antisense oligonucleotide tablet for-
mulated with sodium caprate. J. Pharm. Sci., 93(6):1431–1439, 2004.
[262] T. Ren, Y. Feng, Z. Zhang, L. Li, and Y. Li. Shell-sheddable mi-
celles based on star-shaped poly (ε-caprolactone)-SS-poly (ethyl glycol)
407
copolymer for intracellular drug release. Soft Matter, 7(6):2329–2331,
2011.
[263] T. Ren, W. Xia, H. Dong, and Y. Li. Sheddable micelles based
on disulfide-linked hybrid PEG-polypeptide copolymer for intracellular
drug delivery. Polymer, 52(16):3580–3586, 2011.
[264] B. D. Riquelme, D. Dumas, A. Fontana, M. Delannoy, J. R. Valverde,
D. Sondag, and C. Grandfils. Hemocompatibility and biofunctionality of
two poly(2-(dimethylamino)ethyl methacrylate-co-poly(ethyleneglycol)
copolymers. J. Biomed. Mater. Res. Part A, 99A(3):445–454, 2011.
[265] A. Rubinstein. Microbially controlled drug delivery to the colon. Bio-
pharm. Drug Dispos., 11(6):465–475, 1990.
S
[266] M. Sahnoun, M.-T. Charreyre, L. Veron, T. Delair, and F. D’Agosto.
Synthetic and characterization aspects of dimethylaminoethyl methacry-
late reversible addition fragmentation chain transfer (RAFT) polymer-
ization. J. Polym. Sci., Part A: Polym. Chem., 43(16):3551–3565, 2005.
[267] F. Sanda, T. Abe, and T. Endo. Syntheses and radical polymerizations
of optically active (meth) acrylamides having amino acid moieties. J.
Polym. Sci., Part A: Polym. Chem., 35(13):2619–2629, 1997.
408
[268] P. Sanguansri and M. A. Augustin. Nanoscale materials development -
-a food industry perspective. Trends Food Sci. Technol., 17(10):547–556,
2006.
[269] N. Sanson and J. Rieger. Synthesis of nanogels/microgels by conventional
and controlled radical crosslinking copolymerization. Polym. Chem.,
1(7):965–977, 2010.
[270] R. Say, S. Emir, B. Garipcan, S. Patir, and A. Denizli. Novel methacry-
loylamidophenylalanine functionalized porous chelating beads for ad-
sorption of heavy metal ions. Adv. Polym. Technol., 22(4):355–364, 2003.
[271] A. Schallon, V. Jérôme, A. Walther, C. Synatschke, A. Müller, and
R. Freitag. Performance of three PDMAEMA-based polycation archi-
tectures as gene delivery agents in comparison to linear and branched
PEI. React. Funct. Polym., 70(1):1–10, 2010.
[272] A. Schmalz, M. Hanisch, H. Schmalz, and A. H. E. Müller. Dou-
ble stimuli-responsive behavior of linear and star-shaped poly (N,
N -diethylaminoethyl methacrylate) in aqueous solution. Polymer,
51(6):1213–1217, 2010.
[273] G. Schmalz, H. Langer, and H. Schweikl. Cytotoxicity of dental al-
loy extracts and corresponding metal salt solutions. J. Dent. Res.,
77(10):1772–1778, 1998.
409
[274] N. Sharifi-Sanjani, A. R. Mahdavian, and P. Bataille. Emulsion poly-
merization of styrene and DEAEMA with a core–shell structure. J. Appl.
Polym. Sci., 78(11):1977–1985, 2000.
[275] A. Shatkay and I. Michaeli. Potentiometric titrations of polyelectrolytes
with separation of phases. J. Phys. Chem., 70(12):3777–3782, 1966.
[276] M. Shiau, H. Chiou, Y. Lee, T. Kuo, and Y. Chang. Establishment of
a consistent L929 bioassay system for TNF-α quantitation to evaluate
the effect of lipopolysaccharide, phytomitogens and cytodifferentiation
agents on cytotoxicity of TNF-α secreted by adherent human mononu-
clear cells. Mediat. Inflamm., 10(4):199–208, 2001.
[277] D. A. Shipp. Reversible-deactivation radical polymerizations. Polym.
Rev., 51(2):99–103, 2011.
[278] R. Shrestha, M. Elsabahy, S. Florez-Malaver, S. Samarajeewa, and K. L.
Wooley. Endosomal escape and siRNA delivery with cationic shell
crosslinked knedel-like nanoparticles with tunable buffering capacities.
Biomaterials, 33(33):8557–8568, 2012.
[279] D. Siegwart, M. Leiendecker, R. Langer, and D. Anderson. Automated
ARGET ATRP accelerates catalyst optimization for the synthesis of
thiol-functionalized polymers. Macromolecules, 45(3):1254–1261, 2012.
[280] D. J. Siegwart, J. K. Oh, and K. Matyjaszewski. ATRP in the design
410
of functional materials for biomedical applications. Prog. Polym. Sci.,
37(1):18–37, 2012.
[281] S. J. Sigg, F. Seidi, K. Renggli, T. B. Silva, G. Kali, and N. Bruns.
Horseradish peroxidase as a catalyst for atom transfer radical polymer-
ization. Macromol. Rapid Commun., 32(21):1710–1715, 2011.
[282] Sigma-Aldrich. Material safety data sheet: Tetraethylene glycol
dimethacrylate, January 2012.
[283] Sigma-Aldrich. Material safety data sheet: Tris(2-pyridylmethyl)amine,
March 2012.
[284] A. Simakova, S. E. Averick, D. Konkolewicz, and K. Matyjaszewski.
Aqueous ARGET ATRP. Macromolecules, 45(16):6371–6379, 2012.
[285] A. Simakova, M. Mackenzie, S. E. Averick, S. Park, and K. Maty-
jaszewski. Bioinspired iron-based catalyst for atom transfer radical poly-
merization. Angew. Chem. Int. Ed., 2013. doi: 10.1002/anie.201306337.
[286] M. R. Simmons, E. N. Yamasaki, and C. S. Patrickios. Cationic
amphiphilic model networks: Synthesis by group transfer polymeriza-
tion and characterization of the degree of swelling. Macromolecules,
33(8):3176–3179, 2000.
[287] A. Singh, H. Nie, B. Ghosn, H. Qin, L. W. Kwak, and K. Roy. Efficient
modulation of T-cell response by dual-mode, single-carrier delivery of
411
cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells.
Mol. Ther., 16(12):2011–2021, 2008.
[288] T. J. Singh and S. V. Bhat. Morphology and conductivity studies of
a new solid polymer electrolyte:(PEG) xLiClO4. Bull. Mater. Sci.,
26(7):707–714, 2003.
[289] V. R. Sinha and R. Kumria. Polysaccharides in colon-specific drug de-
livery. Int. J. Pharm., 224(1):19–38, 2001.
[290] V. R. Sinha and R. Kumria. Microbially triggered drug delivery to the
colon. Eur. J. Pharm. Sci., 18(1):3–18, 2003.
[291] C. A. Stein and J. S. Cohen. Oligodeoxynucleotides as inhibitors of gene
expression: a review. Cancer Res., 48(10):2659, 1988.
[292] M. Stenzel. RAFT polymerization: an avenue to functional polymeric
micelles for drug delivery. Chem. Commun., (30):3486–3503, 2008.
[293] F. Stoffelbach, N. Griffete, C. Bui, and B. Charleux. Use of a sim-
ple surface-active initiator in controlled/living free-radical miniemulsion
polymerization under AGET and ARGET ATRP conditions. Chem.
Commun., (39):4807–4809, 2008.
[294] K. Sui, X. Shan, S. Gao, Y. Xia, Q. Zheng, and D. Xie. Dual-responsive
supramolecular inclusion complexes of block copolymer poly (ethy-
lene glycol)-block-poly [(2-dimethylamino) ethyl methacrylate] with α-
412
cyclodextrin. J. Polym. Sci., Part A: Polym. Chem., 48(10):2143–2153,
2010.
[295] T.-M. Sun, J.-Z. Du, L.-F. Yan, H.-Q. Mao, and J. Wang. Self-assembled
biodegradable micellar nanoparticles of amphiphilic and cationic block
copolymer for siRNA delivery. Biomaterials, 29(32):4348–4355, 2008.
[296] D. V. Svintradze and G. M. Mrevlishvili. Fiber molecular model of
atelocollagen-small interfering RNA (siRNA) complex. Int. J. Biol.
Macromol., 37(5):283–286, 2005.
[297] C. V. Synatschke, A. Schallon, V. Jérôme, R. Freitag, and A. H. E.
Müller. Influence of polymer architecture and molecular weight of
poly (2-(dimethylamino) ethyl methacrylate) polycations on transfec-
tion efficiency and cell viability in gene delivery. Biomacromolecules,
12(12):4247–4255, 2011.
T
[298] K. Tahara, T. Sakai, H. Yamamoto, H. Takeuchi, and Y. Kawashima.
Establishing chitosan coated PLGA nanosphere platform loaded with
wide variety of nucleic acid by complexation with cationic compound for
gene delivery. Int. J. Pharm., 354(1-2):210–216, 2008.
[299] K. Tahara, S. Samura, K. Tsuji, H. Yamamoto, Y. Tsukada, Y. Bando,
H. Tsujimoto, R. Morishita, and Y. Kawashima. Oral nuclear factor-
κB decoy oligonucleotides delivery system with chitosan modified poly
413
(d,l-lactide-co-glycolide) nanospheres for inflammatory bowel disease.
Biomaterials, 32(3):870–878, 2011.
[300] A. Tamura, M. Oishi, and Y. Nagasaki. Enhanced cytoplasmic deliv-
ery of siRNA using a stabilized polyion complex based on PEGylated
nanogels with a cross-linked polyamine structure. Biomacromolecules,
10(7):1818–1827, 2009.
[301] J. H. Tan, N. A. J. McMillan, E. Payne, C. Alexander, F. Heath, A. K.
Whittaker, and K. J. Thurecht. Hyperbranched polymers as delivery
vectors for oligonucleotides. J. Polym. Sci., Part A: Polym. Chem.,
50(13):2585–2595, 2012.
[302] TEVA Pharmaceuticals USA, Inc. Paragard intrauterine copper contra-
ceptive, 2012. http://www.paragard.com/default.aspx.
[303] TEVA Pharmaceuticals USA, Inc. Prescribing Information: ParaGard
T 380A Intrauterine Copper Contraceptive, 2012.
[304] Q. Tian, S. B. Stepaniants, M. Mao, L. Weng, M. C. Feetham, M. J.
Doyle, C. Y. Eugene, H. Dai, V. Thorsson, J. Eng, D. Goodlett, J. P.
Berger, B. Gunter, P. S. Linseley, R. B. Stoughton, R. Aebersold, S. J.
Collins, W. A. Hanlon, and H. L. E. Integrated genomic and proteomic
analyses of gene expression in mammalian cells. Mol. Cell. Proteomics,
3(10):960–969, 2004.
414
[305] K. Tiemann and J. J. Rossi. RNAi-based therapeutics-current status,
challenges and prospects. EMBO Mol. Med., 1(3):142–151, 2009.
[306] L. G. Tillman, R. S. Geary, and G. E. Hardee. Oral delivery of antisense
oligonucleotides in man. J. Pharm. Sci., 97(1):225–236, 2008.
[307] A. W. Tong, C. M. Jay, N. Senzer, P. B. Maples, and J. Nemunaitis.
Systemic therapeutic gene delivery for cancer: Crafting Paris’ arrow.
Curr. Gene Ther., 9(1):45–60, 2009.
[308] H. H. Tønnesen and J. Karlsen. Alginate in drug delivery systems. Drug
Dev. Ind. Pharm., 28(6):621–630, 2002.
[309] N. V. Tsarevsky. Catalytic activity and performance of copper-based
complexes mediating atom transfer radical polymerization. Isr. J.
Chem., 52(3-4):276–287, 2012.
[310] N. V. Tsarevsky and K. Matyjaszewski. Environmentally benign atom
transfer radical polymerization: Towards "green" processes and materi-
als. J. Polym. Sci., Part A: Polym. Chem., 44(17):5098–5112, 2006.
[311] D. Türkmen, N. Öztürk, S. Akgöl, A. Elkak, and A. Denizli. Pheny-
lalanine containing hydrophobic nanospheres for antibody purification.
Biotechnol. Prog., 24(6):1297–1303, 2008.
U
415
[312] M. N. Uddin, N. J. Patel, T. Bhowmik, B. D’Souza, A. Akalkotkar,
F. Etzlar, C. W. Oettinger, and M. D’Souza. Enhanced bioavailability
of orally administered antisense oligonucleotide to nuclear factor kappa
B mRNA after microencapsulation with albumin. J. Drug Targeting,
21(5):450–457, 2013.
[313] United States Environmental Protection Agency. Ba-
sic information about copper in drinking water, 2012.
http://water.epa.gov/drink/contaminants/basicinformation/copper.cfm.
[314] Z. ur Rehman, I. S. Zuhorn, and D. Hoekstra. How cationic lipids trans-
fer nucleic acids into cells and across cellular membranes: Recent ad-
vances. J. Control. Release, 166(1):46–56, 2013.
[315] U.S. Food and Drug Administration. CFR - Code of
Federal Regulations Title 21 Sec. 172.860 Fatty acids,
2011. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/
CFRSearch.cfm?fr=172.863.
[316] U.S. Food and Drug Administration. CFR - Code of Fed-
eral Regulations Title 21 Sec. 172.863 Salts of Fatty Acids,
2011. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/
CFRSearch.cfm?fr=172.860.
[317] U.S. Food and Drug Administration. Everything
Added to Food in the United States (EAFUS), 2011.
http://www.fda.gov/Food/FoodIngredientsPackaging/ucm115326.htm.
416
[318] U.S. Food and Drug Administration. Everything Added




[319] K. Van Butsele, M. Morille, C. Passirani, P. Legras, J. P. Benoit, S. K.
Varshney, R. Jérôme, and C. Jérôme. Stealth properties of poly(ethylene
oxide)-based triblock copolymer micelles: A prerequisite for a pH-
triggered targeting system. Acta. Biomater., 7(10):3700–3707, 2011.
[320] P. van de Wetering, J. Cherng, H. Talsma, D. J. A. Crommelin, and
W. E. Hennink. 2-(Dimethylamino) ethyl methacrylate based (co) poly-
mers as gene transfer agents. J. Control. Release, 53(1):145–153, 1998.
[321] P. van de Wetering, E. E. Moret, N. M. E. Schuurmans-Nieuwenbroek,
M. J. van Steenbergen, and W. E. Hennink. Structure-activity relation-
ships of water-soluble cationic methacrylate/methacrylamide polymers
for nonviral gene delivery. Bioconjugate Chem., 10(4):589–597, 1999.
[322] S. Vermeire, D. P. McGovern, G. Van Assche, and P. Rutgeerts. Ge-
netics of Inflammatory Bowel Disease: How Modern Genomics Informs
Basic, Clinical and Translational Science, Inflammatory Bowel Disease:
Translating basic science into clinical practice. Wiley Online Library,
2010.
417
[323] T. Vickers and S. Crooke. siRNAs targeted to certain polyadenyla-
tion sites promote specific, RISC-independent degradation of messenger
RNAs. Nucleic Acids Res., 40(13):6223–6234, 2012.
W
[324] G. Wallraff, J. Hutchinson, W. Hinsberg, F. Houle, P. Seidel, R. Johnson,
and W. Oldham. Thermal and acid-catalyzed deprotection kinetics in
candidate deep ultraviolet resist materials. J. Vac. Sci. Technol. B,
12(6):3857–3862, 1994.
[325] T. Wang, J. R. Upponi, and V. P. Torchilin. Design of multifunctional
non-viral gene vectors to overcome physiological barriers: Dilemmas and
strategies. Int. J. Pharm., 427(1):3–20, 2012.
[326] J. Wataha. Biocompatibility of dental casting alloys: a review. J. Pros-
thet. Dent., 83(2):223–234, 2000.
[327] J. C. Wataha, C. T. Hanks, and R. G. Craig. The in vitro effects of
metal cations on eukaryotic cell metabolism. J. Biomed. Mater. Res.,
25(9):1133–1149, 1991.
[328] J. K. Watts and D. R. Corey. Silencing disease genes in the laboratory
and the clinic. J. Pathol., 226(2):365–379, 2011.
[329] J. V. M. Weaver, Y. Tang, S. Liu, P. D. Iddon, R. Grigg, N. C. Billing-
ham, S. P. Armes, R. Hunter, and S. P. Rannard. Preparation of shell
418
cross-linked micelles by polyelectrolyte complexation. Angew. Chem.,
116(11):1413–1416, 2004.
[330] J. V. M. Weaver, R. T. Williams, B. J. L. Royles, P. H. Findlay, A. I.
Cooper, and S. P. Rannard. pH-Responsive branched polymer nanopar-
ticles. Soft Matter, 4(5):985–992, 2008.
[331] W. Wei, P. Lv, X. Chen, Z. Yue, Q. Fu, S. Liu, H. Yue, and G. Ma. Code-
livery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles
promoted synergistic tumor suppression. Biomaterials, 34(15):3912–
3923, 2013.
[332] J. Weiss, P. Takhistov, and D. J. McClements. Functional materials in
food nanotechnology. J. Food Sci., 71(9):R107–R116, 2006.
[333] K. A. Whitehead, J. E. Dahlman, R. S. Langer, and D. G. Anderson.
Silencing or stimulation? siRNA delivery and the immune system. Annu.
Rev. Chem. Biomol., 2(1):77–96, 2011.
[334] K. A. Whitehead, R. Langer, and D. G. Anderson. Knocking down
barriers: advances in siRNA delivery. Nat. Rev. Drug Discov., 8(2):129–
138, 2009.
[335] D. S. Wilson, G. Dalmasso, L. Wang, S. V. Sitaraman, D. Merlin, and
N. Murthy. Orally delivered thioketal nanoparticles loaded with TNF-α
siRNA target inflammation and inhibit gene expression in the intestines.
Nat. Mater., 9(11):923–928, 2010.
419
[336] C. Wu and S. Zhou. Volume phase transition of swollen gels: Discontin-
uous or continuous? Macromolecules, 30(3):574–576, 1997.
[337] L. Wu, J. Zhang, and W. Watanabe. Physical and chemical stability of
drug nanoparticles. Adv. Drug Deliver. Rev., 63(6):456–469, 2011.
[338] G. Wulff, B. Chong, and U. Kolb. Soluble single-molecule nanogels of
controlled structure as a matrix for efficient artificial enzymes. Angew.
Chem., Int. Ed., 45(18):2955–2958, 2006.
X
[339] T. Xing, S. Li, X. Xu, and G. Chen. Structure and proper-
ties of silk grafted with N, N -dimethylaminoethyl methacrylate via
the ARGET ATRP method. J. Eng. Fiber Fabr., Retrieved from
http://www.jeffjournal.org/(Special Issue: Fibers), 2012.
[340] Q. Xiong, P. Ni, F. Zhang, and Z. Yu. Synthesis and characterization of
2-(dimethylamino)ethyl methacrylate homopolymers via aqueous RAFT
polymerization and their application in miniemulsion polymerization.
Polym. Bull., 53(1):1–8, 2004.
[341] F. Xu, K. Neoh, and E. Kang. Bioactive surfaces and biomaterials via




[342] M. Yang and J. Mattes. Discovery, biology and therapeutic potential
of RNA interference, microRNA and antagomirs. Pharmacol. Ther.,
117(1):94–104, 2008.
[343] X. Z. Yang, S. Dou, T. M. Sun, C. Q. Mao, H. X. Wang, and
J. Wang. Systemic delivery of siRNA with cationic lipid assisted PEG-
PLA nanoparticles for cancer therapy. J. Control. Release, 156(2):203–
211, 2011.
[344] Y. Q. Yang, W. J. Lin, L. J. Zhang, C. Z. Cai, W. Jiang, X. D. Guo, and
Y. Qian. Synthesis, characterization and pH-responsive self-assembly be-
havior of amphiphilic multiarm star triblock copolymers based on PCL,
PDEAEMA, and PEG. Macromol. Res., 21(9):1011–1020, 2013.
[345] J. Yoo, D. J. Irvine, D. E. Discher, and S. Mitragotri. Bio-inspired,
bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug
Discov., 10(7):521–535, 2011.
[346] J. Yoon, J. Oh, W. Li, T. Kowalewski, and K. Matyjaszewski. ATRP: A
Versatile Tool toward Uniformly Crosslinked Hydrogels with Controlled
Architecture and Multifunctionality, Hydrogel Micro and Nanoparticles.
Wiley Online Library, 2012.
[347] E. Yoshii. Cytotoxic effects of acrylates and methacrylates: Relation-
421
ships of monomer structures and cytotoxicity. J. Biomed. Mater. Res.,
37(4):517–524, 1997.
[348] S. Yusa, M. Sugahara, T. Endo, and Y. Morishima. Preparation and
characterization of a pH-responsive nanogel based on a photo-cross-
linked micelle formed from block copolymers with controlled structure.
Langmuir, 25(9):5258–5265, 2009.
Z
[349] F. Zeng, Y. Shen, S. Zhu, and R. Pelton. Atom transfer radical poly-
merization of 2-(dimethylamino) ethyl methacrylate in aqueous media.
J. Polym. Sci., Part A: Polym. Chem., 38(20):3821–3827, 2000.
[350] J. Zhang, C. He, C. Tang, and C. Yin. Ternary polymeric nanoparticles
for oral siRNA delivery. Pharm. Res., 30(5):1228–1239, 2013.
[351] J. Zhang, C. Tang, and C. Yin. Galactosylated trimethyl chitosan–
cysteine nanoparticles loaded with Map4k4 siRNA for targeting acti-
vated macrophages. Biomaterials, 34(14):3667–3677, 2013.
[352] W. Zhang, J. He, Z. Liu, P. Ni, and X. Zhu. Biocompatible and ph-
responsive triblock copolymer mPEG-b-PCL-b-PDMAEMA: Synthesis,
self-assembly, and application. J. Polym. Sci., Part A: Polym. Chem.,
48(5):1079–1091, 2010.
422
[353] Y. Zhang, A. Aigner, and S. Agarwal. Degradable and biocompatible
poly (N, N -dimethylaminoethyl methacrylate-co-caprolactone) s as dna
transfection agents. Macromol. Biosci., 13(9):1267–1275, 2013.
[354] Y. Zhang, A. Satterlee, and L. Huang. In vivo gene delivery by nonviral
vectors: Overcoming hurdles? Mol. Ther., 20(7):1298–1304, 2012.
[355] Y. Zhang, M. Zheng, T. Kissel, and S. Agarwal. Design and biophysical
characterization of bioresponsive degradable poly(dimethylaminoethyl
methacrylate) based polymers for in vitro DNA transfection. Biomacro-
molecules, 13:313–322, 2012.
[356] C. Zhu, S. Jung, S. Luo, F. Meng, X. Zhu, T. G. Park, and Z. Zhong.
Co-delivery of siRNA and paclitaxel into cancer cells by biodegrad-
able cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock
copolymers. Biomaterials, 31(8):2408–2416, 2010.
[357] J. Zoldan, A. K. R. Lytton-Jean, E. D. Karagiannis, K. Deiorio-Haggar,
L. M. Bellan, R. Langer, and D. G. Anderson. Directing human em-
bryonic stem cell differentiation by non-viral delivery of siRNA in 3D
culture. Biomaterials, 32(31):7793–7800, 2011.
423
Vita
Diane Forbes was born in Lawrence, Kansas and grew up in Des Moines,
Iowa where she attended Johnston High School and Des Moines Central
Academy. After graduation from high school, she participated in biotech-
nology research in Mexico as a World Food Prize Borlaug-Ruan International
Intern. Diane studied chemical engineering as an undergraduate at Iowa State
University. As a first-year student, she worked with Dr. Brent Shanks in
catalysis research. In following years, Diane worked with plant metabolic en-
gineering researcher Dr. Jacqueline Shanks on an Honors Research Project
for alkaloid extraction and purification from Catharanthus roseus hairy root
tissue. After receiving a B.S. from Iowa State University, Diane joined the
Department of Chemical Engineering at the University of Texas at Austin as
a National Science Foundation Graduate Research Fellow. She completed the
research described in this thesis under the direction of Dr. Nicholas Peppas.
Permanent address: DianeCForbes@gmail.com
This dissertation was typeset with LATEX† by the author.
†LATEX is a document preparation system developed by Leslie Lamport as a special
version of Donald Knuth’s TEX Program.
424
